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FOREWORD 
 
What is cancer? 
Despite being a well-known and widely used word, the precise definition of “neoplasia” 
is still debatable. One of the most cited definitions of neoplasia belongs to Rupert A. Willis in his 
famous book “The spread of tumours in the human body” published in 1952: “A neoplasm is an 
abnormal mass of tissue, the growth of which exceeds and is uncoordinated with that of the 
normal tissues and persists in the same excessive manner after cessation of the stimuli which 
evoked the change.” 1. 
In the last decades, the study of carcinogenesis has been focused on the somatic mutation 
theory. According to this theory, cancer has been considered a genetic disease, characterized by 
sequential accumulation of mutations in key-genes, centring cancer as a cellular problem 2. 
However, several studies have showed that the majority of genetic alterations are considered 
harmless passenger mutations, with no selection advantage 3,4. Moreover, the context in which 
the genetic modifications occur are extremely relevant. The associations between genotype and 
phenotype that are found in one type of cancer cannot be generalized to all cancer types 5. For 
instance, studying the effect of targeted therapy in different tumors with the same mutation, it 
was found that one of the most important determinants of response rate was the histologic 
diagnosis 6. Following this line of thought, one of the most amazing set of studies that have been 
done showing the importance of context in cancer began in the sixties (more than 50 year ago) 
with experimental pathology. Stevens showed that it was possible to create experimentally 
teratomas from fetal gonadal ridges transplanted into the testis of adult mice 7. Later, it was 
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demonstrated that embryonal carcinoma cells could be inoculated into the mouse blastocyst 
where they would lose their malignant behavior and assumed normal embryonic cell features 
into the new chimeric mouse 8. These experiments show that normal embryonic cells and 
embryonal carcinoma cells have many common features, providing a link between embryonic 
development and carcinogenesis. 
Later in the eighties, the group of Mina Bissell showed that inoculation of infected cells 
with Rous sarcoma virus (RSV), a known oncovirus, in chick embryos did not produce 
malignant tumors as it happens in adult chickens. Instead, these infected cells assumed normal 
phenotype becoming part of normal embryonic structures. Nevertheless, the same infected cells 
explanted from these embryos would became transformed in cell culture 9. These findings also 
support that context and microenvironment has a profound effect in the malignant transformation 
of mutated cells. 
Summing up, two key facts are taught with these experiments: first, somatic mutations 
are not required to develop fully malignant tumors and second, malignant behavior can be 
reprogramed to normal phenotype in the proper context, even in the presence of oncogenic 
mutations. As such, recently, many authors realize that neoplasia, besides being, literally, the 
formation of something new, through the proliferation or increased survival of the neoplastic 
cells, is instead a complex tissue made of several different cell types that establish interactions 
with each other 10. The somatic mutation theory is now questioned and challenged, giving origin 
to different views on cancer initiation and development. For instance, the tissue organization 
field theory (TOFT) proposes that carcinogenesis takes place at the tissue level of biological 
organization and that aberrant interactions between different cells and their surroundings are 
responsible for the formation of cancer 11. Cancer would not be a cell disease but a tissue disease, 
13 
 
a complex system composed of different cells. Such different cell types include not only the 
neoplastic cells, but also cells of the microenvironment, like fibroblasts, immune cells, pericytes 
and even bone marrow-derived cells, among others 12-20. Far from being considered static 
elements, the cells of the microenvironment can be recruited to the neoplastic tissue and promote 
the evolution of this tissue – in other words, normal cells with normal genotype can regulate the 
malignant behavior of the neoplastic cells. These different theories should not be regarded 
individually but instead complementing each other, resulting in an extraordinary complex theory 
of carcinogenesis 21. 
As a complex tissue that does not respect the boundaries of normal tissue architecture, 
neoplasia is also regulated by non-cellular elements of the microenvironment which carry 
autocrine and paracrine signals. These signals that control normal and neoplastic tissue 
architecture imbalance (cell number and position) are transmitted from one cell to the other, 
through the stroma, in a very tightly regulated fashion, in which variations over time are a very 
important factor. Although, the effects of the non-cellular elements and their temporal variations 
are very difficult to access experimentally, the mechanisms involved in the maintenance of 
architecturally complex tissues should be investigated to achieve a more precise knowledge on 
neoplasia behavior 10,22,23. 
Recently, the characterization of the genomes of neoplastic cells microdissected from 
different areas of the same tumor has revealed intratumoral genetic heterogeneity, the 
recognition of which has relevant implications in cancer therapy as well as in the establishment 
of cancer study strategies 24,25. Accordingly, it is no longer sufficient to understand the biology of 
neoplasia just to keep the study focus on neoplastic cell genome but through the study of the 
cross-talk between neoplastic cells and their microenvironment 26. Moreover, the architectural 
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relationship of the different sub-clones in the neoplastic tissue might be important to the 
understanding of the disease, although this study is a very difficult one if we are considering the 
evaluation of several sub-clones. 
Using breast cancer as a model, we studied the role of tumor-based biomarkers in 
prognostication, exploring heterogeneity and tumor microenvironment. The study of morphology 
and the quantification of immunohistochemistry and in situ hybridization in different series of 
breast cancer cases, allowed us to correlate the status of human epidermal growth factor receptor 
2 (HER2) and programmed cell death-ligand 1 (PDL1) in breast cancer tissue, as well as the 
presence of stromal tumor-infiltrating lymphocytes (TILs) in the microenvironment, with 
clinicopathological features and patient´s outcome. In the end, we identify solutions to clinical-
based problems and attempted to shed some light in breast cancer carcinogenesis, hoping to help 
finding new directions for cancer research. 
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ABSTRACT 
Breast cancer is the most commonly diagnosed cancer in women, responsible for nearly 
one-third of all new cases diagnosed every year. The probability of developing breast cancer is 
between 10% and 15%, continuously increasing throughout life, being the main cause of cancer-
related death in women. Fortunately, more than half of breast cancer cases are diagnosed in a 
localized stage, which have a very high survival rate (more than 95%). Nevertheless, breast 
cancer is a heterogeneous group of lesions, comprising cancers with very different clinical 
outcomes. The overall goal of this work was to improve the value of prognostic and predictive 
biomarkers in breast cancer pathology, focusing on the study of human epidermal growth factor 
receptor 2 (HER2), stromal tumor-infiltrating lymphocytes (TILs) and programmed cell death-
ligand 1 (PDL1). 
Regarding the study of HER2 in breast cancer, one of the aims was to evaluate the impact 
of the recent changes introduced on the ASCO/CAP guidelines on the result of HER2 status. A 
series of primary invasive breast cancer cases was evaluated for HER2 amplification status 
according to both 2007 and 2013 ASCO/CAP guideline criteria. We observed a significant 
increase of HER2-positive cases and a decrease of HER2-equivocal cases. Reclassification of the 
cases from before the introduction of the new ASCO/CAP guideline with the 2013 ISH criteria 
resulted in an increase of cases with a HER2-positive status and in a decrease of HER2-
equivocal cases. In conclusion, the 2013 ASCO/CAP guideline selects more patients for anti-
HER2 targeted-therapy, mostly based on the modifications of criteria to evaluate ISH-HER2. 
The second aim was to evaluate the intraobserver and interobserver interpretative 
reproducibility of the HER2 gene amplification assay, by measuring the impact of counting 
increasing numbers of invasive cancer cells. A cohort of primary invasive breast cancer cases 
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were evaluated for HER2 gene amplification and the concordance among four observers with 
different levels of experience was determined. We observed an increase in the intraobserver 
concordance rate between the first and second evaluations with an increase in cell count. A count 
of 60 invasive cells was needed to obtain a concordance rate near 95%. The interobserver 
concordance rate of the HER2 test also increased with the increase in cell count, reaching at least 
a 90% concordance rate with a count of 60 invasive cells. In conclusion, the minimal cell number 
recommend in current guidelines should be raised. Moreover, cases with amplification levels 
close to the threshold should be subjected to a dual count from an experienced observer. 
The third aim was to evaluate and compare the HER2 gene amplification status in 
invasive and adjacent in situ breast carcinoma and to document the possible presence of HER2 
genetic heterogeneity in both components. A cohort of primary invasive carcinomas associated 
with carcinoma in situ were evaluated for HER2 gene amplification. A second cohort of all the 
cases with HER2 genetic heterogeneity since the introduction of the updated ASCO/CAP HER2 
guideline was also characterized, and an evaluation of the HER2 gene amplification in the 
carcinoma in situ component, if present, was also done. In the first cohort, the HER2 
amplification in the invasive carcinoma was positive in 13% of the cases, without the presence of 
HER2 genetic heterogeneity. All the cases had an associated carcinoma in situ with the same 
HER2 status as invasive carcinoma, with four cases of carcinoma in situ presenting HER2 
genetic heterogeneity. In these last cases, two cases presented HER2 gene amplification in the 
invasive carcinoma. The second cohort included 12 cases with HER2 genetic heterogeneity in a 
total of 1243 invasive carcinoma cases (0.97%). Additionally, we identified two cases associated 
with non-amplified carcinoma in situ. In conclusion, HER2 genetic heterogeneity is a rare event 
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in invasive carcinoma and can already be present in carcinoma in situ, not being an important 
step in the acquisition of invasive features. 
Regarding the study of stromal TILs and PDL1 expression, the aim was to assess the 
clinical impact of the expression of these biomarkers in breast cancer, namely their correlation 
with classical pathological features, cancer molecular subtypes, as well as patients’ prognosis. 
Two independent series of invasive breast cancer, one including DCIS pair-matched cases, were 
selected, and quantification of stromal TILs and expression of PDL1 was determined. In both 
cohorts evaluated, increased stromal TILs and PDL1 expression were present in about 10% of 
invasive carcinomas, being significantly associated with each other and both with grade 3 and 
triple-negative subtype. We observed a similar distribution of stromal TILs and PDL1 expression 
between carcinoma in situ and invasive carcinoma. Finally, we observed that increased stromal 
TILs and PDL1 expression were significantly associated with cancer stem cell markers, basal 
cell markers and vimentin expression. Interestingly, in invasive carcinoma cases with vimentin 
expression, increased stromal TILs, as well as decreased PDL1 expression, disclosed a better 
clinical outcome, independently of the main classical breast cancer prognostic factors. In 
conclusion, we have confirmed the association of stromal TILs and PDL1 expression with 
aggressive forms of breast cancer and that both are already found in in situ stages. We also 
showed that stromal TILs and PDL1 expression are associated with clinical outcome in cases 
enriched for a mesenchymal immunophenotype. We also described for the first time a close 
relationship between cancer stem cell markers and PDL1 expression. 
In this thesis, we try to clarify the value of prognostic and predictive biomarkers in breast 
cancer pathology. 
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RESUMO 
O carcinoma da mama é o carcinoma mais frequente em mulheres, responsável por quase 
um terço de todos os casos novos por ano. A probabilidade de desenvolver carcinoma da mama é 
entre 10% e 15%, aumentando continuamente ao longo da vida, sendo a principal causa de morte 
por cancro em mulheres. Felizmente, mais de metade dos casos são diagnosticados em estádios 
localizados, que têm uma taxa de sobrevivência muito alta (mais de 95%). No entanto, trata-se de 
um grupo heterogêneo de lesões, que inclui carcinomas com diferentes prognósticos clínicos. O 
principal objetivo deste trabalho foi melhorar o valor dos biomarcadores prognósticos e 
preditivos em patologia mamária, com especial foco no estudo do HER2 (human epidermial 
growth factor receptor 2), dos LITs estromais (linfócitos intra-tumorais) e do PDL1 
(programmed cell death-ligand 1). Em relação ao estudo do HER2, um dos objetivos foi avaliar 
o impacto das mudanças recentes introduzidas nas orientações ASCO/CAP sobre o resultado do 
HER2. Uma série de casos de carcinoma da mama invasivos foi avaliada para o estudo de 
ampliação de HER2 de acordo com os critérios de orientação ASCO/CAP de 2007 e 2013. 
Observámos um aumento significativo dos casos HER2-positivos e uma diminuição dos casos 
equívocos de HER2. A reclassificação dos casos antes da introdução da nova orientação 
ASCO/CAP com os critérios ISH de 2013 resultou num aumento de casos com status HER2-
positivo e numa diminuição dos casos equívocos de HER2. Em conclusão, a orientação 2013 
ASCO/CAP seleciona mais pacientes para terapia dirigida anti-HER2, principalmente com base 
nas modificações dos critérios ISH. 
O segundo objetivo foi avaliar a reprodutibilidade interpretativa intraobservador e 
interobservador do estudo de amplificação do gene HER2, medindo o impacto da contagem de 
um número crescente de células tumorais. Uma série de casos de carcinoma da mama invasivos 
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foi avaliada quanto à amplificação do gene HER2 e a concordância entre quatro observadores 
com diferentes níveis de experiência foi determinada. Observámos um aumento na taxa de 
concordância intraobservador entre a primeira e a segunda avaliação com o aumento na 
contagem de células. Foi necessária uma contagem de 60 células invasivas para obter uma taxa 
de concordância próxima a 95%. A taxa de concordância interobservador do teste HER2 também 
aumentou com o aumento da contagem celular, atingindo pelo menos uma taxa de concordância 
de 90% com uma contagem de 60 células invasivas. Em conclusão, o número mínimo de células 
recomendadas nas orientações atuais deve ser aumentado. Além disso, casos com níveis de 
amplificação próximos do limiar de positividade devem ser submetidos a uma contagem dupla 
por um observador mais experiente. 
O terceiro objetivo foi avaliar e comparar o estado de amplificação do gene HER2 em 
carcinoma da mama invasivo e in situ adjacente, documentando a possível presença de 
heterogeneidade genética HER2 em ambos os componentes. Uma série de carcinomas invasivos 
primários associados a carcinoma in situ foi avaliada quanto à amplificação do gene HER2. Uma 
segunda série compreendendo todos os casos com heterogeneidade genética HER2 desde a 
introdução da nova orientação ASCO/CAP também foi caracterizada, avaliando a amplificação 
do gene HER2 no componente in situ do carcinoma, se presente. Na primeira série, a 
amplificação HER2 no carcinoma invasivo foi positiva em 13% dos casos, sem a presença de 
heterogeneidade genética. Todos os casos apresentaram carcinoma invasivo e in situ com o 
mesmo status de HER2, com quatro casos de carcinoma in situ apresentando heterogeneidade 
genética. Nestes últimos casos, dois casos apresentaram amplificação HER2 no carcinoma 
invasivo. A segunda série incluiu 12 casos com heterogeneidade genética HER2, num total de 
1243 casos (0,97%). Além disso, identificámos ainda dois casos associados a carcinoma in situ 
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não amplificado. Em conclusão, a heterogeneidade genética HER2 é um evento raro no 
carcinoma invasivo e já pode estar presente no carcinoma in situ, não sendo um passo importante 
na aquisição de características invasivas. 
No que se refere ao estudo dos LITs estromais e da expressão de PDL1, o objetivo foi 
avaliar o impacto clínico da expressão desses biomarcadores no carcinoma da mama, 
nomeadamente correlacionar com características anátomo-patológicas clássicas, com os subtipos 
moleculares de carcinoma, bem como com o prognóstico dos pacientes. Foram selecionadas duas 
séries independentes de carcinoma da mama invasivo, uma incluindo casos com carcinoma in 
situ, e foi determinada a quantificação dos LITs estromais e a expressão de PDL1. Em ambas as 
séries avaliadas, o aumento de LITs estromais e a expressão de PDL1 estavam presentes em 
cerca de 10% de carcinomas invasivos, estando significativamente associados entre si e ambos 
com o grau histológico 3 e o subtipo triplo negativo. Observámos uma distribuição semelhante 
de LITs estromais e expressão de PDL1 entre carcinoma in situ e carcinoma invasivo. 
Finalmente, observámos que o aumento de LITs estromais e a expressão de PDL1 estavam 
significativamente associados com os marcadores de células estaminais, marcadores de células 
basais e expressão de vimentina. Curiosamente, nos casos de carcinoma invasivo com expressão 
de vimentina, o aumento dos LITs estromais, bem como a diminuição da expressão de PDL1, 
revelaram um melhor prognóstico clínico, independentemente dos principais fatores prognósticos 
do carcinoma da mama. Em conclusão, confirmámos a associação de LITs estromais e expressão 
de PDL1 com formas agressivas de carcinoma da mama e que ambos já se encontram em fases in 
situ. Também mostrámos que os LITs estromais e a expressão de PDL1 estão associados ao 
prognóstico clínico em casos com um imunofenótipo mesenquimatoso. Também descrevemos 
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pela primeira vez uma estreita relação entre os marcadores de células estaminais e a expressão de 
PDL1. 
Nesta tese, tentámos clarificar o valor dos biomarcadores prognósticos e preditivos em 
patologia mamária. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1 BREAST CANCER 
 
1.1.1 Epidemiology 
The lifetime likelihood of being detected with cancer in the general population is about 40%, 
being slightly higher for men than for women, making cancer an important public health problem 
in western world. As such, cancer is the second leading cause of death, following cardiovascular 
diseases, accounting for about 25% of all deaths, and already the primary reason of mortality in 
the 5th to the 8th decade of life 27,28. 
The most frequent cancers diagnosed in men are prostate, lung and bronchus, and colorectal 
cancers, representing nearly half of all cancer cases (44%). On the other hand, in women, breast, 
lung and bronchus, and colorectal cancers are the most common types of cancer, together 
accounting for about 50% of the cases (Figure 1). Prostate and breast cancers alone are 
responsible for more than 20% and nearly one-third of new cancer diagnoses in men and women, 
respectively 27. 
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Figure 1 
Leading cancer types for the estimated new cancer cases by sex (from Siegel et al 27) 
 
Although the global cancer incidence rate has been declining since the beginning of the 
millennium, in women it has remained constant 27. The decline has been mainly attributed to the 
decrease of incidence of prostate cancer, as well as colorectal and lung and bronchus cancers in 
men. The main reasons are due to the falling of routine prostate cancer screening with the PSA 
test, the introduction of a colorectal cancer screening by colonoscopy, which can detect and 
remove precancerous lesions, and, lastly, the reduction in smoking habits 27. However, the 
increased cancer incidence in women in the 80s was partially due to the increase in lung and 
breast cancers, reflecting smoking prevalence and deviations in female reproductive patterns as 
well as the increased detection of asymptomatic disease during mammography screening 27. 
In the last decades, it has been observed, in both genders, a constant decrease in overall 
cancer death rate, most pronounced in men 27. In women, the decay in overall cancer death rate 
reflects the decrease in death rates of breast and colorectal cancers, mostly because of 
developments in early detection through screening programs and improvements in treatment 27. 
Therefore, the most frequent causes of cancer death in men are lung and bronchus, prostate and 
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colorectal cancers whereas in women are lung and bronchus, breast and colorectal cancers 
(Figure 2) 27. 
 
 
 
 
 
 
 
 
 
Figure 2 
Leading cancer types for the estimated deaths by sex (from Siegel et al 27) 
 
In Portugal, as in several western European countries, breast cancer (BC) is the most 
commonly diagnosed cancer, representing about 30% of all cancers in women, followed by 
colorectal, thyroid and gastric cancers, representing nearly 60% of all cancer cases. In men, 
prostate, colorectal and lung and bronchus cancers are the most frequent cancers diagnosed, 
together accounting for more than 50% of the cases. Consequently, the main causes of cancer-
related death in men are lung and bronchus, prostate and colorectal cancers whereas in women 
are breast, colorectal and gastric cancers 29. 
In women, the probability of developing BC in their lifetime is between 10% and 15%, 
continuously increasing throughout life 27. BC is identified at a younger age than other frequent 
cancers, with a median age of diagnosis at 61 years, with about 20% of the cases between ages 
30 and 49 years 30. Remarkably, in adults younger than 50 years, the probability of developing 
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cancer is actually higher for women than for men due to the prevalence of breast, genital and 
thyroid cancers in young women. Concerning the median age of BC death, that is at 68 years, 
with a mortality rate about 15% of the incidence rate and a wide variation according to the 
available treatment 27,31. Notably, BC is the most frequent cause of cancer death in women aged 
between 20 and 59 years old 27. 
Of notice, there are important discrepancies to be considered amongst different ethnicities. 
For example, black women have slightly lower BC incidence rate than white women, whereas 
BC death rate is about 40% higher. The precise explanation remains unknown, although 
probably represents a mixture of biologic and environmental factors, including differences in the 
molecular subtype and stage at diagnosis, as well as higher prevalence of comorbidities, limited 
access to care and differences in response to therapy. Regarding the molecular subtype (for 
details see below), black women have the lowest proportion of luminal A and nearly the double 
proportion of triple-negative BC, which explains the higher death rate amongst them 31. 
More than half of BC cases are diagnosed in a localized stage (about 60%), a third of patients 
present regional metastases and only less than 10% are detected with distant metastases at 
diagnosis. Importantly, the 5-year survival rate decreases from more than 95% in localized stages 
to 85% in regional stages, and to 25% in patients with distant metastases 27. 
When a localized BC is diagnosed, breast conserving surgery (BCS), followed by radiation 
therapy, has the same long-term survival than a total mastectomy 32,33. Nevertheless, total 
mastectomy is still required for a proportion of patients with aggressive disease (such as locally 
advanced stage, large or multiple tumors) or when post-surgery radiation is not possible (such as 
preexisting medical condition) 34. Curiously, an increasingly number of women eligible for BCS 
choose total mastectomy due to fear of recurrence and side effects of radiation therapy 34. 
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Additionally, in almost 15 years, contralateral prophylactic mastectomy has dramatically 
increased from 5% to 30% 35. 
In the last 40 years, the overall 5-year relative survival rate for BC has improved from about 
75% to nearly 90%, mostly attributed to improvements in earlier detection and treatment (such as 
chemotherapy, hormone therapy and targeted therapy) 36. The 5-year, 10-year, and 15-year 
relative survival rates for BC are 89%, 83%, and 78%, respectively 30. 
 
1.1.2 Risk factors 
Studies of populations migrating from low- to high-risk areas of developing BC show that the 
risk for migrant populations increases to similar levels of the host country within two 
generations, suggesting that environmental factors play an important role in the etiology of BC 
37. 
Specific environmental factors identified in the development of BC include high-calorie diet, 
rich in animal fat and proteins, and lack of physical exercise 38,39. Additionally, alcohol 
consumption has also been associated with increased risk of BC 40,41. However, all these factors 
are associated with lower risk of BC, implying that BC has a multifactorial origin. 
More relevant is the unequivocal evidence from epidemiologic studies that both endogenous 
and exogenous sex hormones contribute to the origin of BC 42. Reproductive risk patterns 
include early menarche, nulliparous, late motherhood, fewer offspring and late menopause 27. 
Additionally, breast feeding for at least four months is usually related with a decrease risk of 
developing BC 43-45. Additionally, oral contraceptives were thought to increase the risk of BC 
due to the presence of estrogen and progestin (a synthetic progestogen similar to progesterone) 
46. However, recent studies have shown that the risk of developing BC associated with the use of 
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oral contraceptives is very small, if any, even in women who have been using it for prolonged 
periods of time 47,48. Regarding hormone-replacement therapy in postmenopausal women, 
researchers observed a significant link between unopposed estrogen therapy and risk of BC, 
mainly among leaner women with the longest duration of its use 43,49. Still, the above therapy is 
usually given with the addition of a progestin, which decreases the increased risk of endometrial 
carcinoma associated with the use of unopposed estrogen regimens. Nevertheless, not only the 
impact of progestin does not have a BC protective effect, as the relative risk of BC for users of 
estrogen-plus-progestin combinations was significantly higher than for users of estrogen-only 
preparations 43,49,50. 
Although body mass index (BMI) is also positively associated to risk of postmenopausal BC, 
it is inversely associated to risk of premenopausal BC 51. In fact, overweight and obesity is 
thought to be responsible for about 10% of cases of postmenopausal BC 37. Additionally, weight 
loss after menopause is linked with a decreased risk of BC 52. The reduced risk of premenopausal 
BC in heavier women is probably related to the irregular menstrual cycles and increased 
anovulatory cycles, which reduces the cumulative exposure to sex hormones and, consequently, 
the risk for hormone sensitive tumors 53. Moreover, obesity is linked with increased levels of 
insulin and related growth factors, which can increase the risk for some BC subtypes 54,55. 
Finally, genetic susceptibility also impacts on the risk of BC, with near 10% of BC cases 
being triggered by inherited germline mutations 5. Most familial BC arises in the background of 
the hereditary breast-ovarian cancer syndrome (about 90%), which is caused by germline 
mutations in tumor suppressor genes (BRCA1 and BRCA2) in an autosomal dominant manner 
with variable penetrance, with tumors showing somatic loss of the second allele. Interestingly, 
BRCA1 and BRCA2 BCs are very different regarding their expression of hormone receptors. 
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BRCA1 BCs are usually estrogen receptor (ER) negative, whereas BRCA2 are typically ER 
positive 56,57. Additionally, there are several inherited syndromes in which BC can be a 
manifestation, which include Li-Fraumeni syndrome (TP53 mutation), Cowden syndrome 
(PTEN mutation), Peutz-Jeghers syndrome (STK11 mutation), hereditary diffuse gastric cancer 
syndrome (CDH1 mutation) and ataxia-telangiectasia syndrome (ATM mutation) 5. 
Evaluation for hereditary BC predisposition is an essential component of the clinical BC 
management. Considering just features that a pathologist can identify, according to NCCN 
guidelines, germ line testing for BRCA should be recommended in patients with: BC at age ≤ 45 
years, multiple BC at age ≤ 50 years, triple-negative BC at age ≤ 60 years, male BC and ovarian 
cancer. Additionally, germ line testing for TP53 should also be recommended in BC at age ≤ 31 
years 58. 
The identification of a germline mutation can increase the screening and treatment of the 
patient and their relatives, which can take risk-reducing salpingo-oophorectomy and bilateral 
mastectomy, procedures known to increase life expectancy 5. 
 
1.1.3 Histological classification and grading 
Invasive BC is a heterogeneous group of lesions and the basis for its classification includes 
the evaluation of histological criteria mostly based on morphology (architectural patterns and 
cytological features). Classical pathological features assessed such as histological type and 
grade, tumor size and axillary lymph-node involvement are known to correlate with clinical 
prognosis and, along with immunohistochemical analyses, provide the basis for therapeutic 
selection performed by clinicians 59,60. 
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According to the World Health Organization (WHO) classification, the most frequent type of 
invasive BC is invasive carcinoma of no special type (NST) representing about 75% of the cases 
37. Regarding special subtypes, the most common is the invasive lobular carcinoma (Figure 3A), 
accounting for 5% to 15% of the cases, and the remaining 10% to 20% of the cases incorporates 
more than 15 special subtypes of BC, some of which associated to an excellent prognosis, such 
as tubular, mucinous and papillary encapsulated carcinomas (Figure 3B to 3D, respectively), and 
others with unfavorable prognosis, like metaplastic or invasive micropapillary carcinomas 
(Figure 3E and 3F, respectively). As such, BC histologic classification has been shown to be an 
important prognostic factor correlating with long term survival 61. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
Examples of special BC histologic subtypes 
A: lobular carcinoma; B: tubular carcinoma; C: mucinous carcinoma; D: papillary encapsulated carcinoma; E: 
metaplasic carcinoma; F: micropapillary carcinoma; G: medullary carcinoma; H: adenoid cystic carcinoma (from 
personal cases) 
 
All invasive breast carcinomas should be graded according to the Nottingham grading system 
(NGS – Elston-Ellis modification of Scarff-Bloom-Richardson grading system) 62. NGS is based 
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on a semi-quantitative evaluation of three morphological characteristics: the amount of glandular 
and tubular differentiation, the degree of nuclear atypia and the mitotic rate. Each feature is 
assessed independently in a scoring system of 1 to 3, and the scores are added to produce a 
grade. Glandular and tubular differentiation is evaluated over the whole tumor in a low-power 
view, where only structures with central lumina bordered by polarized cells are accepted. 
Nuclear atypia is assessed in the area with tumor cells presenting a high degree of pleomorphism, 
by comparing the regularity of nuclear size and shape with nuclei of epithelial cells in benign 
adjacent breast parenchyma. Lastly, mitotic rate is counted in an area showing the most 
proliferation activity, involving the standardization to a fixed field area and is depicted as the 
total number of mitotic figures in 10 high-power fields (HPF). Only clearly identifiable mitotic 
figures should be accepted, excluding hyperchromatic, karyorrhectic or apoptotic nuclei. At last, 
the final grading corresponds to the addition of the three individual scores: Grade 1 (score 3 to 
5), Grade 2 (score 6 or 7) and Grade 3 (score 8 or 9) (Figure 4) 37. 
 
 
 
 
 
 
 
Figure 4 
Histological grade of breast cancer as assessed by the Nottingham Grading System (from Rakha et al 59) 
 
Numerous studies have shown that histological grade is an independent prognostic factor in 
BC, equivalent to that of lymph node status and even greater than that of tumor size 63. 
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Furthermore, low-grade and high-grade tumors show distinct molecular profiles at the genomic 
and transcriptomic levels, suggesting that they probably represent distinct diseases 64. 
Additionally, it has been demonstrated a significant association between histological grade and 
survival of patients with invasive BC 59,65. Several studies applying molecular signatures showed 
that histological grade is an independent prognostic factor for ER-positive BC 66. 
Histological grade should also be performed in needle-core biopsy (NCB) samples because it 
shows good concordance rate with surgical excision specimens 59,67. Typically, the discordant 
cases are due to the decreased ability to evaluate mitotic activity on NCB, underestimating the 
true histological grade of the tumor 67,68. As such, the upgrade is usually seen in grade 1 or 2 in 
the NCB to grade 2 or 3 in the surgical specimen, respectively. Despite these limitations, 
evaluation of histological grade on NCB provides predictive information for neoadjuvant 
chemotherapy, independently of the type of regimen used for the treatment 69. 
One of the critics towards NGS is the suboptimal inter- and intra-observer concordance rate, 
with most of the studies showing moderate agreement, especially in grade 2 tumors 59. It is well 
known that histological grading is dependent on pre-analytical parameters, such as ischemic time 
and fixation time, and that its impairment usually compromises the evaluation of the mitotic 
count, one of the features evaluated in NGS, leading to a downregulation of the grade 59. 
Fortunately, the application of optimized and standardized methods can provide an improvement 
of agreement rates in histological grading. 
 
1.1.4 Molecular classification 
More than 15 years ago, gene expression profiling through microarray analysis provided a 
molecular classification of invasive BC with distinct clinical outcomes and response to therapy 
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70. Hierarchical cluster analysis included genes that varied more in expression between different 
tumors than between repeated samples from the same tumor (known as intrinsic genes). The 
subsequent molecular classification revealed two important BC subgroups: ER positive and ER 
negative (Figure 5). Each subgroup is composed of two intrinsic subtypes, namely luminal A and 
B, and human epidermal growth factor receptor 2 (HER2)-overexpressing and basal-like (or 
triple-negative), respectively 71-73. In general, about three quarters of BC are classified as luminal 
A, about 10% as basal-like and luminal B each, and about 5% as HER2-overexpressing 31. 
 
 
 
 
 
 
 
 
Figure 5 
Gene expression patterns analyzed by hierarchical clustering (from Sorlie et al 72) 
 
Luminal BC has a bimodal age distribution with main late modes just below age 70 years and 
minor modes around age 50 years, whereas basal-like BC has a predominant early-onset mode 
near age 50 years. Curiously, the age distribution of HER2-positive BC lays between the luminal 
and basal-like BC. Regarding BC-specific death, luminal A BC have a relatively constant death 
rate of about 2% every year after BC diagnosis, while luminal B, HER2-positive and basal-like 
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present a death rate peak around 8% per year two years after initial diagnosis and then a strong 
decline 74. 
Usually, luminal A BC are smaller, with lower histological grade and less likely to have 
lymph node metastases 43. Consequently, it is associated with higher survival rates mostly due to 
the predictive response to hormonal therapy 75. On the contrary, luminal B, HER2-
overexpressing and basal-like are more often high grade with more frequent lymph node and 
distant metastases 43. 
The complexity of BC is not entirely understood just by examining the histopathology 
features and the gene expression profiling 76. The characterization of structural DNA changes by 
array comparative genomic hybridization and next-generation sequencing analysis has provided 
additional prognostic information 77,78. 
The METABRIC group (Molecular Taxonomy of Breast Cancer International Consortium) 
has characterized the genomic and transcriptomic architecture of near 2000 BCs to evaluate the 
impact of genomic changes on the transcriptome and were able to identify 10 new molecular 
subgroups (integrative clusters) each associated with distinct genomic aberrations, gene 
expression profiling and clinical outcome (Figure 6) 76,79. 
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Figure 6 
The integrative subgroups (from Curtis et al 79) 
 
Briefly, in this classification, the 3 subgroups with better clinical prognosis (integrative 
cluster 3, 7 and 8) included predominately luminal A cases with low histological grade, resulting 
in a disease-specific survival rate at 10 years of 80-90%. Interestingly, the METABRIC group 
also identified a specific subgroup of BC (integrative cluster 4) composed by both ER-positive 
and ER-negative cases (including basal-like) associated with favorable prognosis with a disease-
specific survival rate at 10 years near 80%. Several of these cases displayed abundant 
lymphocytic infiltration, low levels of genomic instability and about 20% revealed deletions at 
the T-cell receptor (TCR) loci. Finally, it was possible to distinguish a subgroup of luminal A 
and B tumors (integrative cluster 2) associated with the worst disease-specific survival rate at 10 
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years of ER-positive cases (about 50%). The genetic alterations apparently responsible for the 
aggressive behavior were the relatively high levels of genomic instability of these tumors and the 
amplification of 11q13/14 which includes genes involved in cell-cycle regulation (such as 
CCND1 – cyclin D1) 76. 
Luminal BC cases are the most heterogeneous regarding gene expression profiling, mutation 
range, copy number changes and clinical outcomes. The most frequently genomic alterations in 
these tumors include mutations in PIK3CA, TP53, GATA3 and MAP3K1 genes, amplifications of 
CCND1, MDM2 and CDK4, as well as deletions of PTEN and INPP4B 78. Besides HER2 gene 
amplification, the most commonly genomic alterations in HER2-positive BC include mutations 
in TP53 and PIK3CA genes, amplifications of CCND1, MDM2 and CDK4, as well as deletions 
of PTEN and INPP4B 78. The overlap of genomic alterations between HER2-positive and 
luminal BC cases comes from the fact that the former is composed of both ER-negative and ER-
positive cases in almost evenly amounts 76. Finally, the most frequently genomic alterations in 
basal-like BC include mutations in TP53 gene, amplifications of MDM2 and MYC, as well as 
deletions of PTEN, INPP4B and RB1 78. 
Gene expression profiling analysis has also been applied to carcinoma in situ (CIS), which 
identified the same intrinsic subtypes as the molecular classification described for invasive BC 
and even allowing discrimination between low-grade and high-grade CIS 80,81. Remarkably, CIS 
preferentially cluster with invasive lesions of similar grade, implying that CIS are precursors of 
invasive BC with similar grade progressing along different pathways 82. Additionally, molecular 
heterogeneity from gene expression analysis has also shown that there are more differences 
between separate molecular subgroups than between in situ and invasive lesions within a 
subgroup 83. 
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Lastly, while invasive carcinomas of NST and invasive lobular carcinomas comprise 
different molecular subtypes, the remaining histological special types are very homogeneous, 
belonging predominantly to one molecular subtype, supporting the existence of these histological 
specific entities. Furthermore, it was also showed that basal-like tumors usually associated with 
poor prognosis included histological special types with favorable outcome, such as medullary 
and adenoid cystic carcinomas (Figure 3G and 3H, respectively) 84. 
Comparative studies have shown that different molecular tests evaluate distinct groups of 
genes, the majority of which with little overlap amongst them, and that different algorithms used 
for molecular classification create unreliable results, achieving only moderate agreement rates 85. 
Curiously, although several thousands of genes can be differentially expressed between different 
tissues, any randomly selected set of genes that are large enough (as few as 100 genes) can 
mimic the classification achieved with the full set of genes 86. Interestingly, only basal-like 
subtype reveals high concordance rate when compared with different molecular tests, revealing 
that the other subtypes are critically dependent on the applied algorithm and that the results from 
different studies should not be generalized. 
Concerning HER2 subtype, the problem of molecular classification has additional clinical 
implications. Cases classified as HER2-positive by FDA-approved methods 
(immunohistochemistry (IHC) and in situ hybridization (ISH)) can be classified as different 
molecular subtypes by gene profiling analysis in a considerable proportion of cases 85. As such, 
the molecular classification is not equivalent to the clinical identification of HER2-positive BC 
and should not be used to select patients for targeted therapy. 
As mentioned before, HER2-positive BCs are heterogeneous, including both ER-positive and 
ER-negative cases, with significant differences on their response to targeted therapies. In fact, 
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various clinical trials have shown that the variability in response to trastuzumab depends on ER 
status of the tumors 87-89. The Breast Cancer Working Group from the International Cancer 
Genome Consortium (ICGC) studied a series of HER2-positive BC cases, identifying 4 groups 
(A to D) of gene expression, each with typical genomic alterations. The first two (A and B) were 
mainly composed of ER-positive and luminal B subtypes, whereas the last two (C and D) were 
typically composed of ER-negative and HER2-enriched subtype. Notably, group A did not show 
TP53 mutations while group D lacked PIK3CA mutations, in comparison with the other groups 
90. Considering all these molecular studies, HER2-positive BC rather than represent a specific 
oncogenic pathway, is just a subtype characterized by a specific gene amplification that can 
appear in both luminal (ER-positive) and basal (ER-negative) BC progenitor cells. 
Additionally, the study could characterize more accurately the HER2 amplicon region, which 
included 6 genes: TCAP, PNMT, PGAP3, MIEN1, GRB7 and, evidently, HER2 90. Interestingly, 
the genomic alterations present in various tumors were consistent with a breakage-fusion-bridge 
(BFB) cycle. BFB is a DNA amplification mechanism that initiates with a double-strand break 
followed by the fusion of the two loose ends of the sister chromatids during replication. During 
mitosis, in the next anaphase, the centromere breaks and sister chromatids are pulled in the 
opposite direction forming a bridge as the ends are fused and a new break is induced at a random 
location, perpetuating the cycle. Consequently, at each cycle, segments of DNA are unevenly 
inherited by daughter cells leading to a population of cells with heterogenous copy numbers. As 
such, genomic segments amplified by BFB mechanism display two signatures: fold-back 
inversions in the region containing breakpoints (palindromic sequences) and copy number 
heterogeneity 91. Nevertheless, not all cases were expected to have occurred through a BFB 
45 
 
cycle, and different gene amplification mechanisms, like the formation of double-minutes 
chromosomes, could also be involved in the formation of HER2-positive BC 90. 
Additional to the identification of the molecular intrinsic subtypes, several studies of gene 
expression profiling have also identified groups of genes that are able to provide prognostic and 
predictive information on BC patients. Numerous studies have found similar prognostic 
performances between different molecular signatures (in around 80% of the cases), suggesting 
robustness across several genomic platforms, especially regarding poor outcome subtypes (such 
as basal-like, HER2-overexpression and luminal B) 92,93. Not unexpectedly, it is among luminal 
A tumors that greater variability in the outcome has been found 92. Currently, according to 
ASCO guidelines, clinicians may use the 21-gene recurrence score (Oncotype DX), the 12-gene 
risk score (EndoPredict), the Prediction Analysis of Microarray-50 (PAM50) risk of recurrence 
score and the Breast Cancer Index to guide decisions on adjuvant systemic chemotherapy only in 
ER-positive, HER2-negative and node-negative BC patients. In the remaining situations (ER-
negative, HER2-positive and node-positive BCs), these molecular signatures should not be used 
in the above setting 94. 
Finally, all the components within a tumor sample (neoplastic and non-neoplastic cells) 
contribute to the expression profiling analysis and the relative amount of these elements have 
significant effects on the final molecular classification 95. As such, the contamination with 
normal breast parenchyma, proliferating stromal cells or inflammatory infiltrate can switch the 
molecular classification based on the evaluation of ER- and proliferation-related genes. This 
weakness probably accounts for the existence of a “normal breast-like” cancer in molecular 
profiling, not mentioned earlier, which disappears after microdissection of the tumor samples 
85,96. 
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1.1.5 Prognostic and predictive biomarkers 
The current cancer care guidelines for BC recommend that estrogen receptor (ER), 
progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) status must 
be routinely determined in all patients with invasive BC, BC recurrences and BC metastases 75,97. 
These guidelines were published to improve laboratory performance in the determination of 
these markers, which provide useful predictive information regarding response to targeted 
therapy. 
The importance of measuring ER expression in BC samples derives from the fact that ER-
positive BCs, representing about 75-80% of all BC cases, benefit from endocrine therapy 
whereas ER-negative BCs do not 98-100. Early studies suggested that patients with ER-
positive/PgR-negative BC could have a worse prognosis than patients with ER-positive/PgR-
positive BC, probably because PgR expression is estrogen dependent and, thus, would serve as a 
marker of an undamaged estrogen response pathway 101,102. Nevertheless, patients with ER-
positive/PgR-negative BC should not be excluded from endocrine therapy, nor the curious ER-
negative/PgR-positive BC cases 100. 
The same principle applies to HER2 expression, where numerous clinical trials have 
demonstrated that HER2-targeted therapy given during and/or after chemotherapy improves 
progression-free survival and overall survival only in patients with BC disclosing HER2 gene 
amplification/protein overexpression 103-106. For this reason, HER2 is a helpful marker for 
therapy decision making in patients with BC and the accurate assessment of HER2 status 
identifies patients who are most likely to benefit from targeted therapy. 
47 
 
Gene expression profiling studies have revealed that the prognostic impact of the gene 
signatures derives mainly from the proliferation-related genes. Interestingly, when these 
signatures are split into ones with and without proliferation-related genes, only the gene 
signatures with proliferation-related genes maintain prognostic information, sometimes even 
improving their performance 93. 
One of the most frequent assessments of cell proliferation in formalin-fixed paraffin-
embedded (FFPE) tumor samples consists in the evaluation by IHC of Ki67 antigen, a nuclear 
protein expressed in all phases of the cell cycle other than G0 phase 107. 
In fact, the St Gallen BC consensus allows the discrimination of ER-positive tumors between 
luminal A-like (low proliferation and better prognosis) and luminal B-like (higher proliferation 
and worse prognosis) BCs by IHC testing, although the use of Ki67 should be interpreted 
considering the knowledge of the local laboratory values and the fact that significant discordance 
can exist between the gene-based and IHC-based expression profiles for the classification of 
tumors into the molecular intrinsic subtypes 60. 
Nevertheless, although IHC measurements of proliferative activity using the Ki67 antibody 
convey prognostic information, as well as the high Ki67 values predict the benefit of adding 
chemotherapy to BC patients, the identification of suitable cutoffs for clinical management has 
been a challenging task 108,109. The main problem derives from both pre-analytic and analytic 
methodologic variations. First, there is few data on the effects of ischemic time, duration of 
fixation and antigen retrieval in the staining of Ki67; second, there is a lack of consensus, despite 
the existence of international guidelines, on which part of the tumor should be scored (periphery 
of the tumor, hot spots or overall average), which introduces significant variability across 
laboratories 110,111. 
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The Breast Cancer Working Group has already provided guidelines for analysis and reporting 
Ki67 expression 111. After the implementation of the guidelines, which aimed to reduce 
preanalytical and analytical variations in the evaluation of Ki67, a reproducibility study of Ki67 
in BC among experienced pathology laboratories from North America and Europe, with a record 
of publishing literature regarding the clinical usefulness of Ki67, was performed. The study 
found high intra-laboratory reproducibility but only moderate inter-laboratory reproducibility of 
Ki67 expression in BC making its use difficult in clinical decision-making settings 110. 
Interestingly, the laboratories that showed highest intra-laboratory reproducibility were the ones 
with the highest inter-laboratory reproducibility, which preferentially used formal counting 
methods rather than visual estimation measurements 110. 
For all the reasons mentioned above, routine testing of BC samples for Ki67 expression is 
optional and not currently recommended by either the College of American Pathologists (CAP) 
or the American Society of Clinical Oncology (ASCO) or the National Comprehensive Cancer 
Network (NCCN) guidelines 94,112. Nevertheless, the lack of assess to molecular tests in clinical 
practice, only available in international reference centers and still expensive, supports the request 
by oncologists for Ki67 evaluation in specific cases to assist in treatment decision scenarios. 
Therefore, in clinical practice, IHC can be used to classify BC cases into the molecular 
intrinsic subtypes routinely evaluating ER, PgR, HER2 and Ki67 60. This approach to molecular 
classification has been shown to be clinically useful 113,114. Accordingly, BC cases can be 
subdivided into luminal tumors which are recognized by the presence of ER and/or PgR 
expression 115. Moreover, proliferation markers, such as Ki-67, can sub-classify luminal tumors 
into luminal A (low-proliferation) and luminal B (high-proliferation) cases 116. Luminal B tumors 
also include cases with both hormone-receptor and HER2 positivity. The ER-negative subgroup 
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can be additionally split based on the expression of HER2 giving origin to HER2-positive and 
triple-negative BC (TNBC), usually also expressing basal cell markers. 
Remarkably, no international consensus still exists regarding which basal cell markers should 
be used to define basal-like tumors 117. The suggested IHC markers include the expression of 
high-molecular-weight cytokeratins (CK5/6, CK14 or CK17), epidermal growth factor receptor 
(EGFR) and p-cadherin 118-120. 
Although the resemblance of TNBC and basal-like BC are striking, these two nomenclatures 
are not identical, even though it has been used synonymously. Nevertheless, most TNBC express 
basal-like phenotype in gene expression profiling (around 70%) and most basal-like tumors are 
negative for ER, PgR and HER2 (near 80%) 121. 
In the same way, almost 25% of clinically ER-positive BCs are classified by gene expression 
profiling as non-luminal BC and almost half of clinically HER2-positive BCs are not classified 
as HER2-overexpression by molecular classification 96,122. Interestingly, when molecular 
profiling analysis is compared to current clinicopathological characteristics plus IHC routinely 
used, it has been shown that the difference in prognostic information in BC patients is minimal, 
with most of the benefit limited to ER-positive tumors 123. 
Other biomarkers have been recently studied in BC, which include cancer stem cell (CSC) 
markers. CSCs are responsible for tumor growth, progression and metastasis due to their stem 
cell-like features: self-renewal and aberrant differentiation.124 Additionally, it has been shown 
that CSCs are more resilient to several types of treatment, such as radio and chemotherapy 125-127. 
In BC, CD44 was found to be associated with stem cell-like features and CD24 with 
differentiated epithelium.128 Consequently, the combination of these cell surface markers 
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(CD44+/CD24-/low) was considered a marker of CSCs.129-131 Additionally, CD49f and ALDH1 
have also been demonstrated as CSC markers, being associated to worse prognosis.132-135 
Within these biomarkers, and including some more, some have shown independent 
prognostic information, and much more will certainly be studied in the future. In this 
introduction, we chose to mention the biomarkers that are currently mandatory in the evaluation 
of BC cases according to the most updated international guidelines, as well as the ones that are 
relevant to understand this thesis. Nonetheless, the major limitation to the inclusion of a new 
biomarker in the clinical practice, despite the obvious increase in the cost of the pathology 
examination, is the usual absence of predictive information regarding current BC treatment. The 
biomarkers that prove to add predictive information, specially related to targeted therapy, will 
immediately be introduced in the clinical practice. 
 
1.2 HER2 oncogene 
HER2 (ERBB2, formerly HER2/neu, c-erbB2) is a member of a family of 4 
transmembrane protein receptors with tyrosine kinase activity (human epidermal growth factor 
receptor 1 to 4 - HER1 to HER4) 136. This 185 kilodalton (kDa) glycoprotein had several names 
throughout time as it was being identified in several types of cells. The name Neu appeared 
because it was originally identified in ethylnitrosourea-induced rat neuroblatomas. In addition, 
the human gene was defined as ErbB-2 due to its homology with ErbB (avian erythroblastosis 
oncogene B) 137. 
The binding of a ligand to the extracellular domains of HER proteins promote a 
conformational change that will allow its dimerization and subsequent transphosphorylation of 
their intracellular domains. With no known ligand, HER2 is assumed to play a regulatory role 
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through its heterodimerization with other HER family members or homodimerization with itself 
when expressed at very high levels 138. Additionally, HER2 can also heterodimerize with other 
membrane receptors, for example with insulin-like growth factor receptor I 139. Furthermore, 
HER2 has the strongest catalytic kinase activity and, as such, HER2 heterodimers have the 
strongest signaling activity. The phosphorylated tyrosine residues activate several downstream 
intracellular signaling molecules, including the PI3K/AKT, RAS/MEK/MAPK and STAT kinase 
cascades, ultimately regulating transcription factors of genes involved in cell proliferation, 
survival, differentiation, angiogenesis, invasion and metastasis (Figure 7) 136. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 
The HER signaling network and HER2-targeted therapy in breast cancer (from Gutierrez and Schiff 136) 
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The HER2 gene is located on the long arm of chromosome 17 (17q12) and was found to 
be amplified in human BC cell line more than 30 years ago, and shortly proved to be highly 
relevant in the pathogenesis and progression of BC 140,141. Additionally, numerous studies have 
shown that HER2 gene amplification can already be present in CIS of the breast, the immediate 
precursor of invasive carcinoma, and that frequently HER2 status is concordant with the invasive 
component 142,143. 
In invasive BC, HER2 is amplified and/or overexpressed in approximately 15-20% of the 
cases, representing a clinically important subset of BC associated with higher metastatic 
potential and poor clinical outcome but also with a high likelihood of response to HER2-targeted 
therapy 104,141,144-148. HER2-positve BCs are correlated with particular pathological 
characteristics, such as high histologic grade, low ER and PgR expression, and high proliferation 
rates. Clinically, these BCs show a tendency to metastasize to the central nervous system and to 
visceral organs, as well as present an increased sensitivity to doxorubicin and resistance to 
endocrine therapy 136. The increased sensitivity to doxorubicin is presumably explained by the 
co-amplification of topoisomerase-2 gene (TOP2A), which is located near the HER2 locus 149. 
Importantly, the poor patient prognosis in HER2-positive BC is deeply overcome with 
HER2 targeting therapy. Available therapeutic drugs for HER2-positive BC include humanized 
monoclonal antibodies (trastuzumab and pertuzumab), tyrosine kinase inhibitors (lapatinib) and 
trastuzumab-emtansine (T-DM1), an antibody-drug conjugate 137. Trastuzumab, the first 
antibody targeting HER2, is well tolerated by patients, with little toxicity, which is due to its 
specificity for HER2 overexpressing cancer cells 136. Although the mechanism of action of 
monoclonal antibodies are not fully understood, they recognize the external domain of HER2, 
inhibiting downstream signaling 150. In contrast, lapatinib is a tyrosine kinase inhibitor, 
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representing a drug with a different mechanism of action against HER2 protein. This drug is still 
effective in BC patients with the truncated variant of HER2 protein (named p95), which is 
resistant to trastuzumab and pertuzumab 136. This aberrant form, without the extracellular 
domain, is constitutively active due to the absence of inhibitory signals from the external 
domain. As such, in this setting, antibodies that target the external domain of HER2 (either for 
targeted therapy or for IHC analysis) are useless 151. 
HER2 targeted therapy appears to benefit mainly tumors overexpressing HER2 protein or 
with HER2 gene amplification, making the accuracy of HER2 testing an important practical 
problem for successful treatment. At present, HER2 evaluation is most frequently performed by 
IHC, which detects HER2 protein overexpression, resulting in three possible outcomes: negative 
(score of 0 or 1+), equivocal (score of 2+) and positive (score of 3+). In cases of equivocal 
results, reflex testing should be performed on the same specimen with ISH assays for the 
assessment of HER2 gene amplification (Figure 8) 97. 
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Figure 8 
Algorithm for evaluation of HER2 protein expression by IHC assay (from Wolff et al 97) 
 
The principles of ISH assay rely on labeled DNA probes that hybridize to genomic 
sequences of interest through base pair complementarity. Fortunately, this method can be applied 
on several types of samples, from cell lines to frozen or paraffin-embedded tissues 152. 
Fluorescence ISH (FISH), the more traditional assay, requires a fluorescence microscope with 
multiband filters and specific training. Manual counting is time consuming and automated 
counting requires a high-resolution digital camera 136. Bright-field ISH, unlike FISH, presents 
some advantages, such as the use of a light microscope, permanent staining and easy 
identification of target cells, which can detect tumor heterogeneity more easily 153. Manual 
counting is less time consuming and more easily performed by pathologists given the 
resemblances with IHC 154. 
 The new 2013 ASCO/CAP guideline has updated the definition of HER2-positive status 
by modifying both IHC and ISH criteria, reducing the thresholds for post-analytical 
interpretation of positive results in comparison with the previous 2007 ASCO/CAP guideline 
97,155. In the new guideline, a HER2 score 3+ is defined as the presence of complete and intense 
membrane staining, in at least 10% of tumor cells 97. This represented a return to the IHC criteria 
originally used in the first-generation clinical trials 156. A similar approach was used regarding 
ISH criteria. In the updated guideline, a case is considered HER2-positive if HER2/CEP17 ratio 
is higher than 2.0, as initially used. Moreover, it was added that, even in assays with internal 
control probes, a case is also considered HER2-positive if the average of HER2 copy number per 
cell is higher than 6.0, regardless of the value of HER2/CEP17 ratio (Figure 9). 
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Figure 9 
Algorithm for evaluation of HER2 gene amplification by ISH assay (from Wolff et al 97) 
 
Regarding ISH assays, the 2013 ASCO/CAP guideline accept bright-field ISH and 
recommend counting at least 20 non-overlapping cells in two separate areas of invasive cancer 
97. Although this is usually interpreted as counting a total of 40 cells (at least 20 cells per area), 
the supplementary data of the guidelines actually explain that the minimum cell number is, in 
fact, a total of 20 cells in two separate areas of invasive cancer (at least 10 cells per area). It has 
already been shown that high ISH interobserver reproducibility exists; nevertheless, the 
minimum number of cells that should be counted to obtain a reproducible result is yet to be 
determined 157,158. Even if the current ASCO/CAP guideline recommendations are adhered to, the 
imprecision of HER2 testing remains a relevant issue, for both IHC and ISH techniques 159,160. 
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Heterogeneity has been notice in almost all types of cancer, including BC, being related 
to several aspect of disease progression and clinical outcome 161. The first recommendation 
regarding HER2 genetic heterogeneity (HER2-GH) was published in 2009 as an extension of the 
2007 ASCO/CAP HER2 guidelines after the acknowledgment that some tumors displayed 
intratumoral heterogeneity and such cases could originate discrepant results between IHC and 
ISH analysis 162. At that time, HER2-GH was defined as HER2 gene amplification in 5 to 50% of 
invasive cancer cells. Importantly, the definition was based on studies that did not include 
clinical outcome, being the first step to investigate the clinical significance of HER2-GH and the 
possible role of target-therapy in this setting 163,164. Thereafter, numerous studies have shown that 
HER2-GH could be present in BC from 5% to 40% of the cases 165,166. Additionally, it was 
shown that HER2-GH was more frequent in cases near the threshold of positivity and that 
heterogeneity measured in individual cells is not informative of clonal heterogeneity within a 
tumor population 167. 
Currently, the definition of HER2-GH has changed from individual cells to discrete 
population of tumor cells with HER2 gene amplification. According to the 2013 ASCO/CAP 
HER2 guideline, a tumor is considered HER2 positive if HER2 gene amplification is present in 
at least 10% of the total tumor cell population 97. 
Genomic heterogeneity has important practical implications. It has been documented that 
some tumors lose HER2 expression after treatment with trastuzumab, probably through a 
positive selection of a HER2-negative clone not sensible to anti-HER2 targeted therapy. 
Likewise, some tumors can gain HER2 expression over time, especially after endocrine therapy 
targeting ER, representing either a selection of a HER2-positive clone in an initial heterogeneous 
tumor or a new genetic acquisition in an original HER2-negative tumor 136. 
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1.3 Tumor infiltrating lymphocytes (TILs) 
Cancer development and progression is dependent on a complex system of different 
factors, including genetic and epigenetic alterations, and on factors from the tumor 
microenvironment, such as stromal and immune cells.10 In fact, in recent years, numerous studies 
have focused on the presence and function of the host immune system and its relationship with 
tumor progression in a variety of solid tumors, including BC, showing that spontaneous 
intratumoral lymphocytic infiltrate is related to patient prognosis.168-174 
In colorectal cancer, the presence of peritumoral lymphocytic infiltrate has been 
correlated with tumors with microsatellite instability (MSI), a known factor associated with 
better prognosis 175. Additionally, the presence of effector memory T cells was related with 
tumors without pathological signs of early metastatic invasion, supporting an active anti-tumor 
immune response. Moreover, an elevated number of the same cells were independently 
correlated with an improved clinical outcome 168. Similarly, in different models such as 
melanoma, intratumoral lymphocytic infiltrate was associated with histological regression and 
absence of regional lymph node involvement 176. Lastly, in squamous cell carcinoma of the head 
and neck (SCCHN), the presence of functional T cells is also associated with better clinical 
prognosis 174. 
Stromal TILs include several types of T and B lymphoid cells, along with macrophages, 
natural killer (NK) cells and dendritic cells, in different proportions with distinct associations 
with clinical outcome. For instance, CD4+ T helper 1 (Th1) cells, CD8+ cytotoxic T cells, NK 
cell, M1 macrophages and dendritic cells have a protective role against tumor growth. Inversely, 
CD4+/FOXP3+ immunosuppressive cells, CD4+ Th2 cells and M2 macrophages promote tumor 
growth 177. In fact, cytotoxic T cells are significantly increased in high grade, ER-negative BC 
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and BC with increased proliferative activity, as well as associated with improved clinical 
outcome.178-180 On the other side, immunosuppressive T cells have been shown to be associated 
with worse prognosis in invasive BC and even with increased risk of relapse in ductal CIS 
(DCIS).181-183 This data suggest that cytotoxic T cells are responsible for the antitumor immune 
activity and immunosuppressive T cells can inhibit this response. Furthermore, B lymphocytes 
are also associated with higher histological grade, ER-negative cases and basal phenotype, as 
well as with better prognosis.184 In the same way, T follicular helper (Tfh) cells are important to 
develop and attract memory B cells, being associated with increase response to conventional 
chemotherapy in BC 177. This indicates that humoral immune response, along with cell-mediated 
immune response, acts in convergence to achieve effective anti-tumor response. Based on this 
knowledge, it would be important to evaluate the clinical value of subtyping the composition of 
stromal TILs in BC and reveal the potential predictive role of these markers in response to 
immunotherapy. Nonetheless, it is remarkable that the quantification of stromal TILs alone, 
regardless of its specific subpopulation of lymphoid cells, has prognostic and predictive 
information. Curiously, there is no cut-off regarding the evaluation of stromal TILs, given that its 
prognostic value follows a continuous scale: each 1% increment is associated with an increase in 
the level of pathologic complete response (pCR) 177. 
Although the BC’s inflammatory infiltrate has been studied for several decades with 
conflicting results, large cohorts have recently shown an association between the presence of 
stromal tumor-infiltrating lymphocytes (TILs) with improved prognosis and better response to 
neoadjuvant chemotherapy, regardless of the absence of information of its specific immune 
cells.185,186 The association between stromal TILs at diagnosis with disease-free and overall 
survival has been shown to be significant only in TNBC and HER2-positive BC 177. In contrast, 
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luminal BCs, apparently, are less immunogenic probably due to the low mutation rate when 
compared to HER2-positive and TNBCs 177. 
Tumor cell death by conventional therapies, like chemotherapy and radiotherapy, causes 
the release of tumor-associated antigens, which in turn are used by antigen presenting cells 
(APCs) to stimulate downstream effector cell and increase anti-tumor response. In TNBC, for 
instances, the presence of stromal TILs in tumor tissue at diagnosis associates with better patient 
outcome after adjuvant anthracycline-based chemotherapy.187 Likewise, in HER2-positive BC, 
the number of TILs in tumor tissue associates with a better response to trastuzumab treatment.188 
In the same way, radiotherapy was shown to increase the variability of the T-cell receptor in 
intratumoral T cells 189. 
Additionally, the relationship between stromal TILs in BC and the response to 
neoadjuvant chemotherapy (NAC) has also been already evaluated. Several studies demonstrated 
higher stromal TILs as an independent marker for pCR after NAC 178,185,186,188,190. In addition, the 
expression of inflammatory genes was also associated with stromal TILs and pCR, specifically T 
cell markers 185,191. Furthermore, NAC significantly decreases immunosuppressive T cells on 
surgical specimens, while the number of cytotoxic T cells remains constant, being associated 
with pCR 192. As such, an increase in stromal TILs in the neoplastic tissue after NAC is 
obviously associated with improved prognosis, as well as the ratio of cytotoxic T cells to 
immunosuppressive T cells 177. This means that chemotherapy not only acts through the direct 
action against tumor cells, but also through the induction of an antitumor immune response, by 
causing a differential change in the composition of stromal TILs, specifically decreasing 
immunosuppressive T cells. Moreover, the use of immunotherapies that decrease de number of 
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immunosuppressive cells might add an increase in the efficacy of neoadjuvant and adjuvant 
chemotherapy. 
 
1.4 Programmed cell death-ligand 1 (PDL1) expression 
Tumor cells express new antigens that should be recognized by patient’s immune system, 
although most of the time the immunologic response is unable to eliminate cancer cells. 
Currently, many efforts have been made to identify molecular mechanisms that enable tumor 
cells to escape from the host immune system.10 An example of such immune checkpoint pathway 
is the expression of programmed cell death-ligand 1 (PDL1) by neoplastic cells conveying an 
inhibitory signal to T lymphocytes through the interaction with its receptor programmed cell 
death protein 1 (PD1). The PD1/PDL1 signaling pathway is present in physiologic processes to 
control self-tolerance and self-damage by normal tissues, being manipulated by tumor cells to 
protect from elimination by the immune system (Figure 10) 193. 
 
 
 
 
 
 
 
 
Figure 10 
Immune checkpoint blockade (from Drake et al 194) 
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PD1 is a cell surface protein that is part of the CD28 family, being expressed mainly on 
activated T-cells. Nevertheless, PD1 is also present on other activated lymphoid cells, such as B 
cells, NK cells and monocytes, which means that regulates T-cell independent immune 
surveillance 195. PD1 is encoded by the PDCD1 gene, located in chromosome 2q37, and has two 
main ligands: programmed cell death-ligand 1 (PDL1) and 2 (PDL2), both located in 
chromosome 9p24.1 (PDCD1LG1 and PDCD1LG2, respectively) 193. 
The specific binding of either PDL1 or PDL2 to PD1 leads to the activation of inhibitory 
kinases responsible for T-cell proliferation as well as cytokine production and secretion.196-199 A 
few differences between the expression of PDL1 and PDL2 need to be referred. PDL1 is mainly 
expressed on immune cells (for instance, T cells, B cells, macrophages and dendritic cells) along 
with non-immune cells, such as vascular endothelial cells and, obviously, tumor cells. PDL2 is 
mostly limited to APCs, such as macrophages and dendritic cells 193. 
PDL1 is expressed in various solid tumors and hematopoietic tumors, being currently 
evaluated in non-small cell lung carcinoma (NSCLC) and urothelial carcinoma, since it brings 
additional information to patient prognosis and to the selection of immunotherapy currently 
available.200 On the other way, PDL2 is mostly expressed in hematologic malignancies 193. 
Several signaling pathways have been proved to regulate PDL1 expression in various 
cancer models. There are two main pathways regulating the escape of tumor cells from immune 
surveillance. The first pathway comprises an innate/intrinsic immune response triggered by 
active oncogenic signaling, such as the PTEN/PI3K/AKT or ALK/STAT3 pathways, that are 
known to up-regulate PDL1 expression in glioblastomas and ALK-positive T-cell lymphoma and 
NSCLC, respectively 201-203. The second pathway represents an adaptive immune response 
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induced by inflammatory signals, such as interferon gamma and interleukins, that have been 
shown to up-regulate PDL1 expression on TILs and tumor cells 204. 
A classification system into 4 classes has been proposed combining the presence or 
absence of stromal TILs with the expression of PDL1 205. Therefore, type I represents tumors 
with stromal TILs and PDL1 expression (adaptive immune resistance), type II represents tumors 
without stromal TILs and no PDL1 expression (immune ignorance), type III represents tumors 
without stromal TILs but with PDL1 expression (intrinsic induction) and type IV represents 
tumors with stromal TILs but no PDL1 expression (immune tolerance by other suppressors). 
Type I and type IV tumors are probably the ones most likely to respond to immune 
checkpoint inhibitors, leaving stromal TILs in the tumor microenvironment to act against tumor 
cells. Although type I tumors would benefit from PD1/PDL1 targeted-therapy, type IV tumors, 
which do not have PDL1 expression, would probably profit from targeting other immune 
checkpoint inhibitors. On the other side, in type II and III tumors, which do not have preexisting 
stromal TILs, make therapies planned to recruit T cells to the tumor site, such as vaccination or 
even conventional chemotherapy/radiotherapy that promotes immunogenic action against tumor 
cells, probably useful approaches. Furthermore, type III tumors, with innate/intrinsic PDL1 
induction through active oncogenic signaling, would also benefit from adding PD1/PDL1 
targeted-therapy to induce a more effective anti-tumor immune response. 
Although contradictory information has been published regarding PDL1 expression and 
patient prognosis, in theory, the expression of PDL1 in the neoplastic tissue should have an 
adverse effect on prognosis, given the inhibitory effect of PDL1 in the antitumor immune 
response.206 However, it has been reported that PDL1 expression can be related with better 
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survival rates in several tumor models, probably due to the close association of PDL1 with the 
presence of increased stromal TILs, the effectors against tumor cells.207,208 
The use of specific monoclonal antibodies targeting either PD1 or PDL1 has been shown 
to promote tumor cell death induced by the host immune system in many cancer models.198,209 
For instance, nivolumab, the first FDA-approved humanized monoclonal antibody against PD1, 
has been selected for several solid tumors, including melanoma, NSCLC, renal cell carcinoma 
(RCC), classical Hodgkin lymphoma, SCCHN, urothelial carcinoma and even colorectal 
carcinoma with mismatch repair deficiency (dMMR) or MSI. Pembrolizumab, an alternative 
anti-PD1 antibody, has also been approved for melanoma, NSCLC, SCCHN, classical Hodgkin 
lymphoma and urothelial carcinoma, as well as any solid tumor with dMMR or MSI. Regarding 
anti-PDL1-targeted therapy, atezolizumab has been approved for urothelial carcinoma and 
NSCLC, and avelumab for Merkle cell carcinoma and urothelial carcinoma 193. 
There are a few characteristics to be mentioned regarding the inhibition of PD1 or PDL1. 
The inhibition of PD1 prevents the interaction of both ligands (PDL1 and PDL2), which can 
increase the probability of toxicity, and does not block the ligation of PDL1 to the costimulatory 
molecule CD80, leaving PDL1 still partially active. On the contrary, the inhibition of PDL1 
blocks the ligation of both PD1 and CD80, leaving intact the interaction of PDL2 to PD1, which 
can preserve immune tolerance and explain the fewer immune-related side effects in patients 
treated with anti-PDL1 205. 
The combination of PD1 and PDL1 inhibitors with conventional chemotherapy as well as 
with other targeted-therapy (such as EGFR, ALK or BRAF) has been shown to be improve 
patient outcome in various clinical trials 193. This means that cancer immunotherapy, by 
modulating the immune system to increase its response towards tumor cells, adds an additional 
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effect to current therapy, representing a valuable new strategic tool to be used in the treatment of 
cancer. Evidently, all drugs have unwanted actions and both anti-PD1 and anti-PDL1 options 
have an increased risk of developing auto-immune side effects. The most affected organs with 
immune-related manifestations are the skin, the gastrointestinal system, the liver and the lungs 
193. 
Given the potential toxicity that PD1/PDL1 targeted therapy can present, it would be 
useful to have a predictive biomarker that helped in the selection of patients who most likely 
benefit from these treatments. The expression of PDL1 by IHC has been explored as a possible 
predictive biomarker with some conflicting results. For instance, nivolumab was shown to 
achieve objective responses in about a third of patients with PDL1-positive tumors (melanoma, 
NSCLC and RCC) and no response in patients with PDL1-negative tumors 210. In the same way, 
pembrolizumab was also shown to reach significantly higher response rates in patients with 
PDL1-positive NSCLC 211. Similarly, atezolizumab was also shown to accomplish better results 
in several cancer patients with PDL1-positive tumors, such as RCC and urothelial carcinoma 
212,213. 
Interestingly, it has also been shown that objective responses to nivolumab can still occur 
in patients with PDL1-negative squamous cell carcinoma of the lung 214. In fact, a recent meta-
analysis showed clinical responses significantly different in about a third of patients with PDL1-
positive tumors and in about a fifth of patients with PDL1-negative tumors when treated with 
nivolumab, pembrolizumab or atezolizumab. Additionally, the predictive value of PDL1 
expression was even greater in NSCLC and melanoma patients as well as in nivolumab and 
pembrolizumab treated patients 215. 
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Although some inconsistencies exist, there is enough evidence for a link between PDL1 
expression and efficacy of PD1/PDL1 targeted-therapy. The different results of PDL1 expression 
are probably related to different methods in evaluating PDL1 expression, different thresholds 
values and monoclonal antibodies used as well as heterogeneity within tumors.216 Currently, the 
assays to evaluate the role of PDL1 expression for prognosis and predictive information are not 
standardized neither in methodology, nor interpretation of the staining. In practice, there are 
several companion diagnostic tests measuring the expression of PDL1, in both tumor cells and 
stromal TILs, using different monoclonal antibodies associated with specific drugs. Therefore, 
nivolumab, pembrolizumab and atezolizumab are associated with clone 28-8 from Dako, clone 
22C3 from Dako and clone SP142 from Roche Ventana, respectively 217. 
Recently, a working group named Blueprint Project was created by an industrial-
academic collaborative partnership, including medical societies, pharmaceutical and diagnostic 
companies, as well as regulatory agencies. The objective was to evaluate the expression of 4 
different PDL1 assays in NSCLC, assessing the possibility of interchangeable results. Initial 
results show that clones 22C3 and 28-8 from Dako have comparable precision in the evaluation 
of PDL1 expression in tumor cells whereas SP142 from Roche Ventana systematically stains 
fewer tumor cells. Additionally, it was also demonstrated that there is higher variability in the 
evaluation of PDL1 expression in immune cells than in tumor cells 218. In conclusion, almost 
40% of the cases could present discordant classification making the use of different antibodies to 
predict targeted therapy other than the already approved very problematic. 
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CHAPTER 2 
THESIS GOAL AND SPECIFIC AIMS 
 
 
The overall goal of this thesis was to improve the value of prognostic and predictive 
biomarkers in breast cancer pathology. With this purpose, we focused the study on specific 
biomarkers: 
 
1) the oncogenic receptor tyrosine kinase HER2, which expression is already routinely 
assessed in the clinical practice due to its sustained prognostic and predictive value; 
 
2) the presence of stromal TILs and the expression of PDL1 to evaluate the possibility of 
using immunotherapy to treat BC patients in the near future. 
 
 
Regarding the oncogene HER2, which overexpression and gene amplification is 
evaluated in all BC cases to identify patients that will most probably benefit of being treated with 
HER2 targeted therapy, our specific aims were the following: 
 
1 - To evaluate the impact of the recent alterations introduced on the ASCO/CAP 
guidelines on the result of HER2 gene amplification test, by the use of bright-field 
ISH (Chapter 3); 
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2 - To evaluate the intraobserver and interobserver interpretative reproducibility of the 
HER2 gene amplification assay, by measuring the impact of counting increasing 
numbers of invasive cancer cells (Chapter 4); 
 
3 - To evaluate the heterogeneity of HER2 gene amplification in invasive and in in situ 
BC cases (Chapter 5). 
  
 
Regarding stromal TILs and PDL1 expression, the specific aim was to assess the clinical 
impact of the expression of these biomarkers in BC, namely their correlation with classical 
pathological features, cancer molecular subtypes, as well as patients’ prognosis (Chapter 6). 
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CHAPTER 3 
APPLICATION OF THE 2013 ASCO/CAP GUIDELINE AND THE 
SISH TECHNIQUE FOR HER2 TESTING OF BREAST CANCER SELECTS 
MORE PATIENTS FOR ANTI-HER2 TREATMENT 
(Polonia A et al. Virchows Arch. 2016;468(4):417-423) 
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3.1 Abstract 
 
The aim of this study is to assess the impact of changes of the 2013 ASCO/CAP 
guideline on the results of HER2 testing in breast cancer. A series of 916 primary invasive breast 
cancer cases, assessed as HER2 2+ by IHC in part using the 2007 and in part the 2013 
ASCO/CAP criteria, was evaluated for HER2 amplification status by SISH and classified 
according to both 2007 and 2013 ASCO/CAP ISH guideline criteria. We observed a significant 
increase of HER2-positive cases (12.4% to 16.8%) and a decrease of HER2-equivocal cases 
(3.6% to 0.7%). Of the cases studied, 52.1% fulfilled both criteria of HER2/CEP17 ratio and 
average HER2 copy number per cell to be classified as HER2-positive. Reclassification of the 
cases from before the introduction of the new ASCO/CAP guideline with the 2013 ISH criteria 
resulted in an increase of cases with a HER2-positive status (12.4% to 14.2%) and in a decrease 
of HER2-equivocal cases (3.6% to 1.6%). The 2013 ASCO/CAP guideline selects more patients 
for anti-HER2 targeted therapy, mostly based on the modifications of criteria to evaluate ISH-
HER2. 
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3.2 Introduction 
 
In the western world, breast cancer (BC) is the most commonly diagnosed malignancy 
among women, representing about 30% of all new cancer cases, and after lung cancer the second 
leading cause of cancer death 219,220. The current cancer care guidelines for BC recommend that 
estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor 
receptor 2 (HER2) status must be routinely determined in all patients with invasive BC, BC 
recurrence and BC metastases 75,97. These guidelines were published to help improve laboratory 
performance in the determination of these markers, which provide useful predictive information 
regarding response to targeted therapy. 
HER2, located on the long arm of chromosome 17 (17q12), is amplified and/or 
overexpressed in about 15% to 20% of invasive BC. Cases with a HER2-positive status represent 
a clinically important subset of BC associated with poor outcome but also with a high likelihood 
of response to HER2-targeted therapy 104,141,147,148. Several studies have shown that anti-HER2 
therapy given during and/or after chemotherapy results in a significant improvement in disease-
free and overall survival 103,105,106. Therefore, HER2 is a helpful marker for therapy decision 
making in patients with BC and appropriate evaluation of HER2 status ensures that the right 
patient receives the right treatment 97. 
At present, HER2 protein expression is determined in BC samples by 
immunohistochemistry (IHC) resulting in three possible outcomes: negative (score 0 or 1+), 
equivocal (score 2+), and positive (score 3+). If the IHC result is equivocal, reflex testing should 
be performed on the same specimen using an alternative assay, such as in situ hybridization 
(ISH) 97. 
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 The new 2013 ASCO/CAP (American Society of Clinical Oncology/College of American 
Pathologists) guideline has updated the definition of HER2-positive status by modifying both 
IHC and ISH criteria, reducing the thresholds for the post-analytical interpretation of positive 
results in comparison with the previous 2007 ASCO/CAP guideline 97,155. In the new guideline, a 
HER2 score 3+ is defined as the presence of complete and intense membrane staining, in at least 
10% of tumor cells 97. This represented a return to the IHC criteria originally used in the first-
generation clinical trials 156. A similar approach was used regarding ISH criteria (see below). 
 In this study, we aim to compare the impact of the change from the 2007 to the 2013 
ASCO/CAP guidelines on the result of HER2 amplification test in BC. 
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3.3 Materials and methods 
 
Cases 
 A series of 916 primary invasive BC cases was retrieved from the archives of Ipatimup 
Diagnostics, including cases evaluated one year before (494 cases from November 2012 to 
October 2013) and one year after (422 cases from December 2013 to November 2014) the 
publication of the new ASCO/CAP guideline (November 2013). All BC cases (core biopsies and 
surgical specimens) had been fixed in 10% formalin, embedded in paraffin, and were referred to 
our institution (national reference center for HER2 ISH) with an equivocal IHC HER2 score (2+) 
to perform the HER2 amplification assay with a silver marker (SISH). 
 Ethics approval and informed consent were not required for this study. 
 
SISH 
 SISH testing was performed on 3-µm sections of formalin-fixed, paraffin-embedded 
tissue of all BC cases using dual-hapten, dual-colour ISH. The dual-probe assay (INFORM 
HER2 Dual ISH DNA Probe Cocktail Assay; Ventana Medical Systems, Inc., Tucson, Arizona) 
contains a HER2 locus-specific probe and a control probe specific for the centromere of 
chromosome 17 (CEP17). The entire procedure was carried out on an automated staining system 
(Ventana BenchMarkTM XT Staining System) according to the manufacturer’s instructions. 
Positive and negative controls were used for each staining run. 
Evaluation of the results included recording the number of HER2 and CEP17 signals in at 
least 20 nuclei in two different areas. The samples were classified by pathologists (AP and FS) 
according to the 2007 and 2013 ISH criteria for HER2 amplification. Corresponding 
73 
 
hematoxylin and eosin staining were used for the identification of the invasive component of the 
tumor. 
The 2007 ASCO/CAP guideline defines HER2 amplification as positive at a 
HER2/CEP17 ratio >2.2, equivocal at a HER2/CEP17 ratio ≤2.2 and ≥1.8, and negative at a 
HER2/CEP17 ratio <1.8 155. The 2013 ASCO/CAP guideline establishes the result of HER2 
amplification as positive at a HER2/CEP17 ratio ≥2.0 or a HER2/CEP17 ratio <2.0 and an 
average HER2 copy number per cell of ≥6.0, equivocal when HER2/CEP17 ratio <2.0 and 
average of HER2 copy number ≥4.0 and <6.0 signals per cell, and negative when HER2/CEP17 
ratio <2.0 and average HER2 copy number of <4.0 signals per cell 97. 
Chromosome 17 polysomy was defined as an average of ≥ 3.0 CEP17 signals per cell 166. 
Genomic heterogeneity was also recorded and considered present if a discrete population of 
tumor cells with HER2 amplification represented at least 10% of the total tumor cell population 
97. 
 
Statistical analysis 
 Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS) version 21.0 for Windows. The Pearson´s chi-squared (χ2) test and McNemar test were 
used for comparison of qualitative variables and the t test for quantitative variables. The level of 
significance was set at p < 0.05. 
Agreement rates between the 2007 and the 2013 ASCO/CAP guidelines regarding HER2 
gene amplification assay were evaluated with kappa (k) statistics 221. 
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3.4 Results 
 The 916 BC cases concerned 97.2% women and 1.2% men. The age ranged from 24 to 
103 years, with a median age at diagnosis of 59 years. 
The distribution of gender, age, HER2/CEP17 ratio, and average HER2 copy number per 
cell were not statistically different between the pre- and post-new guideline cases (Table 1 and 
Fig. 1). The only parameters that changed significantly with the new guideline were the average 
CEP17 copy number per cell (1.98 to 1.78; p<0.001; Table 1) and the presence of chromosome 
17 polysomy (4.1% to 0.9%; p=0.003; Table 1). 
 
Table 1 Differences between the cases before and after the introduction of the 2013 ASCO/CAP guideline 
 Cases before 
2013 ASCO/CAP guideline 
Cases after 
2013ASCO/CAP guideline 
 
p 
Gender 
(female / male / NI) 
481 / 6 / 7 409 / 5 / 8 ns (0.974)a 
Age 
(mean ± sd) 
58.17 ± 13.76 59.12 ± 14.10 ns (0.346)b 
HER2/CEP17 ratio 
(mean ± sd) 
1.68 ± 1.57 1.68 ± 1.50 ns (0.930)b 
Average of HER2 copy 
number per cell 
(mean ± sd) 
3.17 ± 2.56 2.88 ± 2.42 ns (0.077)b 
Average of CEP17 copy 
number per cell 
(mean ± sd) 
1.98 ± 0.51 1.78 ± 0.42 <0.001b 
Chromosome 17 polysomy 
(present / absent) 
 
20 (4.1%) / 474 (95.9%) 
 
4 (0.9%) / 418 (99.1%) 
 
0.003 a 
NI – not informed; sd – standard deviation; ns – not significant; a – Pearson´s chi-squared test; b – t test 
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Figure 1 Examples of results of HER2 detection by SISH technique (x400) 
A: HER2-positive / B: HER2-negative 
 
 Table 2 and Fig. 2A present the results of HER2 test performed on the pre-new guideline 
cases (using the ISH criteria from the 2007 ASCO/CAP guideline): 415 cases (84.0%) HER2-
negative, 18 cases (3.6%) HER2-equivocal, and 61 cases (12.4%) HER2-positive. Table 2 and 
Fig. 2B present the results of HER2 test performed on the post-new guideline cases (using the 
ISH criteria from the 2013 ASCO/CAP guideline): 348 cases (82.5%) HER2-negative, 3 cases 
(0.7%) HER2-equivocal, and 71 cases (16.8%) HER2-positive. The differences are statistically 
significant (Table 2 – statistical analysis A; p=0.003). We also observed that 52.1% of the 
positive cases (37/71) fulfill both criteria of HER2/CEP17 ratio ≥2.0 and average of HER2 copy 
number per cell ≥6.0 (Table 3 and Figure 2B). We furthermore classified the pre- and post-new 
guideline cases using the 2007 and 2013 ISH criteria and observed a slight but non-significant 
increase in HER2-positive cases and a similar decrease in HER2-equivocal cases (Table 2 – 
statistical analysis B and C; p=0.185 and p=0.261, respectively). 
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Table 2 Classification of HER2 test according to the 2007 and 2013 ISH criteria 
HER2 result Cases before 2013ASCO/CAP guideline Cases after 2013ASCO/CAP guideline 
ISH criteria 2007 ISH criteria 2013 ISH criteria 2007 ISH criteria 2013 
Positive 12.4% (61) 14.2% (70) 15.9% (67) 16.8% (71) 
Equivocal 3.6% (18) 1.6% (8) 2.4% (10) 0.7% (3) 
Negative 84.0% (415) 84.2% (416) 81.7% (345) 82.5% (348) 
Total 494 422 
 
Statistical 
analysis 
A   A 
B  B  
 C  C 
D D E E 
A - Cases before (ISH criteria 2007) vs after (ISH criteria 2013) 2013 ASCO/CAP guideline: p=0.003a 
B - Cases before vs after 2013ASCO/CAP guideline (ISH criteria 2007): p= 0.185a 
C - Cases before vs after 2013ASCO/CAP guideline (ISH criteria 2013): p= 0.261a 
D - Cases before 2013ASCO/CAP guideline – ISH criteria 2007 vs ISH criteria 2013: p=0.011b 
E - Cases after 2013ASCO/CAP guideline – ISH criteria 2007 vs ISH criteria 2013: p=0.071b 
a – Pearson´s chi-squared test; b – McNemar test 
 
 
 
 
 
 
 
 
 
 
Figure 2 Cases before (A) and after (B) the introduction of the 2013 ASCO/CAP guideline 
A B 
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Table 3 Classification of the cases after the 2013 ASCO/CAP guideline 
HER2/CEP17 
ratio 
Average of HER2 copy number signals per cell 
<4.0 ≥4.0 and <6.0 ≥6.0 
< 2.0 348 3 0 
≥ 2.0 11 23 37 
 
In the reclassification of the two case series using the 2007 and 2013 ISH criteria, we 
observed an increase in HER2-positive cases (12.4% to 14.2% and 15.9% to 16.8%, 
respectively) and a decrease in HER2-equivocal cases (3.6% to 1.6% and 2.4% to 0.7%, 
respectively). This was statistically significant in the pre-new guideline cases (Table 2 – 
statistical analysis D; p=0.011) and near significant in the post-new guideline cases (Table 2 – 
statistical analysis E; p=0.071). 
In the pre-new guideline cases, the 2013 ISH criteria reclassified 22 (4.5%) of the cases, 
9 as HER2-positive (from HER2-equivocal), 7 as HER2-negative (from HER2-equivocal), and 6 
as HER2-equivocal (from HER2-negative). All HER2-positive cases according to the 2007 
guideline remained HER2 positive with the 2013 guideline. Therefore, the concordance rate 
between 2007 and 2013 ISH criteria was 95.5% (472/494), with an agreement rate of 0.838 
(p<0.001) (Table 4). 
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Table 4 Classification of the cases before the 2013 ASCO/CAP guideline 
 
2007 ISH criteria 
2013 ISH criteria  
Positive Negative Equivocal Total 
Positive 61 0 0 61 
Negative 0 409 6 415 
Equivocal 9 7 2 18 
Total 70 416 8 494 
k statistics – 0.838; p<0.001 
 
 In the post-new guideline cases, genomic heterogeneity was detected in 0.47% of the 
cases (2/422), the proportion of HER2 amplified cells varying between 25 and 40% of the tumor 
cell population. 
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3.5 Discussion 
Our center (Ipatimup) is one of the reference centers for SISH test of BC in Portugal. In 
our center, the introduction of the updated ASCO/CAP guideline for HER2 test by SISH resulted 
in a significant increase of positive cases (12.4% to 16.8%) and decrease of equivocal cases 
(3.6% to 0.7%). 
Several studies recently reported an increase of HER2-positive cases evaluated by FISH 
but also an increase of HER2-equivocal cases with the introduction of 2013 ASCO/CAP 
guideline 222-226. However, the study by the group of Garbar et al. had results similar to ours 
using FISH, with an increase of HER2-positive cases and a slight decrease in HER2-equivocal 
cases 227. The explanation for these differences is not clear, but might be related to the number of 
cases, pre-analytical conditions, and different ISH platforms. Current guidelines recommend that 
any specimen used for ER, PgR and HER2 testing should go into fixation immediately (time to 
ﬁxative within 1 hour), fixed in 10% neutral buffered formalin for 6 to 72 hours and that routine 
processing is done according to standardized analytically validated protocols 97. In our study, 
most cases had incomplete information regarding pre-analytical conditions and we did not 
review centrally the IHC performed externally, which might explain the decrease in equivocal 
cases in comparison with recent literature. Nevertheless, the proportion of SISH indeterminate 
cases was 1.8% (data not shown), which is below published literature 160,228. 
As yet, the published concordance rates between SISH and FISH vary between 92 and 
99%, the majority fulfilling the ASCO/CAP validation requirement of a concordance rate 
exceeding 95% (Table 5) 154,158,229-236. However, the requirement in the 2013 ASCO/CAP 
guideline to determine the average of HER2 copy number (first applied to bright field ISH and 
now applied to the FISH test) introduces a problem that did not exist previously. 
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Autofluorescence in FISH might result in overestimation of both HER2 and CEP17 signals, 
resulting in HER2/CEP17 ratios below 2.0 and average of HER2 copy numbers above 4 per cell 
and an increase of equivocal HER2 results 152,237. If an increase of HER2-equivocal cases by 
FISH and a decrease of HER2-equivocal cases by SISH is confirmed, the concordance rate of 
these two ISH tests might decrease to under 95%. This would open up the question which of 
these techniques provides the most reliable information on HER2 amplification status. 
 
Table 5 Concordance rates of SISH vs FISH according 
to the 2007 ASCO/CAP guideline 
Publication Concordance 
(%) 
Year 
Dietel et al 158 96 2007 
Shousha et al 229 94 2009 
Bartlett et al 230 96 2009 
Papouchado et al 154 98.9 2010 
Koh et al 231 97 2011 
Lee et al 232 96.7 2011 
Park et al 233 96.5 2012 
Jacquemier et al 234 97 2013 
Lim et al 235 93 2013 
Unal et al 236 92.3 2013 
 
For nearly half of the cases studied (52.1%), both criteria (HER2/CEP17 ratio and 
average of HER2 copy number per cell) were fulfilled to allow them to be classified as HER2-
positive. This is particularly relevant given the fact that half the cases would be excluded from 
targeted therapy if HER2 amplification would be evaluated using just the HER2 probe (as some 
methods do). 
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Classification of the pre-new guideline and post-new guideline case series with the 2007 
and 2013 ISH criteria did not result in significant changes in the HER2 test results. This suggests 
that modifying the threshold in IHC, from 30 to 10% of cells with moderate staining, had little 
effect on the HER2 amplification test results. Lee et al. found that cases with equivocal IHC 
(score 2+) in 10-30% of the cells had a probability of being amplified of 5-12% 238. It is then not 
surprising that inclusion of these cases does not significantly change the HER2 amplification test 
results. 
In contrast, classification of pre-new guideline and post-new guideline cases with 
different ISH criteria (2007 and 2013) resulted in significant changes in HER2 amplification test 
results. Our findings suggest that the 2013 modified ISH criteria had a stronger impact on the test 
results than the modified IHC criteria. We found that the 2013 ISH criteria reclassified only 
4.5% of the cases, leaving more than 95% of the cases with the same classification. Other 
publications have shown a reclassification rate of up to 15% of cases 223,224. 
Polysomy of chromosome 17 changed from 4.1% to 0.9% with the introduction of the 
2013 ASCO/CAP guideline, which is probably due to modification of the definition of equivocal 
IHC HER2 staining (score 2+) rather than a change in the biology of the tumors. Several studies 
have shown that polysomy of chromosome 17 (measured on the basis of CEP17) varies between 
3 and 49% of the cases, depending on the definitions of polysomy and on the method used 
155,166,239,240. The approach is based on the notion that CEP17 copy number is a surrogate marker 
for chromosome 17 copy number. However, molecular karyotyping has revealed that an 
increased CEP17 signal number is usually due to gain of the pericentromeric region rather than 
to duplication of the entire chromosome 241-246. CEP17 might therefor not be a good marker for 
polysomy 17, making true polysomy 17 probably a rare event in BC. Nevertheless, CEP17 
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amplification can still be the cause of misleading HER2 amplification and false-negative test 
results, excluding patients from anti-HER2 targeted therapy 239. 
Tumors with polysomy 17 are thought to be different from non-HER2 amplified tumors, 
associated with a more aggressive clinical behavior and not responsive to conventional therapy 
166,247. However, in BC, the relationship between polysomy of chromosome 17 and the response 
to anti-HER2 therapy remains to be determined 248-250. 
 We found the presence of genomic heterogeneity to be rare as observed in just 0.47% of 
cases. Several studies have addressed this issue in the past and reported genomic heterogeneity in 
5 to 40% of BC cases 165-167,251,252. Studies on the relationship between genomic heterogeneity 
and prognosis have shown that tumors with a HER2 amplification in at least 30% of the cells 
have a reduced disease-free survival 251,252. However, the definition of genomic heterogeneity has 
also changed from individual cells (between 5 and 50% of tumor cells with HER2 amplification) 
to discrete populations of tumor cells (at least 10% of the total tumor cell population with HER2 
amplification) 97,162. Additional work is needed to determine the prevalence of genomic 
heterogeneity with this new definition and the response to anti-HER2 targeted therapy in these 
patients. 
 In conclusion, we show that the new HER2 guideline results in an increased number of 
HER2-positive and a decreased number of HER2-equivocal cases using the SISH technique, 
primarily because of modifications of ISH rather than of IHC criteria. As a consequence, the 
2013 ASCO/CAP guideline selects more patients for anti-HER2 targeted therapy. 
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Chapter 4 
Counting invasive breast cancer cells in the HER2 SISH test: 
how many cells are enough? 
(Polonia A et al. Histopathology. 2017;71(2):247-257) 
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4.1 Abstract 
 
Aim: To evaluate the intraobserver and interobserver reproducibility of the HER2 ISH 
test in breast cancer by measuring the impact of counting different numbers of invasive cancer 
cells. Methods and results: A cohort of 101 primary invasive breast cancer cases were evaluated 
for HER2 gene amplification by SISH, and the concordance among four observers with different 
levels of experience, counting different numbers of invasive cancer cells, was determined. The 
evaluation of the samples included scoring 20 nuclei, in three different areas. The cases were 
scored twice, with a washout interval of at least 2 weeks. We observed an increase in the 
intraobserver concordance rate between the first and second evaluations with an increase in cell 
count. A count of 60 invasive cells was needed to obtain a concordance rate near 95% and an 
agreement rate greater than 0.80 by all observers. The interobserver concordance rate of the 
HER2 test also increased with the increase in cell count, reaching at least a 90% concordance 
rate with a count of 60 invasive cells. The median variability of both the HER2/CEP17 ratio and 
the average HER2 copy number between different evaluations decreased with the increase in cell 
count, being statistically higher in HER2-positive cases. Conclusions: The minimal cell number 
recommended in current guidelines should be raised to at least 40, and preferably 60, invasive 
cells. Moreover, cases with amplification levels close to the threshold should be subjected to a 
dual count from an experienced observer. 
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4.2 Introduction 
 
HER2 is a transmembrane protein receptor with tyrosine kinase activity, and is amplified 
and/or overexpressed in approximately 15-20% of invasive breast cancer (BCs) 144-146. Numerous 
clinical trials have demonstrated that HER2-targeted therapy improves progression-free survival 
and overall survival only in patients with BCs showing HER2 amplification 103-106. For this 
reason, the accurate assessment of HER2 amplification identifies patients who are most likely to 
benefit from targeted therapy. 
HER2 evaluation is most frequently performed by immunohistochemistry (IHC), 
resulting in three possible outcomes: negative (score of 0 or 1+), equivocal (score of 2+), and 
positive (score of 3+). In cases of equivocal results, reflex testing should be performed with in 
situ hybridization (ISH) assays for the assessment of HER2 amplification 97. 
 Regarding ISH assays, the 2013 American Society of Clinical Oncology (ASCO)/College 
of American Pathologists (CAP) guidelines accept bright-field ISH and recommend counting at 
least 20 non-overlapping cells in two separate areas of invasive cancer 97. Although this is 
usually interpreted as counting a total of 40 cells (at least 20 cells per area), the supplementary 
data of the guidelines actually explain that the minimum cell number is, in fact, a total of 20 cells 
in two separate areas of invasive cancer (at least 10 cells per area). It has already been shown 
that high ISH interobserver reproducibility exists; nevertheless, the minimum number of cells 
that should be counted to obtain a reproducible result is yet to be determined 157,158. Even if the 
current ASCO/CAP guideline recommendations are adhered to, the imprecision of HER2 testing 
remains a relevant issue, for both IHC and ISH techniques 159,160.  
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In the present study, HER2 amplification status was determined in a series of primary BC 
cases by four different observers, who scored the cases twice according to the 2013 ASCO/CAP 
guidelines for HER2 testing. Specifically, we aim to evaluate the intraobserver and interobserver 
interpretative reproducibility of the HER2 assay in BCs by using bright-field ISH to evaluate the 
impact of counting different numbers of invasive cancer cells. 
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4.3 Materials and methods 
 
Cases 
 A cohort of 101 consecutive primary invasive BC cases was retrieved from the archives 
of Ipatimup Diagnostics from April to June 2015 to determine the concordance of the HER2 
amplification assay among four observers counting different numbers of invasive cancer cells. 
The cases included formalin-fixed paraffin-embedded core biopsies and surgical 
specimens referred to our institution with an equivocal HER2 result by IHC (score of 2+) for 
performance of an evaluation of HER2 amplification with bright-field ISH. All cases were 
reviewed for diagnosis and histological grade. Ethical approval and informed consent were not 
required for this study. 
 
Silver ISH 
 Silver ISH was performed on 3-µm-thick sections with dual-hapten, dual-colour ISH. The 
dual-probe assay (INFORM HER2 Dual ISH DNA Probe Cocktail Assay; Ventana Medical 
Systems, Tucson, AZ, USA), which is Food and Drug Administration-approved, contains an 
HER2 locus-specific probe (black signal) and a control probe specific for the centromere of 
chromosome 17 [centromere enumeration probe 17 (CEP17), red signal] that allows detection of 
HER2 amplification by light microscopy. The entire procedure was carried out on an automated 
staining system (Ventana BenchMark XT Staining System; Ventana Medical Systems, Tucson, 
AZ, USA) according to the manufacturer’s instructions. Appropriated positive and negative 
controls were used in every set of slides. Optimal staining consists of an absence of non-specific 
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background staining, distinct nuclear morphology, and clear and specific signals within the 
nucleus. 
 
SISH interpretation 
The samples were classified by two pathologists (A.P. and C.E.) and two pathology 
residents (J.P. and A.B.) according to the 2013 ASCO/CAP ISH criteria for HER2 amplification. 
Pathologists had different levels of experience, one with >500 cases evaluated per year (A.P.) 
and the other with <50 cases evaluated per year (C.E.). Both pathology residents had attended a 
previous molecular pathology training course, where they learned how to perform SISH 
interpretation. Corresponding hematoxylin and eosin staining was used for the identification of 
the invasive component of the tumor, and only cells with a minimum of one copy of HER2 and 
CEP17 each were scored. The number of HER2 signals was estimated in clusters, except for 
doublets, which counted as a single signal. 
The evaluation of the samples included scoring 20 nuclei, in three different areas, and 
recording the number of HER2 and CEP17 signals in groups of 10 invasive cancer cells. This 
approach allows us to add groups of 10 cells in each area to groups of 10 cells in other areas, 
giving 12 results of scoring 20 cells in two separate areas (10 cells per area) (Figure 1). The same 
can be applied to the evaluation of scoring 40 cells in two separate areas (20 cells per area, 
adding the first area to the second and third areas, and the second area to the third area), creating 
three results. Finally, the three areas can be added, generating one result of scoring 60 cells per 
case. The cases were scored twice with a washout interval of at least 2 weeks, in a blinded mode. 
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Figure 1 Scoring 20 cells in two separate areas (10 cells per area), giving 12 results 
 
The 2013 ASCO/CAP guidelines establish the result of HER2 amplification as: positive 
when the HER2/CEP17 ratio is ≥ 2.0 or < 2.0, and the average HER2 copy number is ≥ 6.0 
signals per cell; equivocal when the HER2/CEP17 ratio is < 2.0, and the average HER2 copy 
number is ≥ 4.0 and < 6.0 signals per cell; and negative when the HER2/CEP17 ratio is < 2.0, 
and the average HER2 copy number is < 4.0 signals per cell 97. 
Cases with discordant results were reviewed by both pathologists during a common 
microscopy session to document genomic heterogeneity, defined in the latest ASCO/CAP 
guideline as a discrete population of tumor cells with HER2 amplification 97. No additional 
testing was performed to resolve the discordance. 
Chromosome 17 polysomy was defined as an average of ≥ 3.0 CEP17 signals per cell 166. 
 
Statistical analysis 
 Statistical analyses were performed with SPSS version 24.0 for Windows. Pearson´s chi-
squared (χ2) test (or Fisher´s exact test, if appropriate) was used for comparison of qualitative 
variables, and the Mann-Whitney U-test (MWU) and Pearson´s correlation coefficient (PCC) 
were used for comparison of quantitative variables. The level of significance was set at p < 0.05. 
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Agreement rates of the same observer (intraobserver) and those between each observer 
(interobserver) regarding interpretation of the HER2 amplification assay were evaluated with 
kappa (k) statistics. k-values range between zero (chance agreement) and 1 (perfect agreement), 
and were considered to be satisfactory if they were >0.80 221. 
Altman-Bland analysis was used to assess the agreement between the first and the second 
measurements of 60 invasive cancer cells. The x-axis represents the mean of the measurements 
and the y-axis shows the difference between the measurements for each case. Altman-Bland 
plots display the mean difference (solid line) and 95% agreement limits (dashed lines) in two 
separate categories: HER2/CEP17 ratio <2.0 and HER2/CEP17 ratio ≥2.0 253,254. If there is high 
agreement between measurements, the differences are expected to be centred around zero, with a 
narrow agreement limits. 
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4.4 Results 
 The cohort included 82 core biopsies and 19 surgical specimens, with 97.03% of the 
cases being diagnosed in women and 2.97% in men. The age of the patients ranged from 35 to 93 
years, with a median age at diagnosis of 65 years. The majority of the histological types were 
invasive carcinomas of no special type, with 11.88% of the cases being classified as grade 1, 
61.39% as grade 2, and 26.73% as grade 3. The cohort characteristics are summarized in Table 1. 
 
Table 1 Cohort characteristics Value (n) 
Procedure 
(core biopsy / surgical specimen) 
 
82 / 19 
Gender 
(female / male) 
 
98 / 3 
Age (years) 
(mean ± sd) 
 
63.67±15.77 
Histological type 
Invasive carcinoma, NST 
Lobular carcinoma 
Mucinous carcinoma 
 
94 
5 
2 
Histological grade 
Grade 1 / Grade 2 / Grade 3 
 
12 / 62 / 27 
sd – standard deviation; NST – no special type 
 
 The final classification of HER2 testing from each observer (first and second evaluations 
of 60 invasive cancer cells) varied between 23% and 26% of HER2-positive cases (Table 2); 
there were no cases with genomic heterogeneity. Moreover, no equivocal results or chromosome 
17 polysomy were reported by any observer. 
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Table 2 Classification of HER2 test (first and second evaluation of 60 cells per case) 
 Pathologist 1 Pathologist 2 Resident 1 Resident 2 
1st 2nd 1st 2nd 1st 2nd 1st 2nd 
Positive    
n (%) 
25 
(24.8%) 
25 
(24.8%) 
23 
(22.8%) 
23 
(22.8%) 
25 
(24.8%) 
24 
(23.8%) 
25 
(24.8%) 
26 
(25.7%) 
Negative    
n (%) 
76 
(75.2%) 
76 
(75.2%) 
78 
(77.2%) 
78 
(77.2%) 
76 
(75.2%) 
77 
(76.2%) 
76 
(75.2%) 
75 
(74.3%) 
Equivocal 
(n) 
0 0 0 0 0 0 0 0 
Total (n) 101 
 
The intraobserver concordance rate of the HER2 test with different cell counts is shown 
in Table 3. We found, for all observers, an increase in the concordance rate between the first and 
second evaluations with the increase in cell count from 20 to 60 invasive cells [93.07-100%, 
86.14-94.06%, 92.08-99.01% and 76.24-95.05% for pathologist 1 (P1), pathologist 2 (P2), 
resident 1 (R1) and resident 2 (R2), respectively]. P1 was the only observer who reached an 
intraobserver agreement rate between the first and second evaluations of >0.80 (0.806) just by 
counting 20 invasive cells; the same goal was achieved by R1 when counting 40 invasive cells 
(0.945). Additionally, both P1 and R1 needed to count at least 40 invasive cells to achieve a 
concordance rate between the first and second evaluations of >95% (97.03% and 98.02%, 
respectively). On the other hand, P2 and R2 needed to count 60 invasive cells to reach an 
intraobserver agreement rate of >0.80 (0.831 and 0.869, respectively) and a concordance rate of 
~95% (94.06% and 95.05%, respectively). We also found that the concordance rates for different 
areas within the first or second evaluations were always higher than those measured between 
different evaluations. The same trend was observed in the intraobserver correlation of both the 
HER2/CEP17 ratio and the average HER2 copy number, whereby it increased with the increase 
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in cell count and was always higher for different areas within each evaluation than for different 
evaluations (Tables S1 and S2). 
 
Table 3 Intraobserver concordance rate of HER2 test results with different cell counts 
 Pathologist 1 Pathologist 2 Resident 1 Resident 2 
Cells 1
st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 
 
 
 
20 
96.04 
- 
100% 
 
(0.891 
- 
1.000) 
95.05 
- 
100% 
 
(0.862 
- 
1.000) 
93.07 
- 
100% 
 
(0.806 
- 
1.000) 
93.07 
- 
100% 
 
(0.800 
- 
1.000) 
91.09 
- 
100% 
 
(0.758 
- 
1.000) 
86.14 
- 
97.03% 
 
(0.632 
- 
0.911) 
95.05 
- 
100% 
 
(0.868 
- 
1.000) 
96.04 
- 
100% 
 
(0.891 
- 
1.000) 
92.08 
- 
99.01% 
 
(0.786 
- 
0.973) 
86.14 
- 
99.01% 
 
(0.638 
- 
0.972) 
86.14 
- 
100% 
 
(0.662 
- 
1.000) 
76.24 
- 
96.04% 
 
(0.442 
- 
0.896) 
 
 
 
40 
99.01 
- 
100% 
 
(0.973 
- 
1.000) 
98.02 
- 
100% 
 
(0.947 
- 
1.000) 
97.03 
- 
100% 
 
(0.919 
- 
1.000) 
96.04 
- 
98.02% 
 
(0.887 
- 
0.944) 
98.02 
- 
99.01% 
 
(0.945 
- 
0.972) 
90.10 
- 
95.05% 
 
(0.727 
- 
0.861) 
99.01 
- 
100% 
 
(0.973 
- 
1.000) 
100% 
 
 
 
(1.000) 
98.02 
- 
99.01% 
 
(0.945 
- 
0.973) 
94.06 
- 
97.03% 
 
(0.842 
- 
0.926) 
98.02 
- 
100% 
 
(0.949 
- 
1.000) 
90.10 
- 
95.05% 
 
(0.752 
- 
0.869) 
 
60 
na na 100% 
 
(1.000) 
na na 94.06% 
 
(0.831) 
na na 99.01% 
 
(0.973) 
na na 95.05% 
 
(0.869) 
Minimal and maximal concordance rate (k statistics); na – not applicable 
 
 The minimal interobserver concordance rate of the HER2 test increased with the increase 
in cell count from 20 to 60 invasive cells (73.27% in the P2-R2 evaluation of 20 cells, to 97.03% 
in the P1-R1 evaluation of 60 cells) (Table 4). A concordance rate of 95.05% and an agreement 
rate of 0.861 were achieved by P1 and R1 with a count of 40 invasive cells. A count of 60 
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invasive cells produced a minimal interobserver concordance rate of 90.10% and an agreement 
rate of 0.734 (R1-R2). In parallel, the same trend described above was found for the correlation 
of both HER2/CEP17 ratio and average HER2 copy number, in which it increased with the 
increase in cell count (Tables S3 and S4). 
 
Table 4 Interobserver concordance rate of HER2 test results with different cell counts 
 Pathologist 2 Resident 1 Resident 2 Cells 
Pathologist 1 87.13-98.02% 
(0.628-0.945) 
92.08-99.01% 
(0.776-0.974) 
77.23-97.03% 
(0.461-0.921) 
20 
91.09-95.05% 
(0.734-0.865) 
95.05-99.01% 
(0.861-0.973) 
88.12-97.03% 
(0.690-0.921) 
40 
93.07-95.05% 
(0.806-0.865) 
97.03-98.02% 
(0.919-0.947) 
92.08-97.03% 
(0.787-0.921) 
60 
Pathologist 2  81.19-98.02% 
(0.515-0.946) 
73.27-96.04% 
(0.386-0.884) 
20 
89.11-97.03% 
(0.704-0.919) 
89.11-95.05% 
(0.695-0.861) 
40 
91.09-96.04% 
(0.750-0.891) 
91.09-94.06% 
(0.751-0.841) 
60 
Resident 1   77.23-95.05% 
(0.461-0.869) 
20 
88.12-96.04% 
(0.681-0.894) 
40 
90.10-95.05% 
(0.734-0.869) 
60 
Minimal and maximal concordance rate (k statistics)  
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The discordant cases of the observers with higher interobserver concordance or 
agreement rates (P1 and R1) showed an HER2/CEP17 ratio of between 1.39 and 2.72 when 20 
invasive cells were counted, of between 1.75 and 2.37 when 40 invasive cells were counted, and 
of between 1.82 and 2.24 when 60 invasive cells were counted (Table 5; Figure 2). The range of 
average HER2 copy number in discordant cases for each observer with different cell counts is 
shown in Table S5. Additionally, we observed at least one discordant case for any observer in 
39.02% of core biopsies (32/82) and in 10.53% of surgical specimens (2/19) when 20 invasive 
cells were counted (χ2 test; p=0.018), and in 14.63% of core biopsies (12/82) and in 10.53% of 
surgical specimens (2/19) when 60 invasive cells were counted (Fisher´s exact test; p=1.000). 
 
Table 5 Minimum and maximum HER2/CEP17 ratio in discordant cases with different cell counts 
 Pathologist 1 Pathologist 2 Resident 1 Resident 2 
Cells 1
st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 
20 1.66 
- 
2.41 
1.70 
- 
2.72 
1.66 
- 
2.72 
1.32 
- 
4.37 
1.21 
- 
4.25 
1.21 
- 
4.37 
1.39 
- 
2.68 
1.65 
- 
2.56 
1.39 
- 
2.68 
1.22 
- 
5.13 
0.79 
- 
3.00 
0.79 
- 
5.13 
40 1.98 
- 
2.05 
1.89 
- 
2.25 
1.89 
- 
2.25 
1.57 
- 
2.13 
1.71 
- 
2.24 
0.99 
- 
3.44 
1.94 
- 
2.15 
na 1.75 
- 
2.37 
1.56 
- 
2.42 
1.80 
- 
2.00 
1.56 
- 
3.32 
60 na na na na na 1.02 
- 
3.34 
na na 1.82 
- 
2.24 
na na 1.56 
- 
2.94 
na – not applicable 
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Figure 2 Examples of results of HER2 detection with the SISH technique (×400) 
A: HER2 negative for all observers; B: HER2 positive for all observers; C: HER2 discordancy among observers 
  
The median variability of the HER2/CEP17 ratio between different evaluations decreased 
with the increase in cell count from 20 to 60 invasive cells in both negative cases (0.36-0.06, 
0.47-0.15, 0.38-0.08 and 0.54-0.19 for P1, P2, R1 and R2, respectively) and positive cases (1.83-
0.50, 1.04-0.31, 1.32-0.27 and 2.44-0.66 for P1, P2, R1 and R2, respectively) (MWU test; 
p<0.001 for all observers). Furthermore, the median variability of the HER2/CEP17 ratio in 
HER2-positive cases was statistically higher than that in HER2-negative cases (MWU test; 
p<0.001 for all observers) (Table 6). 
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Table 6 Variability of HER2/CEP17 ratio in negative and positive cases with different cell counts 
 Pathologist 1 Pathologist 2 Resident 1 Resident 2  
Cells 1
st 2nd 1st- 2nd 1st 2nd 1st-2nd 1st 2nd 1st-2nd 1st 2nd 1st-2nd Result 
20 0.23 
(0.06 
- 
0.77) 
0.24 
(0.09 
- 
0.76) 
0.36 
(0.14 
- 
1.04) 
0.27 
(0.11 
- 
0.73) 
0.34 
(0.04 
- 
0.74) 
0.47 
(0.21 
- 
1.18) 
0.30 
(0.11 
- 
0.56) 
0.26 
(0.09 
- 
0.61) 
0.38 
(0.15 
- 
0.83) 
0.34 
(0.05 
- 
0.86) 
0.28 
(0.08 
- 
0.83) 
0.54 
(0.19 
- 
1.23) 
N 
 0.93 
(0.39 
- 
3.86) 
1.51 
(0.11 
- 
3.30) 
1.83 
(0.82 
- 
5.03) 
1.11 
(0.37 
- 
3.50) 
0.85 
(0.34 
- 
5.31) 
1.04 
(0.52 
- 
5.31) 
0.81 
(0.17 
- 
2.38) 
0.81 
(0.16 
- 
2.73) 
1.32 
(0.24 
- 
4.54) 
1.81 
(0.46 
- 
2.60) 
1.33 
(0.24 
- 
3.91) 
2.44 
(1.09 
- 
4.87) 
P 
40 0.10 
(0.01 
- 
0.31) 
0.08 
(0.00 
- 
0.30) 
0.16 
(0.04 
- 
0.78) 
0.11 
(0.01 
- 
0.32) 
0.13 
(0.01 
- 
0.33) 
0.26 
(0.08 
- 
1.10) 
0.08 
(0.02 
- 
0.43) 
0.07 
(0.00 
- 
0.44) 
0.18 
(0.03 
- 
0.67) 
0.10 
(0.01 
- 
0.40) 
0.07 
(0.01 
- 
0.32) 
0.29 
(0.05 
- 
1.01) 
N 
 0.46 
(0.05 
- 
1.87) 
0.30 
(0.06 
- 
1.24) 
0.92 
(0.21 
- 
3.17) 
0.33 
(0.04 
- 
1.20) 
0.33 
(0.10 
- 
0.84) 
0.54 
(0.18 
- 
1.07) 
0.25 
(0.04 
- 
0.90) 
0.22 
(0.05 
- 
1.37) 
0.53 
(0.08 
- 
3.48) 
0.45 
(0.11 
- 
1.17) 
0.38 
(0.03 
- 
1.12) 
1.25 
(0.27 
- 
4.03) 
P 
60 na na 0.06 
(0.00 
- 
0.63) 
na na 0.15 
(0.00 
- 
0.94) 
na na 0.08 
(0.00 
- 
0.61) 
na na 0.19 
(0.00 
- 
1.08) 
N 
 na na 0.50 
(0.00 
- 
2.48) 
na na 0.31 
(0.07 
- 
2.50) 
na na 0.27 
(0.01 
- 
3.03) 
na na 0.66 
(0.04 
- 
3.24) 
P 
Median (minimum – maximum); N – negative; P – positive; na – not applicable; 
20 cells vs 40 cells, and 40 cells vs 60 cells: MWU test p<0.001; Negative vs Positive: MWU test p<0.001; 
1st vs 2nd: MWU test p>0.05; 1st vs 1st-2nd, and 2nd vs 1st-2nd: MWU test p<0.05 
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In discordant cases the median variability of the HER2/CEP17 ratio presented values 
between those of HER2-negative and HER2-positive cases and decreased with the increase in 
cell count (0.65-0.40, 1.01-0.93, 0.96-0.42 and 1.13-0.63 for P1, P2, R1 and R2, respectively), 
with the majority being statistically different from negative cases, positive cases, or both (Table 
7). 
 
Table 7 Variability of HER2/CEP17 ratio in discordant cases with different cell counts 
 Pathologist 1 Pathologist 2 Resident 1 Resident 2 
Cells 1
st 2nd 1st- 2nd 1st 2nd 1st-2nd 1st 2nd 1st-2nd 1st 2nd 1st-2nd 
20 0.462 
(0.10 
- 
0.59) 
0.551,2 
(0.24 
- 
0.79) 
0.651,2 
(0.52 
- 
1.11) 
0.791 
(0.31 
- 
2.65) 
0.841 
(0.39 
- 
2.58) 
1.011 
(0.39 
- 
3.45) 
0.591 
(0.36 
- 
0.77) 
0.461 
(0.26 
- 
0.66) 
0.961 
(0.43 
- 
1.36) 
0.931,2 
(0.22 
- 
3.63) 
0.751,2 
(0.24 
- 
2.10) 
1.131,2 
(0.52 
- 
6.76) 
40 0.07 
(0.07 
- 
0.07) 
0.241 
(0.17 
- 
0.30) 
0.401 
(0.30 
- 
0.69) 
0.211 
(0.15 
- 
0.53) 
0.431 
(0.33 
- 
0.53) 
0.771 
(0.18 
- 
2.01) 
0.22 
(0.22 
- 
0.22) 
na 0.42 
(0.21 
- 
0.62) 
0.341 
(0.12 
- 
0.57) 
0.17 
(0.13 
- 
0.20) 
0.771 
(0.45 
- 
1.61) 
60 na na na na na 0.931,2 
(0.41 
- 
1.68) 
na na 0.42 
(0.42 
- 
0.42) 
na na 0.631 
(0.25 
- 
1.21) 
Median (minimum – maximum); na – not applicable; 1: MWU test p<0.05 (comparison with variability of negative 
cases); 2: MWU test p<0.05 (comparison with variability of positive cases) 
 
In Figure 3 we observe an Altman-Bland analysis (A) for all observers between the first 
and second evaluations when 60 invasive cells were counted showing narrow agreement limits in 
cases with HER2/CEP17 ratio <2.0 and wider agreement limits in cases with HER2/CEP17 ratio 
≥2.0.  Thus, the relationship of the average of the HER2/CEP17 ratio with its variability 
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confirms the increased variability in cases with a higher HER2/CEP17 ratio (B – PCC 0.881; 
p<0.001). We also found that, for all observers, the median variability of the HER2/CEP17 ratio 
between different areas within the first and second evaluations was similar (MWU test; p>0.05) 
and always lower than the variability between different evaluations (MWU test; p<0.05). The 
same pattern described above was observed in the variability of the average HER2 copy number 
with different cell counts in negative, positive and discordant cases (Tables S6 and S7). 
 
 
Figure 3 Altman-Bland analysis (A) and relationship of the average of the HER2/CEP17 ratio with its variability 
(B) between the first and second measurements when 60 invasive cells are counted 
  
Finally, when we compared the variability of the HER2/CEP17 ratio with the variability 
of the average HER2 copy number, we observed that the former was always inferior to the latter 
(MWU test; p<0.05 for all observers when counting 60 invasive cells) (Tables 6 and S6). 
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4.5 Discussion 
Since the introduction of the new ASCO/CAP guidelines for HER2 testing in BC, 
numerous studies have reported an increase in the number of HER2-positive cases 222-226. 
Recently, using SISH, we showed that the updated ASCO/CAP guidelines resulted in a 
significant increase in the number of HER2-positive cases and a decrease in the number of 
equivocal cases 255. Most of the published literature shows the concordance rates between SISH 
and fluorescent ISH to be >90%, and to almost always fulfil the ASCO/CAP validation 
requirement of a concordance rate of >95% 154,231,234. 
In the present study, we found an increase in the concordance rate of HER2 testing 
between the first and second evaluations with an increase in cell count from 20 to 60 invasive 
cells, as well as a decrease in the variability of HER2/CEP 17 ratios for all observers, which 
demonstrated the value of counting additional cells. The fact that only the observer with more 
experience (P1) could achieve an intraobserver agreement rate of >0.80 between both 
evaluations when counting only 20 invasive cells shows that 20 cells might not be the optimal 
minimal cell number as recommended by current guidelines. In fact, P1 and R1 needed to count 
at least 40 invasive cells to reach an intraobserver concordance rate of >95%, and P2 and R2 
needed to count 60 invasive cells to achieve the same rate. Additionally, no observer reached an 
interobserver concordance rate of >95% or an agreement rate of at least 0.80 by counting only 20 
invasive cells. In fact, only two observers (P1 and R1) achieved that aim, and required a minimal 
count of 40 invasive cells. The remaining observers required a count of 60 invasive cells to 
achieve concordance rates of >90% of the cases and agreement rates near 0.80. According to our 
data, the minimal cell number of 20 invasive cells in HER2 testing in BC is not sufficient, and 
should be raised to at least 40 invasive cells (which is probably already the case in most 
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laboratories) and, preferably, 60 cells if available, which is almost always manageable in most of 
the cases in our experience. 
Interestingly, the observers with higher interobserver concordance/agreement rates were 
those with better intraobserver concordance/agreement rates. Additionally, the major causes of 
discordance in these observers were tumors with an HER2/CEP17 ratio near the threshold, even 
when 60 invasive cells were counted. Given that heterogeneity was ruled out, the discordant 
cases of the observers with lower performance were probably attributable to counting in non-
cancer areas or in areas with excessive background, showing a wider range of HER2/CEP17 
ratios. ISH analysis should start with scanning of the entire slide prior to counting, and compare 
with IHC to define the areas of potential HER2 amplification. Furthermore, the absence of 
information on preanalytical conditions can jeopardize the execution of the ISH technique and 
create artefacts that impair proper measurement of the signals. Although chromosome 17 
polysomy can cause impairment of ISH interpretation, it was not an issue in this study, given that 
no observer found such cases. 
Unexpectedly, we found more discordant cases in core biopsies than in surgical 
specimens. Although counting additional cells eliminates this problem, we think that it is 
probably related to the higher quantity of tumor in surgical specimens, which allows for the 
identification of better scoring areas, with less background and fewer overlapping cells. 
Previously, it has been shown that the identification of amplification status by SISH is very 
robust, as consensus between several observers cannot be reached in <2% of cases, although a 
consensus in discordant cases was not the aim in this study 154. 
As previously shown, the cases with amplification levels close to the thresholds are the 
most likely to be discordant 256. For cases in which the HER2/CEP17 ratio lies between 1.80 and 
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2.20, the ASCO/CAP guidelines recommend that a different person counts an additional 20 
invasive cells, whereas the updated UK guidelines recommend counting at least 60 invasive cells 
(preferably with a dual count by a second observer) 97,257. We agree with the UK guidelines 
recommendation, because 20 additional invasive cells evaluated by a different observer will not 
be sufficient to assess doubtful cases with an HER2/CEP17 ratio around 2.0, as we show in this 
study. Moreover, the similar variability of the HER2/CEP17 ratio within each evaluation, along 
with the divergent measurements between the first and second evaluations, suggests that the 
observers have the same error but different bias in different evaluations. We therefore 
recommend counting additional cells immediately than counting on a different day. 
The UK guidelines for HER2 assessment in BC recommend that, in cases with either 
clear amplification or an HER2/CEP17 ratio lower than 1.5, scoring of 20 tumor cells is 
sufficient 257. Although our data support this recommendation for experienced observers, it is 
more practical to immediately count 40 tumor cells and calculate both the HER2/CEP17 ratio 
and the average HER2 copy number than to count 20 cells, calculate these values, and then 
decide to count additional cells. 
Training and experience in the interpretation of HER2 ISH testing is essential. The UK 
guidelines recommend that laboratories perform at least 100 HER2 ISH assays every year, and, 
when new personnel are being trained in the interpretation of HER2 testing, observations of at 
least 100 ISH tests in parallel with an experienced scorer should be performed until a minimum 
concordance of 95% is achieved 257. In our study, although both residents had the same level of 
experience after training, only one reached a concordance rate of at least 95% with the 
experienced observer, which underlines the importance of validation studies in this field. 
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The variability of both the HER2/CEP17 ratio and of the average HER2 copy number in 
HER2-positive cases were always statistically higher than in HER2-negative cases, probably 
because of the different estimation of the number of HER2 signals in clusters. Another 
explanation could be the genetic instability of HER2 amplification already described between 
primary BC and metastatic lesions in HER2-positive cases, whereby the later had a significant 
increase in HER2 copy number 258. In the same way, separate areas of HER2-positive tumors 
could, in fact, have different HER2/CEP17 ratios and HER2 copy numbers, although this needs 
to be clarified in future studies. Recently, it has even been shown that the variability of the 
HER2/CEP17 ratio and of the average HER2 copy number between manual and automatic 
procedures using imaging analysis is higher in HER2-positive BC cases, although the results in 
separate areas were not compared in each procedure 259. Finally, the lower variability of the 
HER2/CEP17 ratio than of the HER2 copy number shows that the ratio value is probably more 
reproducible among observers, probably because the larger size of the CEP17 signal makes it 
easy to identify 154,260. Although the ISH technique is the gold standard for identifying HER2-
positive BC cases because it evaluates HER2 amplification only in invasive cancer cells, it might 
not be the most accurate method for HER2 quantification. One of the first studies investigating 
the effects of the level of HER2 amplification showed that high-amplification tumors had a 
significantly higher rate of pathologically complete response to neoadjuvant treatment with 
trastuzumab than low-amplification tumors 261. However, the same authors showed later that 
HER2 amplification level was not correlated with either recurrence-free or overall survival in the 
same setting 262. Moreover, the data from the Herceptin Adjuvant (HERA) trial were also used to 
compare the degree of HER2 amplification with clinical outcome in HER2-positive BC (in both 
the untreated and trastuzumab-treated arms) 263. Both the HER2/CEP17 ratio and the HER2 copy 
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number were measured, and no significant effect on prognosis or benefit from trastuzumab was 
observed with different levels of HER2 amplification. In contrast, it was recently reported that 
there was an increased risk of death from BC in the first 5 years after diagnosis in women with 
HER2 copy numbers of  ≥ 6, as well as of ≥ 4.0 and < 6.0, irrespective of HER2/CEP17 ratio 264. 
The conflicting clinical data suggest that the variability of the HER2/CEP17 ratio and the HER2 
copy number, depending on the number of cells counted, may determine the accuracy of the final 
result. Accordingly, to evaluate the putative clinical implications of the degree of HER2 
amplification, alternative methodology that quantifies HER2 amplification more precisely must 
be tested. Therefore, imaging analysis of ISH tests, counting several hundreds of cells more 
objectively, and HER2 quantification by molecular techniques in separate areas of invasive 
carcinoma should be investigated to assess the variability of the results in HER2-positive BC 
cases. 
In conclusion, we show that counting 20 cells in the HER2 ISH test is not sufficient to obtain 
a reproducible result, and that the minimal cell number should be raised to at least 40, and 
preferably 60, invasive BC cells. Additionally, cases with amplification levels close to the 
threshold should have a count of at least 60 cells, and, if possible, a dual count from an 
experienced observer. As far as we know, this is the first time that SISH results have been 
compared between multiple observers counting different numbers of invasive cancer cells. 
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4.6 Supplementary information 
 
Table S1 Minimal and maximal intraobserver correlation of the HER2/CEP17 ratio with different cell counts 
 Pathologist 1 Pathologist 2 Resident 1 Resident 2 
Cells 1
st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 
20 0.951 
- 
0.999 
0.964 
- 
0.995 
0.909 
- 
0.982 
0.897 
- 
0.988 
0.717 
- 
0.988 
0.690 
- 
0.936 
0.972 
- 
0.996 
0.963 
- 
0.995 
0.947 
- 
0.976 
0.889 
- 
0.990 
0.915 
- 
0.988 
0.746 
- 
0.929 
40 0.987 
- 
0.991 
0.991 
- 
0.993 
0.945 
- 
0.983 
0.985 
- 
0.987 
0.982 
- 
0.993 
0.880 
- 
0.913 
0.994 
- 
0.997 
0.992 
- 
0.997 
0.968 
- 
0.976 
0.982 
- 
0.990 
0.989 
- 
0.992 
0.867 
- 
0.890 
60 na na 0.966 na na 0.904 na na 0.977 na na 0.882 
Pearson´s correlation coefficient: p<0.001 for all correlations; na – not applicable 
 
 
Table S2 Minimal and maximal intraobserver correlation of the average HER2 copy number with different cell counts 
 Pathologist 1 Pathologist 2 Resident 1 Resident 2 
Cells 1
st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 
20 0.964 
- 
0.999 
0.963 
- 
0.991 
0.894 
- 
0.962 
0.926 
- 
0.987 
0.694 
- 
0.987 
0.623 
- 
0.908 
0.985 
- 
0.998 
0.985 
- 
0.997 
0.937 
- 
0.969 
0.891 
- 
0.976 
0.889 
- 
0.987 
0.733 
- 
0.893 
40 0.987 
- 
0.994 
0.987 
- 
0.989 
0.922 
- 
0.958 
0.988 
- 
0.990 
0.986 
- 
0.991 
0.811 
- 
0.858 
0.996 
- 
0.998 
0.996 
- 
0.997 
0.950 
- 
0.971 
0.980 
- 
0.988 
0.992 
- 
0.994 
0.846 
- 
0.869 
60 na na 0.946 na na 0.838 na na 0.963 na na 0.864 
Pearson´s correlation coefficient: p<0.001 for all correlations; na – not applicable 
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Table S3 Minimal and maximal interobserver correlation of the HER2/CEP17 ratio with 
different cell counts 
 Pathologist 2 Resident 1 Resident 2 Cells 
Pathologist 1 0.663-0.940 0.876-0.971 0.739-0.954 20 
0.787-0.933 0.910-0.966 0.823-0.951 40 
0.809-0.917 0.921-0.963 0.853-0.943 60 
Pathologist 2  0.614-0.933 0.568-0.951 20 
0.748-0.930 0.765-0.946 40 
0.781-0.923 0.814-0.945 60 
Resident 1   0.716-0.955 20 
0.781-0.948 40 
0.796-0.938 60 
Pearson´s correlation coefficient: p<0.001 for all correlations 
 
 
Table S4 Minimal and maximal interobserver correlation of the average HER2 copy number 
with different cell counts 
 Pathologist 2 Resident 1 Resident 2 Cells 
Pathologist 1 0.657-0.933 0.835-0.964 0.794-0.903 20 
0.763-0.932 0.861-0.952 0.842-0.900 40 
0.805-0.931 0.876-0.946 0.874-0.900 60 
Pathologist 2  0.593-0.925 0.454-0.919 20 
0.706-0.921 0.718-0.924 40 
0.729-0.919 0.737-0.921 60 
Resident 1   0.738-0.932 20 
0.779-0.926 40 
0.802-0.925 60 
Pearson´s correlation coefficient: p<0.001 for all correlations 
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Table S5 Minimum and maximum average HER2 copy number in discordant cases with different cell counts 
 Pathologist 1 Pathologist 2 Resident 1 Resident 2 
Cells 1
st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 1st 2nd 1st vs 2nd 
20 2.45 
- 
3.50 
2.00 
- 
4.35 
2.00 
- 
4.35 
2.45 
- 
8.40 
1.70 
- 
6.20 
1.70 
- 
8.40 
2.70 
- 
4.40 
2.45 
- 
4.20 
2.45 
- 
4.40 
1.85 
- 
6.10 
1.70 
- 
5.40 
1.70 
- 
7.15 
40 2.73 
- 
3.18 
2.23 
- 
3.20 
2.23 
- 
3.20 
2.70 
- 
4.10 
2.33 
- 
3.25 
2.08 
- 
6.38 
2.98 
- 
3.18 
na 2.50 
- 
3.18 
2.03 
- 
4.80 
2.00 
- 
4.00 
2.00 
- 
6.05 
60 na na na na na 2.08 
- 
5.78 
na na 2.67 
- 
2.80 
na na 2.10 
- 
5.38 
na – not applicable 
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Table S6 Variability of the average HER2 copy number in negative and positive cases with different cell counts 
 Pathologist 1 Pathologist 2 Resident 1 Resident 2  
Cells 1
st 2nd 1st- 2nd 1st 2nd 1st-2nd 1st 2nd 1st-2nd 1st 2nd 1st-2nd Result 
20 0.30 
(0.05 
- 
1.00) 
0.30 
(0.10 
- 
1.25) 
0.45 
(0.20 
- 
1.70) 
0.40 
(0.05 
- 
0.90) 
0.50 
(0.15 
- 
1.10) 
0.70 
(0.35 
- 
1.50) 
0.28 
(0.05 
- 
0.75) 
0.25 
(0.10 
- 
0.60) 
0.40 
(0.15 
- 
0.90) 
0.50 
(0.10 
- 
1.55) 
0.35 
(0.00 
- 
1.35) 
0.80 
(0.20 
- 
2.00) 
N 
 1.28 
(0.45 
- 
3.50) 
1.40 
(0.30 
- 
4.10) 
2.10 
(1.20 
- 
7.20) 
1.15 
(0.40 
- 
4.30) 
1.13 
(0.50 
- 
5.40) 
1.50 
(0.80 
- 
5.40) 
1.00 
(0.25 
- 
3.65) 
1.08 
(0.25 
- 
2.45) 
1.50 
(0.40 
- 
7.25) 
1.93 
(0.30 
- 
4.50) 
1.18 
(0.10 
- 
4.60) 
2.95 
(0.70 
- 
7.15) 
P 
40 0.14 
(0.02 
- 
0.53) 
0.10 
(0.00 
- 
0.38) 
0.25 
(0.10 
- 
1.15) 
0.15 
(0.00 
- 
0.63) 
0.15 
(0.05 
- 
0.38) 
0.40 
(0.17 
- 
1.15) 
0.10 
(0.00 
- 
0.48) 
0.08 
(0.00 
- 
0.45) 
0.23 
(0.03 
- 
2.22) 
0.15 
(0.02 
- 
1.15) 
0.10 
(0.00 
- 
0.55) 
0.47 
(0.13 
- 
1.55) 
N 
 0.61 
(0.15 
- 
2.10) 
0.53 
(0.10 
- 
2.20) 
1.10 
(0.35 
- 
5.70) 
0.48 
(0.13 
- 
1.30) 
0.33 
(0.05 
- 
1.08) 
0.73 
(0.32 
- 
1.35) 
0.27 
(0.05 
- 
1.40) 
0.25 
(0.03 
- 
1.38) 
0.55 
(0.22 
- 
5.88) 
0.50 
(0.03 
- 
1.75) 
0.32 
(0.02 
- 
1.23) 
1.50 
(0.40 
- 
4.42) 
P 
60 na na 0.12 
(0.00 
- 
0.99) 
na na 0.25 
(0.03 
- 
0.95) 
na na 0.12 
(0.00 
- 
1.97) 
na na 0.36 
(0.05 
- 
2.12) 
N 
 na na 0.58 
(0.05 
- 
4.34) 
na na 0.42 
(0.05 
- 
3.14) 
na na 0.39 
(0.02 
- 
5.35) 
na na 0.95 
(0.15 
- 
3.97) 
P 
Median (minimum – maximum); N – negative; P – positive; na – not applicable; 
20 cells vs 40 cells, and 40 cells vs 60 cells: MWU test p<0.001; Negative vs Positive: MWU test p<0.001; 
1st vs 2nd: MWU test p>0.05; 1st vs 1st-2nd, and 2nd vs 1st-2nd: MWU test p<0.05 
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Table S7 Variability of the average HER2 copy number in discordant cases with different cell counts 
 Pathologist 1 Pathologist 2 Resident 1 Resident 2 
Cells 1
st 2nd 1st- 2nd 1st 2nd 1st-2nd 1st 2nd 1st-2nd 1st 2nd 1st-2nd 
20 0.432 
(0.20 
- 
0.80) 
0.731 
(0.25 
- 
1.55) 
0.901,2 
(0.65 
- 
1.55) 
1.201 
(0.35 
- 
4.45) 
0.85 
(0.30 
- 
3.20) 
1.581 
(0.55 
- 
6.15) 
0.751 
(0.25 
- 
1.00) 
0.451,2 
(0.40 
- 
0.70) 
1.081 
(0.60 
- 
2.55) 
1.151,2 
(0.30 
- 
2.70) 
0.701 
(0.15 
- 
2.80) 
1.381,2 
(0.50 
- 
5.90) 
40 0.45 
(0.45 
- 
0.45) 
0.391 
(0.38 
- 
0.40) 
0.501,2 
(0.48 
- 
0.52) 
0.22 
(0.10 
- 
0.50) 
0.23 
(0.10 
- 
0.35) 
1.141 
(0.35 
- 
3.60) 
0.20 
(0.20 
- 
0.20) 
na 0.31 
(0.22 
- 
0.40) 
0.591 
(0.05 
- 
1.35) 
0.24 
(0.20 
- 
0.28) 
0.881 
(0.25 
- 
3.15) 
60 na na na na na 1.531,2 
(0.84 
- 
2.93) 
na na 0.13 
(0.13 
- 
0.13) 
na na 0.631 
(0.30 
- 
2.35) 
Median (minimum – maximum); na – not applicable; 1: MWU test p<0.05 (comparison with variability of negative 
cases); 2: MWU test p<0.05 (comparison with variability of positive cases) 
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Chapter 5 
Characterization of HER2 gene amplification heterogeneity 
in invasive and in situ breast cancer using bright-field ISH 
(Polonia A et al. Virchows Arch. 2017;471(5):589-598) 
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5.1 Abstract 
 
The aims of this study were to evaluate and compare the HER2 gene amplification status 
in invasive and adjacent in situ breast carcinoma, using bright-field in situ hybridization, and to 
document the possible presence of HER2 genetic heterogeneity (HER2-GH) in both components. 
A cohort of 100 primary invasive carcinomas (IC) associated with carcinoma in situ (CIS) were 
evaluated for HER2 gene amplification by SISH according to the 2013 ASCO/CAP HER2 
guideline. A second cohort of all the cases with HER2-GH since the introduction of the updated 
ASCO/CAP HER2 guideline was also characterized, and an evaluation of the HER2 gene 
amplification in the CIS component, if present, was also done. In the first cohort, the HER2 
amplification in the IC was negative in 87% of the cases and positive in 13% of the cases, 
without the presence of HER2-GH. All the cases had an associated CIS with the same HER2 
status as IC, with four cases of CIS presenting HER2-GH. In the CIS, we observed a significant 
relationship of HER2 gene amplification with high nuclear grade. In the four cases with HER2-
GH in CIS, two cases presented HER2 gene amplification in the IC. The second cohort included 
12 cases with HER2-GH in a total of 1243 IC cases (0.97%). Additionally, we identified two 
cases associated with non-amplified CIS. HER2-GH is a rare event in IC and can already be 
present in CIS, not being an important step in the acquisition of invasive features. 
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5.2 Introduction 
 
Human epidermal growth factor receptor 2 (HER2) is amplified and/or overexpressed in 
about 15 to 20% of invasive breast cancer (BC), being associated with worse clinical outcome 
and predictive of benefit from HER2-targeted therapy 104,141,148. The incidence rate of carcinoma 
in situ (CIS) of the breast, the immediate precursor of invasive carcinoma (IC), has stabilized 
since the beginning of the millennium in women older than 50 years, but continues to increase 
about 2% every year in younger women 219. Several studies have shown that HER2 amplification 
can already be present in CIS and that frequently HER2 status is concordant with the invasive 
component 142,143. 
Heterogeneity has been notice in almost all types of cancer, including BC, being related 
to several aspects of disease progression and clinical outcome 161. The first recommendation 
regarding HER2 genetic heterogeneity (HER2-GH) was published in 2009 as an extension of the 
2007 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 
HER2 guidelines after the acknowledgment that some tumors displayed intratumoral 
heterogeneity and such cases could originate discrepant results between immunohistochemistry 
(IHC) and in situ hybridization (ISH) analysis 162. At that time, HER2-GH was defined as HER2 
gene amplification in 5 to 50% of invasive cancer cells. Importantly, the definition was based on 
studies that did not include clinical outcome, being the first step to investigate the clinical 
significance of HER2-GH and the possible role of target therapy in this setting 163,164. Thereafter, 
numerous studies have shown that HER2-GH could be present in BC from 5 to 40% of the cases 
165,166. Additionally, it was shown that HER2-GH was more frequent in cases near the threshold 
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of positivity and that heterogeneity measured in individual cells is not informative of clonal 
heterogeneity within a tumor population 167. 
Currently, the definition of HER2-GH has changed from individual cells to discrete 
population of tumor cells with HER2 gene amplification. According to the 2013 ASCO/CAP 
HER2 guideline, a tumor is considered HER2 positive if HER2 gene amplification is present in 
at least 10% of the total tumor cell population 97. 
 The aims of the present study are to compare the HER2 gene amplification status in 
invasive and adjacent in situ BC, using bright-field ISH, and to document the possible presence 
of heterogeneity in both components. 
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5.3 Materials and methods 
 
Case selection 
The cases included formalin-fixed, paraffin-embedded needle core biopsies (NCB) and 
surgical excision specimens (SES) referred to Ipatimup Diagnostics with an equivocal HER2 
result (score of 2+) in IC by IHC for performance of an evaluation of HER2 amplification with 
bright-field ISH. There was no information regarding patient treatment. 
The first cohort included 100 primary invasive BC cases associated with CIS retrieved 
from the archives from November 2015 to July 2016 to determine the concordance of HER2 
gene amplification in both components. During this period, 347 cases with an equivocal HER2 
result by IHC were evaluated for HER2 gene amplification. The cohort comprised 66 NCB and 
34 SES, all diagnosed in women. The age of the patients ranged from 31 to 83 years old, with a 
median age at diagnosis of 54 years. The majority of the histological types were invasive 
carcinomas of no special type (NST), with 14% of the cases being classified as grade 1, 66% as 
grade 2, and 20% as grade 3 (Table 1). 
 
 
 
 
 
 
 
 
115 
 
Table 1 Characteristics of the first cohort 
Procedure (NCB / SES) 66 / 34 
Gender (female / male) 100 / 0 
Age (mean ± SD) 54.68 ± 12.41 
Invasive carcinoma 
Histological type 
Invasive carcinoma, NST 
Lobular carcinoma 
Micropapillary carcinoma 
Mucinous carcinoma 
Encapsulated papillary carcinoma 
 
 
88 
8 
2 
1 
1 
Histological grade 
Grade 1 / Grade 2 / Grade 3 
 
14 / 66 / 20 
HER2 gene amplification 
ISH negative/ISH positive 
 
87/13 
Carcinoma in situ 
Ductal 
Lobular 
 
93 
8 
Nuclear grade 
Low / Intermediate / High 
 
3 / 42 / 56 
Necrosis (absent / present) 58 / 43 
Microcalcifications (absent / present) 73 / 28 
NCB: needle core biopsy; SES: surgical excision specimen; 
SD: standard deviation; NST: no special type 
 
 The second cohort included all cases with HER2-GH (primary invasive or metastatic BC) 
since the introduction of the 2013 ASCO/CAP HER2 guideline (November 2013) to October 
2016. An evaluation of HER2 gene amplification in the CIS component, if present, was also 
done. The cohort comprised 10 NCB and 2 SES with HER2-GH in a total of 1243 cases (0.97%), 
11 of which were primary invasive BC and one lymph node metastasis. The age of the patients 
ranged from 42 to 74 years old, with a median age at diagnosis of 58 years, and two cases were 
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diagnosed in men. All histological types but one were IC, NST, with eight cases being classified 
as grade 2 and four cases as grade 3 (Table 2). 
 
Table 2 Characteristics of the second cohort 
Procedure (NCB / SES) 10 / 2 
Gender (female / male) 10 / 2 
Age (mean ± SD) 59.67 ± 10.92 
Invasive carcinoma 
Histological type 
Invasive carcinoma, NST 
Lobular carcinoma 
 
 
11 
1 
Histologic grade 
Grade 1 / Grade 2 / Grade 3 
 
0 / 8 / 4 
Carcinoma in situ 
Ductal 
 
2 
Nuclear grade 
Low / Intermediate / High 
 
0 / 1 / 1 
Necrosis (absent / present) 1 / 1 
Microcalcifications (absent / present) 2 / 0 
NCB: needle core biopsy; SES: surgical excision specimen; 
SD: standard deviation; NST: no special type 
 
 
All cases were reviewed for histological type and grade (Nottingham Histologic Score) in 
the IC. The characterization of the CIS included nuclear grade, the presence of necrosis, and 
microcalcifications. 
This study has been performed in accordance with the national regulative law for the 
handling of biological specimens from tumor banks, being the samples exclusively available for 
research purposes in retrospective studies, as well as under the international Helsinki declaration. 
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Silver in situ hybridization 
SISH technique was performed on 3-µm-thick sections in one block of each case with 
dual-hapten, dual-colour ISH. The dual-probe assay (INFORM HER2 Dual ISH DNA Probe 
Cocktail Assay; Ventana Medical Systems, Inc., Tucson, AZ, USA), which is Food and Drug 
Administration-approved, contains an HER2 locus-specific probe (black signal) and a control 
probe specific for the centromere of chromosome 17 (centromere enumeration probe-CEP17, red 
signal), which allows detection of HER2 gene amplification by light microscopy. The entire 
procedure was carried out on an automated staining system (Ventana BenchMark XT Staining 
System; Ventana Medical Systems, Inc., Tucson, AZ, USA) according to the manufacturer’s 
instructions. Appropriated positive and negative controls were used in every set of slides. 
 
SISH interpretation 
The evaluation of the samples included scoring of at least 20 nuclei, in two different 
areas, recording the number of HER2 and CEP17 signals. Corresponding hematoxylin and eosin 
(H&E) staining was used for the identification of the invasive and in situ components of the 
tumor, and only cells with a minimum of one copy of HER2 and CEP17 each were scored. The 
number of HER2 signals was estimated in clusters, except for doublets which counted as a single 
signal. The samples were classified by a pathologist (AP) according to the 2013 ASCO/CAP ISH 
criteria for HER2 gene amplification: positive when the HER2/CEP17 ratio is ≥ 2.0 or < 2.0 and 
the average HER2 copy number is ≥ 6.0 signals per cell; equivocal when the HER2/CEP17 ratio 
is < 2.0 and the average HER2 copy number is ≥ 4.0 and < 6.0 signals per cell; and negative 
when the HER2/CEP17 ratio is < 2.0 and the average HER2 copy number is < 4.0 signals per 
cell 97. 
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HER2-GH is defined as tumors with discrete population of tumor cells with different 
HER2 gene status 97. The proportion of amplified areas was quantified by measuring the number 
of fields (power field of 200x) with HER2 gene amplification divided by the number of fields of 
invasive or in situ carcinoma. 
 
Statistical analysis 
 Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS) version 24.0 for Windows. The Pearson´s chi-squared (χ2) test (or the Fisher´s exact test, 
if appropriate) was used for comparison of qualitative variables and the Mann-Whitney U 
(MWU) test, the t test, and Pearson´s correlation coefficient (PCC) were used for comparison of 
quantitative variables. The level of significance was set at p < 0.05. 
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5.4 Results 
 In the first cohort, the HER2 amplification in the IC was negative in 87% of the cases and 
positive in 13% of the cases, without the presence of HER2-GH. All the cases had an associated 
CIS with the same HER2 status than IC, with four cases of CIS presenting HER2-GH. Because 
one case presented both lobular and ductal CIS, we characterized 101 types of CIS, where 92.1% 
were ductal CIS (DCIS) and 2.9% of the cases were classified as low grade, 41.6% as 
intermediate grade, and 55.5% as high grade. We also observed necrosis in 42.6% and 
microcalcifications in 27.7% (Table 1). 
HER2 amplification in the IC were not related with the procedure, the age of the patients 
or the histological grade. However, in the CIS, we observed a significant relationship of HER2 
amplification with high nuclear grade (18.9% vs 4.4%; p=0.030), without an association with the 
remaining characteristics (Table 3). 
Table 3 HER2 amplification in invasive and in situ carcinoma 
Invasive carcinoma Negative Positive p 
Procedure (NCB/SES) 58/29 8/5 0.7591 
Age (mean ± SD) 54.52±12.86 55.69±9.29 0.7532 
Histological grade 
(Grade 1-2/Grade 3) 
72/15 8/5 0.1291 
Carcinoma in situ    
Ductal / Lobular 78/8 12/0 0.5901 
Nuclear grade 
(low-intermediate/high) 
43/43 2/10 0.0303 
Necrosis 
(absent/present) 
52/34 5/7 0.2163 
Microcalcifications 
(absent/present) 
65/21 6/6 0.0851 
NCB: needle core biopsy; SES: surgical excision specimen; 
SD: standard deviation; 1 Fisher´s exact test; 2 t-test; 3 Pearson´s 
Chi-Squared test 
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The distribution of HER2/CEP17 ratio and average of HER2 and CEP17 copy number 
per cell were not statistically different between the IC and CIS (Table S1). Additionally, we 
observed a high correlation of HER2/CEP17 ratio and average HER2 copy number per cell 
between IC and CIS (PCC=0.981; p<0.001 and PCC=0.929; p<0.001, respectively) (Figure 1 
and S1). 
 
Figure 1 Relationship between HER2/CEP17 ratio of in situ and invasive carcinoma 
 
 
 In the four cases with HER2-GH in CIS, only one case was identified in NCB and two 
cases presented HER2 gene amplification in the IC (Figure 2 and 3). The proportion of cells with 
HER2 gene amplification in the CIS varied between 30 and 60% of the total CIS represented in 
the sample, being all high-grade DCIS (for details see Table 4 and S2). 
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Figure 2 
Carcinoma in situ with HER2 genetic heterogeneity associated with HER2-positive invasive carcinoma 
 
Case 1 (1st cohort): A1 - DCIS, H&E 200x; A2 - Amplified DCIS (left) and non-amplified DCIS (right), SISH 200x; 
B1 - Invasive carcinoma, NST, H&E 200x; B2 - Amplified invasive carcinoma, NST, SISH 200x. 
 
 
Figure 3 
Carcinoma in situ with HER2 genetic heterogeneity associated with HER2-negative invasive carcinoma 
 
Case 4 (1st cohort): A1 - LCIS, H&E 200x; A2 – Non-amplified LCIS, SISH 400x; B1 - Invasive lobular carcinoma, 
H&E 200x; B2 – Non-amplified invasive lobular carcinoma, SISH 400x; C1 – DCIS, H&E 200x; C2 – Amplified 
DCIS, SISH, 400x. 
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Table 4 Cases with HER2 amplification discordance between invasive carcinoma and carcinoma in situ 
Case Gender Age Procedure IC Histologic 
grade 
HER2 
status 
CIS Nuclear 
grade 
HER2 
status 
Proportion 
1 F 44 SES NST 2 A ductal high A 40% 
         NA 60% 
2 F 53 SES NST 3 A ductal high A 60% 
         NA 40% 
3 F 48 NCB NST 3 NA ductal high NA 40% 
         A 60% 
4 F 78 SES Lobular 1 NA lobular low NA 70% 
       ductal high A 30% 
F: female; SES: surgical excision specimen; NCB: needle core biopsy; NST: no special type; A: amplified; NA: not 
amplified 
 
In the second cohort, the proportion of cells with HER2 amplification varied between 1 
and 50% of the total tumor cell population represented in the sample. In the negative component, 
HER2/CEP17 ratio varied between 1.00 and 1.52, and in the positive component between 2.06 
and 9.17 (Table S3). 
The primary IC cases had similar morphological features in the amplified and non-
amplified components. The lymph node metastasis case represented a primary lobular carcinoma 
of the breast with an equivocal HER2 result (score of 2+) by IHC and no HER2 gene 
amplification by SISH (case 2). The metastasis showed two types of neoplastic cells, one similar 
with the primary lesion and another one with more pleomorphic nuclei. After additional IHC in 
the metastasis, it was found that the latter areas showed strong and complete membranous 
staining in 40% of the cells (score of 3+) that were confirmed by SISH as HER2 amplified 
(Figure 4). 
 
 
123 
 
Figure 4 
HER2-negative invasive carcinoma associated with HER2 genetic heterogeneity in the lymph node metastasis 
 
Case 2 (2nd cohort): A1 – Invasive lobular carcinoma, H&E 200x; A2 – Non-amplified invasive lobular carcinoma, 
SISH, 400x; B1 and C1 – same lymph node metastasis, H&E 200x; B2 – Non-amplified area in lymph node 
metastasis; C2 – Amplified area in lymph node metastasis, SISH 400x. 
 
 
Additionally, in the primary IC cases, we identified two cases associated with non-
amplified DCIS (Case 11 and 12 - table 5 and S4). Case 12 was classified as equivocal by IHC 
(score of 2+) because it showed strong and complete membranous staining in small groups of 
tumor cells, along with scattered single cells, representing less than 10% of the total tumor cell 
population in the sample. After SISH analysis, the same component presented HER2 gene 
amplification, consequently being classified as HER2 ISH negative (Figure 5). 
 
Table 5 Cases with HER2 genetic heterogeneity in invasive carcinoma associated with carcinoma in situ 
Case Gender Age Procedure IC Histologic 
grade 
HER2 
status 
Proportion CIS Nuclear 
grade 
HER2 
status 
11 F 52 NCB NST 3 A 25%    
      NA 75% ductal high NA 
12 M 73 NCB NST 2 NA 99% ductal intermediate NA 
      A 1%    
F: female; M: male; NCB: needle core biopsy; IC: invasive carcinoma; NST: no special type; A: amplified; NA: not 
amplified; CIS: carcinoma in situ 
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Figure 5 
Invasive carcinoma with HER2 genetic heterogeneity associated with HER2-negative carcinoma in situ 
 
Case 12 (2nd cohort): A1 – DCIS, H&E 200x; A2 – Non-amplified DCIS, SISH 400x; B1 – Invasive carcinoma, 
NST, H&E 200x; B2 – HER2 genetic heterogeneity in invasive carcinoma (HER2 gene amplification in small 
groups of tumor cells (circle areas) along with scattered single cells (arrows)). 
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5.5 Discussion 
The aim of the present study was to compare the amplification status of HER2 gene 
between IC and CIS and search for HER2-GH in both components. Our results show that in all 
the cases, we observed the same HER2 status in both IC and adjacent CIS, according to previous 
studies 265,266. Although, in this work, we only considerer cases with an equivocal HER2 result 
by IHC that can bias the results, these are the cases that require reflex testing making the issue of 
HER2-GH in ISH evaluation more important in this setting. 
Bright-field ISH allows to better correlate tissue morphology and HER2 gene status, 
clearly identifying HER2-GH in IC and CIS 260. In CIS, HER2-GH was recognized more 
frequently in SES, in which more tissue is available for evaluation. Interestingly, in these cases, 
only half of IC presented HER2 gene amplification, confirming that this amplification is not 
relevant for the transition from CIS to IC. In the literature, it has been documented that in HER2-
positive cases, a significant increase occurs in HER2 copy number between primary BC and 
metastatic lesions 258. The high correlation of HER2/CEP17 ratio and HER2 copy number 
between IC and CIS suggests that the described genetic instability of HER2 gene amplification is 
only present in metastatic stages. 
In our study, HER2 gene amplification in IC was not associated with histological grade, 
contrary to what has been published 143,267. Current evidence shows that histological grading of 
NCB can only be concordant with SES in about 75% of the cases 59,67. Most of the discordant 
cases are upgraded in the SES, generally due to an underscored of the mitotic frequency on NCB 
67,68. Although our first cohort included a slight increase of grade 2 tumors compared with 
expected values in the literature, it might be the result of the large number of NCB, which can 
underestimate the histological grade and compromise the statistical relationship with HER2 gene 
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amplification 59. Nevertheless, HER2 gene amplification in CIS was significantly associated with 
high nuclear grade, as previously documented 143,267. 
Before the introduction of the first definition of HER2-GH, intratumoral heterogeneity 
was applied to discrete population of cells and reported as a rare event 268,269. Recently, we also 
showed the presence of HER2-GH in IC, according to the updated ASCO/CAP HER2 guideline, 
to be extremely infrequent 255. In the present work, we identified it in about 1% of the cases, 
including cases of male patients. 
HER2-GH in the IC was observed more often in NCB, because most evaluations are 
performed by this procedure, which represent the first biological material on which the hormone 
receptors (HR) and HER2 markers should be first determined 75,97. The predominant histologic 
type was invasive carcinomas, NST, with no cases classified as grade 1, as previously noticed 
268. Although we had no information regarding previous treatment, the fact that most IC cases 
with HER2-GH were found in NCB shows us that this rare event can occur in patients without 
previous treatment. 
All primary invasive BC cases presented similar histological characteristics in the 
amplified and non-amplified areas, with HER2 gene amplification in a minor component, 
supporting the idea that most cases develop in a single tumor that acquired HER2 gene 
amplification during tumor progression. Even though molecular analysis has shown that cases 
with HER2-GH in the IC can be the result of two distinct tumors (also known as collision 
tumors), most cases appear to be clonally related resulting from clonal divergence from a single 
tumor, as previously shown 270,271. However, it remains to be shown if the same process can 
occur in CIS. 
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In case 2 (second cohort), the HER2-GH was found in the lymph node metastasis rather 
than the primary tumor. This can be the result of tumor evolution in the lymph node metastasis 
or, eventually, the representation of an independent tumor that was not identified in the SES. 
Nevertheless, this case illustrates the importance of pathologists in selecting tumor areas with 
less differentiation and higher nuclear pleomorphism, either in the primary IC or in the lymph 
node metastases, which most likely are going to be HER2 amplified. Additionally, according to 
the 2013 ASCO/CAP guideline, the HER2 test should also be repeated if results are discordant 
with histopathologic findings 97. 
Although it has been previously reported that HRs and HER2 conversion by IHC can 
occur between primary and metastatic lesions, the former is much more frequent (preferentially 
from HR-positivity in the primary tumors to HR-negativity in the metastasis) 258,272. The 
conversion phenomenon could be explained by HER2-GH in the primary tumor, which can be 
more frequently found if more than one block is tested 273,274. In this study, we were restricted to 
the analysis of only one block, which can underestimate the prevalence of HER2-GH. 
Additionally, we also not considered cases with HER2-GH by IHC (score 3+ in >10% and 
<100%). Interestingly, it has also been shown that patients with HER2-GH have worse outcome 
compared to patients with homogeneous amplified or non-amplified HER2 gene, suggesting that 
mixed tumors behave more aggressively 251,275. 
 Furthermore, it has been described that the majority of ICs with HER2-GH have non-
amplified DCIS, consistent with our study, again supporting the idea that IC originates from CIS 
and that HER2 gene amplification can also be acquired in later stages 268. Cases with HER2-GH 
in the IC associated with amplified DCIS probably represent distinct tumors, given the fact that 
the loss of the HER2 gene amplification is an unlikely event. 
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Finally, regarding case 12 (second cohort), which presented HER2 gene amplification in 
less than 10% of the total tumor cell population, a comment was made in the report 
recommending repetition of HER2 test by IHC in the SES to find and accurately quantify the 
HER2 positive component. Moreover, focally amplified small populations can be overlooked 
and IHC should be used to guide ISH analysis, searching for areas of potential amplification 97. 
All cases exhibiting HER2-GH on NCB by ISH should have HER2 test repeated on the SES, 
according to the updated United Kingdom guidelines 257. Additionally, clinical trials have not so 
far been based on the new 10% cut-off for ISH as provided by the 2013 ASCO/CAP guideline 
105,276-279. In fact, the presence of HER2 gene amplification was enough for inclusion of patients 
to HER2-targeted therapy, irrespective of the proportion of amplified cells. Fortunately, the rare 
presence of HER2-GH probably did not influence the clinical results given that any random 
group of cells evaluated will represent, most of the times, the whole tumor 280. However, it 
remains to be demonstrated what is the minimal proportion of amplified tumor cell population 
that achieves clinical response to HER2-targeted therapy. 
In conclusion, we show that HER2-GH is a rare event in IC and can already be present in 
CIS, not being an important step in the acquisition of invasive features. As far as we know, this 
is the first time that HER2-GH, according to the updated ASCO/CAP HER2 guideline, has been 
evaluated in both IC and adjacent CIS using bright-field ISH. Although intratumoral 
heterogeneity of HER2 gene amplification can have clinical significance, not only affecting the 
selection of patients but also explaining some of the variability of the response to targeted 
therapy, this is a rare event in breast cancer cases. 
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5.6 Supplementary information 
 
Table S1 Comparison of HER2 and CEP17 signals between invasive and in situ 
carcinoma 
 Invasive carcinoma Carcinoma in situ p 
HER2/CEP17 ratio 
Median (minimum- maximum) 
1.07 
(0.68-11.62) 
1.07 
(0.65-11.23) 
0.824 
Average HER2 copy number 
Median (minimum- maximum) 
1.62 
(1.03-15.10) 
1.57 
(1.05-14.60) 
0.923 
Average CEP17 copy number 
Median (minimum- maximum) 
1.55 
(1.05-2.70) 
1.53 
(1.05-2.55) 
0.577 
Mann-Whitney U test 
 
 
Table S2 Cases with HER2 status discordance between invasive carcinoma and carcinoma in situ 
Case IC HER2/CEP17 
ratio 
Average HER2 
copy number 
HER2 
status 
CIS HER2/CEP17 
ratio 
Average HER2 
copy number 
HER2 
status 
Proportion 
1  11.62 15.10 A  11.23 
0.94 
14.60 
1.65 
A 
NA 
40% 
60% 
2  2.73 3.00 A  2.20 
1.21 
2.75 
1.75 
A 
NA 
60% 
40% 
3  1.03 1.60 NA  0.88 
6.07 
1.50 
8.50 
NA 
A 
40% 
60% 
4  1.04 1.45 NA  1.12 
3.58 
1.40 
4.30 
NA 
A 
70% 
30% 
IC – invasive carcinoma; A – amplified; NA – not amplified; CIS – carcinoma in situ 
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Table S3 Cases with HER2 genetic heterogeneity in invasive carcinoma 
Case Gender Age Procedure IC Histologic 
Grade 
HER2/CEP17 
ratio 
Average HER2 
copy number 
HER2 
status 
Proportion 
1 F 69 NCB NST 2 7.19 
1.14 
9.70 
1.65 
A 
NA 
25% 
75% 
2 F 45 SES Lobular 2 5.24 
1.00 
8.90 
1.40 
A 
NA 
40% 
60% 
3 F 60 NCB NST 2 4.03 
1.17 
6.65 
1.70 
A 
NA 
15% 
85% 
4 F 55 NCB NST 2 9.17 
1.10 
11.00 
1.15 
A 
NA 
15% 
85% 
5 F 74 SES NST 2 2.06 
1.21 
3.40 
2.00 
A 
NA 
15% 
85% 
6 F 55 NCB NST 3 4.88 
1.07 
6.10 
1.60 
A 
NA 
10% 
90% 
7 F 54 NCB NST 3 3.63 
1.07 
5.45 
2.20 
A 
NA 
10% 
90% 
8 F 72 NCB NST 2 2.71 
1.10 
2.85 
1.15 
A 
NA 
50% 
50% 
9 F 42 NCB NST 3 7.20 
1.11 
7.20 
2.00 
A 
NA 
10% 
90% 
10 M 65 NCB NST 2 3.53 
1.16 
6.00 
1.85 
A 
NA 
30% 
70% 
11 F 52 NCB NST 3 4.50 
1.52 
5.40 
2.20 
A 
NA 
25% 
75% 
12 M 73 NCB NST 2 1.31 
7.14 
1.70 
10.00 
NA 
A 
99% 
1% 
F – female; M – male; NCB – needle core biopsy; SES – surgical excision specimen; IC – invasive carcinoma; NST – no 
special type; A – amplified; NA – not amplified 
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Table S4 Cases with HER2 genetic heterogeneity in invasive carcinoma associated with carcinoma in situ 
Case IC HER2/CEP17 
ratio 
Average HER2 
copy number 
HER2 
status 
Proportion CIS HER2/CEP17 
ratio 
Average HER2 
copy number 
HER2 
status 
11  4.50 
1.52 
5.40 
2.20 
A 
NA 
25% 
75% 
  
1.03 
 
1.55 
 
NA 
12  1.31 
7.14 
1.70 
10.00 
NA 
A 
99% 
1% 
 0.94 1.55 NA 
IC – invasive carcinoma; A – amplified; NA – not amplified; CIS – carcinoma in situ 
 
 
Figure S1 Relationship between average HER2 copy number per cell of in situ and invasive carcinoma 
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Chapter 6 
Prognostic value of stromal TILs and PDL1 expression in 
breast cancer 
(Polonia A et al. J Clin Pathol. 2017;70(10):860-867) 
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6.1 Abstract 
 
Aim The present work aims to evaluate the presence of stromal tumor-infiltrating lymphocytes 
(TILs) and programmed cell death-ligand 1 (PDL1) expression in breast carcinomas and their 
correlation with available clinicopathological features. 
Methods Two independent series of invasive breast cancer (IBC), one including ductal 
carcinoma in situ (DCIS) pair-matched cases, were selected, and quantification of TILs was 
accomplished in each case. Immunohistochemistry was also performed to evaluate the 
expression of PDL1.  
Results In both cohorts evaluated, increased stromal TILs and PDL1 expression were present in 
about 10% of IBCs, being significantly associated with each other and both with grade 3 and 
triple-negative subtype. We observed a similar distribution of stromal TILs and PDL1 expression 
between DCIS and IBC. Finally, we observed that increased stromal TILs and PDL1 expression 
were significantly associated with cancer stem cell (CSC) markers, basal cell markers and 
vimentin expression. Interestingly, in IBC cases with vimentin expression, increased stromal 
TILs, as well as decreased PDL1 expression, disclosed a better clinical outcome, independently 
of the main classical BC prognostic factors. 
Conclusions We have confirmed the association of stromal TILs and PDL1 expression with 
aggressive forms of BC and that both are already found in in situ stages. We also showed that 
stromal TILs and PDL1 expression are associated with clinical outcome in cases enriched for a 
mesenchymal immunophenotype. We describe for the first time a close relationship between 
CSC markers and PDL1 expression. 
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6.2 Introduction 
 
In the western world, breast cancer (BC) is the most frequently diagnosed malignancy 
among women, representing about one-third of all new cancer cases and the second leading 
cause of cancer death after lung cancer.281 BC development and progression is dependent on a 
complex system of different factors, including genetic and epigenetic alterations, and on factors 
from the tumor microenvironment, such as stromal and immune cells.10 In fact, in recent years, 
numerous studies have focused on the presence and function of the host immune system and its 
relationship with tumor progression in a variety of solid tumors, including BC, showing that 
spontaneous intratumoral lymphocytic infiltrate is related to patient prognosis.168-174 
Although the BC’s inflammatory infiltrate has been studied for several decades with 
conflicting results, large cohorts have recently shown an association between the presence of 
tumor-infiltrating lymphocytes (TILs) with improved prognosis and better response to 
neoadjuvant chemotherapy, regardless of the absence of information of its specific immune 
cells.185,186 In triple-negative (TN) BC, for instance, the presence of stromal TILs in tumor tissue 
at diagnosis associates with better patient outcome after adjuvant anthracycline-based 
chemotherapy.187 Similarly, in human epidermal growth factor receptor 2 (HER2)-positive BC, 
the number of TILs in tumor tissue associates with a better response to trastuzumab treatment.188 
However, in contrast to the presumed protective effect of TILs in tumor tissue, it has 
been shown that immune cells can cause the acquisition of stem cell properties by tumor cells, as 
well as a more pronounced mesenchymal phenotype, which are features related with a worse 
patient prognosis.282 Moreover, it was also shown that tumor cells express antigens that should 
be recognized by patient’s immune system, although most of the time the immunologic response 
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is unable to eliminate the cancer cells. Currently, many efforts have been made to identify 
molecular mechanisms that enable tumor cells to escape from the host immune system.10 An 
example of tumor escape from immunosurveillance is the expression of PDL1 (programmed cell 
death-ligand 1) by neoplastic cells, which is a cell surface glycoprotein that conveys an 
inhibitory signal to T lymphocytes, through the interaction with its receptor PD1 (programmed 
cell death protein 1). This specific binding leads to a decrease in cytokine production and an 
increase of T lymphocyte apoptosis, which protect tumor cells from elimination.196-199 
Accordingly, the inhibition of this inhibitory signal by specific monoclonal antibodies, against 
either PDL1 or PD1, has been shown to promote tumor cell death induced by the host immune 
system in many cancer models.198,209 
Based on these data, the expression of PDL1 is already being evaluated in several solid 
tumors, such as melanoma, non-small cell lung carcinoma and renal cell carcinoma, since it 
brings additional information to patient prognosis and to the selection of immunotherapy 
currently available targeting these molecules specifically.200 In line with these studies, the aim of 
the present work was to evaluate the relationship between the presence of stromal TILs and 
PDL1 expression with clinicopathological features in two independent BC series. The 
association with disease-free survival (DFS) and overall survival (OS) was also evaluated. 
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6.3 Materials and methods 
 
Tumor samples 
Two independent series of BC cases were studied, both with clinical and pathological 
characterization performed by our group, previously described and structured in tissue 
microarrays (TMAs). The first cohort includes 440 primary and sporadic invasive ductal 
carcinomas retrieved from the Pathology Department, Hospital Xeral-Cíes, Vigo, Spain, 
diagnosed between 1978 and 1992, with a median age of 60.0 years (from 28 to 92 years) and a 
median follow-up time of 120 months (1-120 months).283 Several parameters were extracted 
from the group database, including age, tumor size, histologic grade, lymph node status, estrogen 
receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2) 
and Ki67 expression, as well as the expression of basal cell markers (CK5, CK14, epidermal 
growth factor receptor (EGFR) and P-cadherin), cancer stem cell (CSC) markers (CD24, CD44, 
CD49f and ALDH1) and the epithelial-mesenchymal transition (EMT) markers E-cadherin and 
vimentin. Data concerning molecular subtype, DFS and OS was also available. The main 
features are detailed in supplementary table S1. 
The second cohort includes 94 primary in situ and invasive BC (IBC) cases, including 32 pair-
matched cases, collected from the Pathology Institute of Araçatuba, São Paulo, Brazil, diagnosed 
between 1996 and 2006, with a median age of 55.0 years (from 32 to 96 years).143 The data 
retrieved from the database include age, histological grade, lymph node status, hormone 
receptors (ER and PgR), HER2, Ki67 and molecular subtype. The main features are detailed in 
supplementary table S2. 
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This study has been performed in accordance with the national regulative law for the handling of 
biological specimens from tumor banks, the samples being exclusively available for research 
purposes in retrospective studies, as well as under the international Helsinki declaration. 
 
Quantification of Tumor-Infiltrating Lymphocytes (TILs) 
Histopathological analysis of the lymphocytic infiltrate was performed according to the 
guidelines for clinical and research practice.284 Briefly, mononuclear cells, including 
lymphocytes and plasma cells (granulocytes excluded), were quantified in the stromal 
compartment as a continuous variable of 10% increment, within the borders of the invasive 
tumor, using visual assessment of H&E-stained sections. Thresholds were then used to 
categorize the continuous variable (absent - absence of TILs; slight - TILs up to 30%; moderate - 
TILs between 30% and 60%; marked - TILs in more than 60%). In ductal carcinoma in situ 
(DCIS), the lymphocytic infiltrate was quantified around the lesion using the same classification. 
 
PDL1 immunohistochemistry 
Immunohistochemical staining for PDL1 was performed in 2-3µm sections from TMAs, using a 
rabbit monoclonal antibody (clone SP142; 1:60 dilution; Spring Bioscience, Pleasanton, 
California, USA). The assay was carried out on an automated immunostaining system (Ventana 
BenchMark XT Staining System), using the OptiView DAB IHC Detection Kit (Ventana 
Medical Systems, Tucson, Arizona, USA) according to manufacturer’s instructions. Positive 
(human placenta) and negative staining controls were performed in parallel with paraffin 
sections. Positivity was defined as membranous and cytoplasmic staining ≥1% in both tumor 
cells and stromal TILs.285 
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Statistical analysis 
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS), 
V.21.0, for Windows. Pearson´s chi-squared (χ2) test (or Fisher´s exact test, when appropriate) 
was used for comparison of qualitative variables, and the t test or the Mann-Whitney U (MWU) 
test for quantitative variables. 
Agreement rates between in situ and invasive pair-matched cases regarding presence of stromal 
TILs and PDL1 expression were evaluated with k statistics. 
Survival rate curves were calculated according to the Kaplan-Meier method and compared by the 
log-rank test. DFS time was deﬁned as the interval between diagnosis and BC recurrence or 
metastasis, whereas OS time was defined as the interval between diagnosis and BC-related death 
or between diagnosis and the last follow-up time for surviving patients. Multivariate survival 
analyses were based on the Cox proportional hazard regression model. The level of significance 
was set at p < 0.05. 
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6.4 Results 
 
Association of stromal TILs and PDL1 expression with clinicopathological 
characteristics 
The quantification of  stromal TILs in the first cohort ranged between 0% and 80% (median of 
10%), with a minority of cases having more than 30% (moderate to marked - 9.2%) (table 1 and 
figure 1). However, the presence of moderate to marked stromal TILs was significantly increased 
in G3 (13.6%; p<0.001), in ER-negative cases (16.2%; p<0.001), in TNBC subtype (19.0%; 
p<0.001) and in cases with high expression of Ki67 (20.0%; p=0.019) (table 2). A significant 
association between moderate to marked stromal TILs with all the evaluated basal cell markers 
was also observed (CK5 – 22.4%; p<0.001 / CK14 – 28.6%; p=0.005 / EGFR – 25.0%; p=0.021 
/ P-cadherin – 15.1%; p=0.007) (table 3). Additionally, we still found a significant association 
between stromal TILs and the expression of the CSC marker ALDH1 (33.3%; p=0.014), as well 
as with the expression of vimentin (17.2%; p=0.008) (table 3). 
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Table 1 Stromal TILs and PDL1 expression in BC cases from the first cohort 
TILs 
Absent / Slight 
Moderate / Marked 
 
178 (41.0%) / 216 (49.8%) 
36 (8.3%) / 4 (0.9%) 
PDL1 expression 
Negative 
Positive 
 
407 (93.6%) 
28 (6.4%) 
BC, breast cancer; PDL1, programmed cell death-ligand 1; TILs, tumor-infiltrating 
lymphocytes.  
 
 
 
 
Figure 1 Stromal TILs and PDL1 expression in invasive breast cancer (200x). 
A: 1 – BC without stromal TILs (H&E); 2 – PDL1 negative expression / B: 1 – BC with increased stromal TILs 
(H&E); 2 – PDL1 expression in cancer cells / C: 1 – BC with increased stromal TILs (H&E); 2 – PDL1 expression 
in stromal TILs. 
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Table 2 Association between clinicopathological features with stromal TILs and PDL1 expression in IBC (first cohort) 
Clinicopathological 
features 
Stromal TILs 
 
 
 
PDL1 expression  
 
 absent/slight moderate/marked p value negative positive p value 
Age (average±sd) 59.40±13.11 54.88±13.48 0.052a 58.89±13.27 60.26±11.57 0.763a 
Tumor size 
≤ 2cm 
< 2 cm to ≤ 5 
> 5 cm 
 
87 (94.6%) 
191 (92.3%) 
45 (88.2%) 
 
5 (5.4%) 
16 (7.7%) 
6 (11.8%) 
0.397b  
92 (98.9%) 
192 (92.3%) 
48 (92.3%) 
 
1 (1.1%) 
16 (7.7%) 
4 (7.7%) 
0.069b 
Histological grade 
G1 
G2 
G3 
 
71 (98.6%) 
105 (97.2%) 
171 (86.4%) 
 
1 (1.4%) 
3 (2.8%) 
27 (13.6%) 
<0.001b  
72 (100%) 
106 (97.3%) 
179 (89.9%) 
 
0 (0%) 
3 (2.7%) 
20 (10.1%) 
0.002b 
Lymph node 
Negative 
Positive 
 
126 (88.7%) 
164 (93.2%) 
 
16 (11.3%) 
12 (6.8%) 
0.164b  
133 (93.0%) 
168 (94.4%) 
 
10 (7.0%) 
10 (5.6%) 
0.612b 
ER 
Positive 
Negative 
 
246 (95.4%) 
114 (83.8%) 
 
12 (4.6%) 
22 (16.2%) 
<0.001b  
253 (96.9%) 
120 (88.9%) 
 
8 (3.1%) 
15 (11.1%) 
0.001b 
PgR 
Positive 
Negative 
 
175 (91.6%) 
186 (91.2%) 
 
16 (8.4%) 
18 (8.8%) 
0.874b  
184 (96.3%) 
190 (92.2%) 
 
7 (3.7%) 
16 (7.8%) 
0.080b 
HER2 
Negative 
Positive 
 
308 (91.9%) 
50 (87.7%) 
 
27 (8.1%) 
7 (12.3%) 
0.308c  
317 (94.6%) 
55 (93.2%) 
 
18 (5.4%) 
4 (6.8%) 
0.757c 
Ki67 
< 14% 
≥ 14% 
 
342 (92.2%) 
20 (80.0%) 
 
29 (7.8%) 
5 (20.0%) 
0.019a  
354 (94.9%) 
21 (84%) 
 
19 (5.1%) 
4 (16.0%) 
0.002a 
Molecular subtype 
Luminal A 
Luminal B 
HER2-positive 
TNBC 
 
248 (95.4%) 
24 (85.7%) 
26 (89.7%) 
64 (81.0%) 
 
12 (4.6%) 
4 (14.3%) 
3 (10.3%) 
15 (19.0%) 
<0.001bd  
253 (97.7%) 
26 (86.7%) 
29 (100%) 
67 (83.8%) 
 
6 (2.3%) 
4 (13.3%) 
0 (0%) 
13 (16.2%) 
<0.001cd 
Bold indicated p<0.05 is statistically significant. a - Mann-Whitney U test; b – Pearson´s χ2 test; c – Fisher´s exact test; d - TN vs 
Others; sd – standard deviation. 
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Table 3 Association between basal cell markers, CSC markers and EMT markers with stromal TILs and PDL1 
expression in invasive breast cancer (first cohort) 
 Stromal TILs 
 
 
 
PDL1 expression  
 
 absent/slight moderate/marked p value negative positive p value 
Basal cell markers 
CK5 
Negative 
Positive 
CK14 
Negative 
Positive 
EGFR 
Negative 
Positive 
P-cadherin 
Negative 
Positive 
 
 
317 (93.8%) 
45 (77.6%) 
 
347 (92.5%) 
15 (71.4%) 
 
347 (92.3%) 
15 (75.0%) 
 
278 (93.6%) 
84 (84.9%) 
 
 
21 (6.2%) 
13 (22.4%) 
 
28 (7.5%) 
6 (28.6%) 
 
29 (7.7%) 
5 (25.0%) 
 
19 (6.4%) 
15 (15.1%) 
 
<0.001a 
 
 
0.005a 
 
 
0.021a 
 
 
0.007b 
 
 
327 (96.5%) 
48 (81.4%) 
 
357 (94.9%) 
18 (81.8%) 
 
359 (95.0%) 
16 (80.0%) 
 
289 (96.7%) 
86 (86.9%) 
 
 
12 (3.5%) 
11 (18.6%) 
 
19 (5.1%) 
4 (18.2%) 
 
19 (5.0%) 
4 (20.0%) 
 
10 (3.3%) 
13 (13.1%) 
 
<0.001a 
 
 
0.031a 
 
 
0.022a 
 
 
<0.001b 
CSC markers 
CD44+/CD24-/low 
Negative 
Positive 
CD49f 
Negative 
Positive 
ALDH1 
Negative 
Positive 
 
 
204 (93.2%) 
157 (89.2%) 
 
318 (91.9%) 
38 (86.4%) 
 
354 (92.2%) 
8 (66.7%) 
 
 
15 (6.8%) 
19 (10.8%) 
 
28 (8.1%) 
6 (13.6%) 
 
30 (7.8%) 
4 (33.3%) 
 
0.165b 
 
 
0.251a 
 
 
0.014a 
 
 
210 (96.3%) 
163 (91.6%) 
 
330 (95.4%) 
39 (84.8%) 
 
365 (94.8%) 
10 (76.9%) 
 
 
8 (3.7%) 
15 (8.4%) 
 
16 (4.6%) 
7 (15.2%) 
 
20 (5.2%) 
3 (23.1%) 
 
0.044b 
 
 
0.011a 
 
 
0.033a 
EMT markers 
E-cadherin 
Negative/Low 
Positive 
Vimentin 
Negative 
Positive 
 
 
21 (95.5%) 
339 (91.1%) 
 
307 (93.0%) 
53 (82.8%) 
 
 
1 (4.5%) 
33 (8.9%) 
 
23 (7.0%) 
11 (17.2%) 
 
0.708a 
 
 
0.008b 
 
 
22 (100%) 
352 (93.9%) 
 
316 (95.5%) 
57 (87.7%) 
 
 
0 (0%) 
23 (6.1%) 
 
15 (4.5%) 
8 (12.3%) 
 
0.628a 
 
 
0.036a 
Bold indicated p<0.05 is statistically significant. a – Fisher´s exact test; b – Pearson´s χ2 test. 
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The expression of PDL1 was mainly found at the cell membrane (in both tumor cells and stromal 
TILs) and only present in 6.4% of the cases (table 1 and figure 1). Although PDL1 expression 
was not observed in normal breast tissue, it was significantly associated to G3 (10.1%; p=0.002) 
and ER-negative carcinomas (11.1%; p=0.001), as well as with the TNBC subtype (16.2%; 
p<0.001) and with cases with high expression of Ki67 (16.0%; p=0.002) (table 2). We also 
observed a significant direct association between PDL1 expression and all the evaluated basal 
cell markers (CK5 – 18.6%; p<0.001 / CK14 – 18.2%; p=0.031 / EGFR – 20.0%; p=0.022 / P-
cadherin – 13.1%; p<0.001), all the evaluated CSC markers (CD44+/CD24-/low - 8.4%; p=0.044 / 
CD49f – 15.2%; p=0.011 / ALDH1 - 23.1%; p=0.033) and with the expression of vimentin 
(12.3%; p=0.036) (table 3). 
Stromal TILs and PDL1 expression were still significantly associated between each other 
(64.3%; p<0.001) (table 4). 
 
Table 4 Association between stromal TILs and PDL1 expression in invasive breast cancer (first cohort) 
 Stromal TILs 
 
 
 
PDL1 expression  
 
 absent/slight moderate/marked p value negative positive p value 
PDL1 expression 
Negative 
Positive 
 
380 (94.8%) 
10 (35.7%) 
 
21 (5.2%) 
18 (64.3%) 
<0.001a  
- 
- 
 
- 
- 
na 
DFS 
(mean of months) 
86.5 97.8 0.087b 87.5 92.3 0.327b 
OS 
(mean of months) 
91.7 99.8 0.108b 92.7 92.9 0.568b 
Bold indicated p<0.05 is statistically significant. a – Fisher´s exact test; b - Kaplan-Meier method/log-rank p value; 
na, not applicable; DFS, disease-free survival; OS, overall survival. 
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Association of stromal TILs and PDL1 expression with patient prognosis 
Overall, neither stromal TILs nor PDL1 expression were significantly associated with DFS or OS 
rates (table 4). However, in both G3 and ER-negative cases, the presence of more than 30% of 
stromal TILs was significantly associated with better DFS rates (94.26 vs 76.36; p=0.045 and 
93.01 vs 68.02; p=0.044, respectively). Additionally, also in G3 BC cases, PDL1 expression was 
significantly associated with improved DFS (96.79 vs 77.39; p=0.043). In vimentin-positive BC 
cases, increased stromal TILs were also significantly associated with better DFS and OS rates 
(110.18 vs 77.35; p=0.037 and 113.36 vs 85.39; p=0.047, respectively) (supplementary table 
S3). 
However, in multivariate analysis, only increased stromal TILs in vimentin-positive BC were 
independently associated with better DFS and OS (HR=0.10, p=0.017 and HR=0.06, p=0.019, 
respectively). Interestingly, also within vimentin-positive cases, PDL1 expression was, in 
contrast, significantly associated with a decreased OS (HR=7.12, p=0.018) (supplementary table 
S4 and figure 2). 
 
 
Figure 2 Survival curves showing the significant DFS and OS for patients with vimentin-positive BC relatively to 
stromal TILs (A and B) and PDL1 expression (C). 
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Concerning molecular subtypes, we observed that moderate to marked stromal TILs were 
associated with better DFS (100.4 vs 72.6) and OS (103.8 vs 79.9) rates (p=0.096 and p=0.080, 
respectively) in TNBC, although without reaching statistical significance (supplementary table 
S5). 
 
Stromal TILs and PDL1 expression in matched in situ and invasive carcinomas 
When stromal TILs and PDL1 expression were compared between DCIS and IBC, a similar 
distribution was found (TILs – 13.0% vs 13.8%; p=0.911; PDL1 expression - 8.7% vs 13.8%; 
p=0.399, respectively), as actually happened for all the other characteristics previously evaluated 
(figure 3, tables 5 and supplementary S2). 
 
 
Figure 3 Stromal TILs and PDL1 expression in pair-matched in situ and invasive breast cancer (200x). 
A: 1 – DCIS without stromal TILs (H&E); 2 – PDL1-negative expression in DCIS; 3 – IBC with few stromal TILs 
(H&E); 4 – PDL1-negative expression in IBC / B: 1 – DCIS with increased stromal TILs (H&E); 2 – PDL1 
expression in DCIS; 3 – IBC with increased stromal TILs (H&E); 3 – PDL1 expression in IBC. 
 
 
 
146 
 
 
Table 5 Tumor-infiltrating lymphocytes and PDL1 expression in breast cancer cases from the second cohort 
 DCIS Invasive carcinoma p value 
Tumor-infiltrating lymphocytes 
Absent/Slight 
Moderate/Marked 
 
40 (87.0%) 
6 (13.0%) 
 
69 (86.2%) 
11 (13.8%) 
0.911a 
PDL1 expression 
Negative 
Positive 
 
42 (91.3%) 
4 (8.7%) 
 
69 (86.2%) 
11 (13.8%) 
0.399a 
a – Pearson´s χ2 test. DCIS, ductal carcinoma in situ. 
 
Validating the results found in the first cohort, the presence of moderate to marked stromal TILs 
was significantly increased in G3 (26.9%; p=0.001), in TNBC subtype (25%; p=0.023) and in 
cases with PDL1 expression (63.6%; p=<0.001) (supplementary table S6). We also observed an 
increase of stromal TILs in ER-negative cases and in cases with high expression of Ki67 (20%; 
p=0.059 and 20%; p=0.057, respectively). Additionally, we found a similar association of 
increased stromal TILs and HER2-positive subtype (25%; p=0.023). In DCIS, moderate to 
marked stromal TILs were enriched in G3 (23.5%; p=0.071), TNBC and HER2-positive 
subtypes (20% and 40%, respectively; p=0.073) and in cases with PDL1 expression (50%; 
p=0.077), although without reaching statistical significance. 
Concerning PDL1 expression, it was significantly associated with G3 (26.9%; p=0.005) and all 
molecular subtypes, except luminal A (0%; p=0.005) (supplementary table S7). Interestingly, we 
also observed PDL1 expression enriched in cases with high expression of Ki67 (30%; p=0.061), 
without reaching statistical significance. 
Finally, regarding the pair-matched cases, we observed a concordance rate of stromal TILs and 
PDL1 expression between DCIS and invasive BC of 93.8% (30/32) and 81.3% (26/32), 
147 
 
respectively (table 6 and 7). Furthermore, in PDL1 expression, we found that 5 out 6 discordant 
cases changed from negative to positive expression between DCIS and IBC, respectively. 
 
Table 6 Concordance of stromal TILs between DCIS and invasive carcinoma 
Stromal TILs Invasive carcinoma  
 absent/slight moderate/marked Total 
DCIS 
absent/slight 
moderate/marked 
Total 
 
27 
0 
27 
 
2 
3 
5 
 
29 
3 
32 
Kappa statistics – 0.72; p=<0.001. Bold indicated p<0.05 is statistically significant. DCIS, ductal 
carcinoma in situ. 
 
Table 7 Concordance of PDL1 expression between DCIS and invasive carcinoma 
PDL1 Invasive carcinoma  
 Negative Positive Total 
DCIS 
Negative 
Positive 
Total 
 
24 
1 
25 
 
5 
2 
7 
 
29 
3 
32 
Kappa statistics – 0.31; p=0.049. Bold indicated p<0.05 is statistically significant. DCIS, ductal 
carcinoma in situ. 
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6.5 Discussion 
Our study confirms that increased stromal TILs are present in a minority of IBC cases 
and that are already present in in situ stages, as previously shown.185,286 Although PDL1 
expression has been reported in the literature from 20% to nearly 60% of the cases, we only 
observed in a small proportion of IBCs and, for the first time, even in DCIS cells.206,207,287-289 
In IBC, increased stromal TILs and PDL1 expression were associated with each other and 
with G3 and TNBC subtype, with statistical significance in both cohorts, which also validates 
previous reports.207,286,288 The association of increased stromal TILs and PDL1 expression with 
the evaluated basal cell markers also reinforces the relationship with the TNBC molecular 
subtype. 
Stromal TILs include several types of T and B lymphoid cells in different proportions 
with distinct associations with clinical outcome that we did not discriminate in our study. For 
instance, cytotoxic (CD8+) T cells are significantly increased in high grade, ER-negative BC and 
BC with increased proliferative activity, as well as associated with improved clinical 
outcome.178-180 On the other side, immunosuppressive (CD4+/FOXP3+) T cells have been shown 
to be associated with worse prognosis in IBC and even with increased risk of relapse in DCIS.181-
183 This data suggest that cytotoxic T cells are responsible for the antitumor immune activity and 
immunosuppressive T cells can inhibit this response. Furthermore, B lymphocytes are also 
associated with higher histological grade, ER-negative cases and basal phenotype, as well as 
with better prognosis.184 This indicates that humoral immune response, along with cell-mediated 
immune response, acts in convergence to achieve effective antitumor response. Based on this 
knowledge, it would be important to evaluate the clinical value of subtyping the composition of 
stromal TILs in BC and reveal the potential predictive role of these markers in response to 
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immunotherapy. Nonetheless, it is remarkable that the quantification of stromal TILs alone, 
regardless of its specific subpopulation of lymphoid cells, has prognostic and predictive 
information. 
Although the use of TMAs in this work could, eventually, miss quantify stromal TILs 
evaluation, several reports suggest that TMAs are a valid choice, as the majority of BC are not 
heterogeneous regarding stromal TILs distribution throughout the tumor.179,284,287,290 While 
recent guidelines recommend the evaluation of TILs as a continuous variable, we were able to 
show that the cut-off values used in this work enclose clinical significance and may be used to 
easily categorize this parameter, possibly reducing the interobserver variability. 
Concerning PDL1 expression, in addition to tumor cells, it has been reported that it can 
be also present in stromal TILs, as observed by us, specifically in CD4+/FOXP3- T cells.288 
However, PDL1 expression is not associated with T cell exhaustion markers, which means that 
PDL1 is only partially inhibiting T cells.207 Nevertheless, this does not contradict the idea of 
blocking PDL1 in order to reactivate partially inhibited T cells and further increase the antitumor 
immune response. 
The monoclonal antibody that has been used in this work was the clone SP142, which 
was developed for anti-PDL1 immunotherapy (atezolizumab, formerly MPDL3280A).200,285,291 
SP142 is specific for the PDL1 cytoplasmic domain giving clear membranous staining, with 
lower background staining.292 The different results of PDL1 expression in BC are probably 
related to different methods in evaluating PDL1 expression, from protein expression (using 
immunohistochemistry or immunofluorescence) to mRNA analysis (using PCR, in situ 
hybridization or microarrays), different cut-offs values, antibodies used and constitution of 
cohorts, as well as heterogeneity within tumors.216 Currently, the assays to evaluate the role of 
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PDL1 expression for prognosis and predictive information are not standardized neither in 
methodology nor interpretation of the staining. Consequently, it is of major importance that the 
clinical significance of PDL1 expression in BC is revealed before its use in daily routine. 
Concerning DCIS, a similar trend in association between stromal TILs and PDL1 
expression with histological grade and molecular subtype was also detected, suggesting that, as 
we previously reported, these features correlate well with the invasive counterpart.143 Very 
recently, the expression of PDL1 has been described in about 80% of stromal TILs associated 
with DCIS cases, as well as an association with TNBC subtype.293 In that work, there was no 
expression of PDL1 in DCIS cells, unlike our observation, in which we detected in both DCIS 
cells and associated stromal TILs. 
The above-mentioned findings in DCIS samples indicate that the immune response to 
tumors exists even at early stages and that distinct molecular subtypes have different 
immunogenicity. The characterization of immune checkpoint markers, in both invasive and 
DCIS cases, may result in potential targets for therapy, such as anti-PDL1 treatment. Moreover, 
we also report a high concordance of stromal TILs and PDL1 expression between DCIS and IBC 
pair-matched cases. This means that stromal TILs and PDL1 expression might not be relevant for 
the progression from in situ to IBC, but instead represent a response to intrinsic characteristics of 
different molecular subtypes. Nevertheless, although the few discordant cases might be due to 
sampling issues, the fact that 5 out of 6 cases changed PDL1 expression from negative to 
positive between in situ and invasive BC, respectively, could also mean that an additional 
activation of the PDL1 pathway can be achieved in BC progression. As such, it remains to be 
clarified the complex role of the immune response in the progression from in situ to invasive 
disease. 
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Finally, we observed that stromal TILs and PDL1 expression were associated with CSC 
markers and vimentin expression. Our results are expected because stromal TILs and PDL1 
expression are associated with TNBC subtype, which in turn is associated with a higher 
proportion of cells with stem cell phenotype (CD44+/CD24-/low, CD49f and ALDH1) and EMT 
features, as shown by our group in the past.120,283,294 In addition, as stated above, both stromal 
TILs and PDL1 expression were associated with basal cell markers, including P-cadherin, which 
was previously demonstrated by our group to be up-regulated in basal–like subtype and 
associated with stem cell properties and EMT phenotype in BC cell lines.120,294-296 
Although the association of stromal TILs with stem cell phenotype and EMT has been 
previously reported, as far as we know, this is the first time that PDL1 expression in BC cases is 
associated with CSC markers (CD44+/CD24-/low, CD49f and ALDH1), which is probably related 
to the close relationship with stromal TILs and TNBC subtype.178 However, we observed an 
association of PDL1 expression with all CSC markers, while stromal TILs were only associated 
with ALDH1. This probably means a potential role of CSCs in the activation of PDL1 
expression, both in tumor cells and stromal TILs, directly regulating the antitumoral immune 
response. 
Equally, PDL1 expression has been characterized recently in relation with EMT 
markers.297 The authors showed that the induction of EMT causes the up-regulation of PDL1 
expression in BC cell lines and that the inhibition of PDL1 originates an EMT reversal state, 
suggesting a dual benefit of inhibiting the PDL1 pathway. They also showed an association of 
PDL1 expression with EMT markers in BC patients, such as vimentin, as our study. 
Despite the association of stromal TILs with CSC and EMT markers, the final effect in 
BC tissue is a protective one, given the fact that, in vimentin-positive BC, the presence of more 
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than 30% of stromal TILs were independently associated with increased DFS and OS rates, 
reflecting an active antitumor immune response with an impact on patient outcome. Although 
contradictory information has been published regarding PDL1 expression and BC prognosis, in 
theory, the expression of PDL1 in BC should have a deleterious effect on prognosis, given the 
inhibitory effect of PDL1 in the antitumor immune response.206 We also showed that in 
vimentin-positive BC, PDL1 expression is independently associated with worse OS. Although it 
has been reported that PDL1 expression can be related with better survival rates in BC, it is 
probably due to the close association of PDL1 with the presence of increased stromal TILs, the 
true effectors against tumor cells.207,208 Finally, because IBC with mesenchymal traits is strongly 
associated with TNBC, a subtype associated with worse prognosis and limited treatment 
strategies, immunologic modulators may represent an alternative approach to improve clinical 
outcome of these patients.186,206,298 
In conclusion, we have confirmed the association of stromal TILs and PDL1 expression 
with aggressive BC (G3 and TNBC/basal subtype) and that both are already expressed in in situ 
stages. We also showed that increased stromal TILs and PDL1 expression are associated with 
clinical outcome in BC with vimentin expression. Notably, we describe a close relationship 
between CSC markers with stromal TILs, and for the first time, with PDL1 expression. 
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6.6 Supplementary information 
 
Table S1 Clinicopathological features of the first cohort 
Age (average ± sd) 59.02 ± 13.14 
Tumor size 
≤ 2cm 
< 2cm to ≤ 5cm 
> 5cm 
 
94 (26.4%) 
210 (59.0%) 
52 (14.6%) 
Histological grade  
G1 
G2 
73 (19.0%) 
110 (28.7%) 
G3 201 (52.3%) 
Lymph node status 
Negative 
Positive 
 
144 (44.7%) 
178 (55.3%) 
ER 
Positive 
Negative 
 
263 (65.8%) 
137 (34.2%) 
PgR 
Positive 
Negative 
 
194 (48.4%) 
207 (51.6%) 
HER2 
Negative 
Positive 
 
339 (85.2%) 
59 (14.8%) 
Ki67 
< 14% 
 ≥ 14% 
 
377 (93.8%) 
25 (6.2%) 
Molecular subtype 
Luminal A 
Luminal B 
HER2-positive 
TNBC 
 
263 (65.4%) 
30 (7.5%) 
29 (7.2%) 
80 (19.9%) 
sd – standard deviation  
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Table S1 Clinicopathological features of the first cohort (cont.) 
Basal cell markers 
CK5 
Negative 
Positive 
CK14 
Negative 
Positive 
EGFR 
Negative 
Positive 
P-cadherin 
Negative 
Positive 
 
 
343 (85.3%) 
59 (14.7%) 
 
380 (94.5%) 
22 (5.5%) 
 
382 (95.0%) 
20 (5.0%) 
 
302 (75.1%) 
100 (24.9%) 
CSC markers 
CD44+/CD24-/low 
Negative 
Positive 
CD49f 
Negative 
Positive 
ALDH1 
Negative 
Positive 
 
 
221 (55.3%) 
179 (44.7%) 
 
348 (88.3%) 
46 (11.7%) 
 
389 (96.8%) 
13 (3.2%) 
EMT markers 
E-cadherin 
Negative/Low 
Positive 
Vimentin 
Negative 
Positive 
 
 
22 (5.5%) 
378 (94.5%) 
 
335 (83.8%) 
65 (16.2%) 
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Table S2 Clinicopathological features of the second cohort 
 DCIS Invasive carcinoma p 
Age (average ± sd) 55.65 ± 13.18 55.65 ± 13.18 na 
Histological grade   0.566a 
G1 21 (26.6%) 27 (34.2%)  
G2 27 (34.2%) 23 (29.1%)  
G3 31 (39.2%) 29 (36.7%)  
Lymph node status 
Negative 
Positive 
 
- 
- 
 
16 (28.1%) 
41 (71.9%) 
na 
ER 
Positive 
Negative 
 
53 (67.1%) 
26 (32.9%) 
 
51 (64.6%) 
28 (35.4%) 
0.431b 
PgR 
Positive 
Negative 
 
35 (44.9%) 
43 (55.1%) 
 
34 (43%) 
45 (57%) 
0.693b 
HER2 
Negative 
Positive 
 
58 (73.4%) 
21 (26.6%) 
 
58 (73.4%) 
21 (26.6%) 
1.000a 
Ki67 
< 14% 
≥ 14% 
 
69 (88.5%) 
9 (11.5%) 
 
67 (85.9%) 
11 (14.1%) 
0.555b 
Molecular subtype   0.901a 
Luminal A 45 (57.0%) 41 (52.0%)  
Luminal B 12 (15.2%) 15 (18.9%)  
HER2-positive 14 (17.7%) 14 (17.7%)  
TNBC 8 (10.1%) 9 (11.4%)  
sd – standard deviation; na – not applicable; a – Pearson´s χ2 test; b – Mann-Whitney U test 
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Table S3 Relationship between stromal TILs and PDL1 expression with DFS and OS in different subgroups 
Subgroup Stromal TILs  PDL1 expression  
 absent/slight moderate/marked p negative positive p 
G3 
DFS 
OS 
 
76.36 
82.98 
 
94.26 
96.62 
 
0.045 
0.062 
 
77.39 
83.99 
 
96.79 
97.47 
 
0.043 
0.100 
ER negative 
DFS 
OS 
 
68.02 
75.02 
 
93.01 
95.97 
 
0.044 
0.056 
 
69.59 
76.64 
 
90.60 
91.47 
 
0.097 
0.201 
Vimentin positive 
DFS 
OS 
 
77.35 
85.39 
 
110.18 
113.36 
 
0.037 
0.047 
 
83.91 
91.91 
 
84.38 
85.00 
 
0.618 
0.926 
DFS and OS: mean of months. Bold indicated p<0.05 is statistically significant. 
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Table S4 Multivariate Cox proportional hazard analysis 
 
Variable 
 
Evaluation 
G3 ER negative Vimentin positive 
DFS DFS DFS OS 
HR 
(95% CI) 
p HR 
(95% CI) 
p HR 
(95% CI) 
p HR 
(95% CI) 
p 
Stromal 
TILs 
absent/slight 
 
1  1  1  1  
 moderate/marked 0.89 
(0.37-
2.17) 
0.800 0.66 
(0.27-
1.61) 
0.365 0.10 
(0.02-0.67) 
0.017 0.06 
(0.01-0.62) 
0.019 
PDL1 Negative 
 
1  1  1  1  
 Positive 0.60 
(0.20-
1.80) 
0.361 0.58 
(0.21-
1.62) 
0.301 3.20 
(0.67-15.25) 
0.144 7.12 
(1.40-36.34) 
0.018 
Tumor size ≤2cm 
 
1  1  1  1  
 <2cm to ≤5cm 
 
1.48 
(0.74-
2.93) 
0.266 1.88 
(0.87-
4.07) 
0.108 1.18 
(0.37-3.84) 
0.779 1.58 
(0.25-9.80) 
0.626 
 >5cm 2.16 
(0.97-
4.80) 
0.059 2.45 
(1.04-
5.75) 
0.040 2.96 
(0.83-10.49) 
0.093 2.25 
(0.29-17.50) 
0.439 
Lymph node 
status 
Negative 1   
nc 
 
nc 
1  
 Positive 1.74 
(1.06-
2.87) 
0.030 1.54 
(0.48-4.98) 
0.471 
Histological 
grade 
G1 
 
 
 
nc 
1  1  1  
 G2 1.43 
(0.38-
5.42) 
0.603 1.13 
(0.18-7.18) 
0.901 2.34 
(0.11-49.18) 
0.585 
 G3 1.73 
(0.54-
5.59) 
0.360 3.40 
(0.66-17.50) 
0.144 1.71 
(0.14-21.35) 
0.679 
ER Positive 
 
 
nc 
 
nc 
1  1  
 Negative 0.60 
(0.14-2.55) 
0.493 2.24 
(0.19-26.48) 
0.523 
HR – hazard ratio; CI – confidence interval; nc – not computed. Bold indicated p<0.05 is statistically significant. 
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Table S5 Relationship between DFS and OS with TILs and PDL1 expression in molecular subtypes 
Molecular subtype Stromal TILs  PDL1 expression  
 absent/slight moderate/marked p negative positive p 
Luminal A 
DFS 
OS 
 
94.8 
99.1 
 
108.6 
108.6 
 
0.130 
0.180 
 
- 
- 
 
- 
- 
 
nc 
nc 
Luminal B 
DFS 
OS 
 
75.5 
77.3 
 
94.3 
94.3 
 
0.507 
0.507 
 
84.4 
86.1 
 
58.8 
58.8 
 
0.312 
0.291 
HER2-positive 
DFS 
OS 
 
49.0 
60.5 
 
56.0 
59.7 
 
0.769 
0.978 
 
- 
- 
 
- 
- 
 
nc 
nc 
TNBC 
DFS 
OS 
 
72.6 
79.9 
 
100.4 
103.8 
 
0.096 
0.080 
 
76.1 
83.6 
 
92.0 
93.0 
 
0.239 
0.417 
DFS and OS: mean of months; nc – not computed 
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Table S6 Association between clinicopathological features with stromal TILs in DCIS and IBC (2nd cohort) 
Clinicopathological 
features 
DCIS 
Stromal TILs 
 Invasive carcinoma 
Stromal TILS 
 
 absent/slight moderate/marked p absent/slight moderate/marked p 
Age (average ± sd) 55.82±14.77 60.00±14.93 0.555a 54.80±12.90 61.86±10.37 0.169a 
Histological grade 
G1/G2 
G3 
 
25 (96.2%) 
13 (76.5%) 
 
1 (3.8%) 
4 (23.5%) 
0.071b  
40 (100%) 
19 (73.1%) 
 
0 (0%) 
7 (26.9%) 
0.001b 
Lymph node status 
Negative 
Positive 
 
- 
- 
 
- 
- 
nc  
11 (91.7%) 
32 (86.5%) 
 
1 (8.3%) 
5 (13.5%) 
1.000b 
ER 
Positive 
Negative 
 
30 (93.8%) 
8 (72.7%) 
 
2 (6.2%) 
3 (27.3%) 
0.241c  
39 (95.1%) 
20 (80%) 
 
2 (4.9%) 
5 (20%) 
0.059c 
PgR 
Positive 
Negative 
 
18 (90%) 
19 (86.4%) 
 
2 (10%) 
3 (13.6%) 
0.706c  
27 (96.4%) 
32 (84.2%) 
 
1 (3.6%) 
6 (15.8%) 
0.207c 
HER2 
Negative 
Positive 
 
31 (91.2%) 
7 (77.8%) 
 
3 (8.8%) 
2 (22.2%) 
0.277b  
44 (91.7%) 
15 (83.3%) 
 
4 (8.3%) 
3 (16.7%) 
0.380b 
Ki67 
< 14% 
≥ 14% 
 
33 (91.7%) 
5 (71.4%) 
 
3 (8.3%) 
2 (28.6%) 
0.308c  
50 (90.9%) 
8 (80%) 
 
5 (9.1%) 
2 (20%) 
0.057c 
Molecular subtype 
Luminal A 
Luminal B 
HER2-positive 
TNBC 
 
24 (96%) 
7 (87.5%) 
3 (60%) 
4 (80%) 
 
1 (4%) 
1 (12.5%) 
2 (40%) 
1 (20%) 
0.073bd  
32 (100%) 
12 (85.7%) 
9 (75%) 
6 (75%) 
 
0 (0%) 
2 (14.3%) 
3 (25%) 
2 (25%) 
0.023bd 
PDL1 expression 
Negative 
Positive 
 
38 (90.5%) 
2 (50%) 
 
4 (9.5%) 
2 (50%) 
0.077b  
65 (94.2%) 
4 (36.4%) 
 
4 (5.8%) 
7 (63.6%) 
<0.001b 
a – t-test; b – Fisher´s exact test; c - Mann-Whitney U test; d - Luminal A/B vs HER2-positive/TNBC; sd – standard 
deviation; nc – not computed. Bold indicated p<0.05 is statistically significant. 
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Table S7 Association between clinicopathological features with PDL1 expression in DCIS and IBC (2nd cohort) 
Clinicopathological 
features 
DCIS 
PDL1 
 Invasive carcinoma 
PDL1 
 
 negative positive p negative positive p 
Age (average ± sd) 57.26±14.38 47.00±16.27 0.186a 55.17±12.95 58.25±11.87 0.527a 
Histological grade 
G1/G2 
G3 
 
24 (92.3%) 
15 (88.2%) 
 
2 (7.7%) 
2 (11.8%) 
1.000b  
39 (97.5%) 
19 (73.1%) 
 
1 (2.5%) 
7 (26.9%) 
0.005b 
Lymph node 
Negative 
Positive 
 
- 
- 
 
- 
- 
nc  
9 (75%) 
33 (89.2%) 
 
3 (25%) 
4 (10.8%) 
0.340b 
ER 
Positive 
Negative 
 
30 (93.8%) 
9 (81.8%) 
 
2 (6.2%) 
2 (18.2%) 
0.531c  
38 (92.7%) 
20 (80%) 
 
3 (7.3%) 
5 (20%) 
0.185c 
PgR 
Positive 
Negative 
 
18 (90%) 
20 (90.9%) 
 
2 (10%) 
2 (9.1%) 
0.951c  
25 (89.3%) 
33 (86.8%) 
 
3 (10.7%) 
5 (13.2%) 
0.878c 
HER2 
Negative 
Positive 
 
31 (91.2%) 
8 (88.9%) 
 
3 (8.8%) 
1 (11.1%) 
1.000b  
43 (89.6%) 
15 (83.3%) 
 
5 (10.4%) 
3 (16.7%) 
0.673b 
Ki67 
< 14% 
≥ 14% 
 
32 (88.9%) 
7 (100%) 
 
4 (11.1%) 
0 (0%) 
0.531c  
50 (90.9%) 
7 (70%) 
 
5 (9.1%) 
3 (30%) 
0.061c 
Molecular subtype 
Luminal A 
Luminal B 
HER2-positive 
TNBC 
 
23 (92%) 
8 (100%) 
4 (80%) 
4 (80%) 
 
2 (8%) 
0 (0%) 
1 (20%) 
1 (20%) 
0.226bd  
32 (100%) 
10 (71.4%) 
10 (83.3%) 
6 (75%) 
 
0 (0%) 
4 (28.6%) 
2 (16.7%) 
2 (25%) 
0.005be 
a – t-test; b – Fisher´s exact test; c - Mann-Whitney U test; d - Luminal A/B vs HER2-positive/TNBC; e – Luminal A 
vs Others; sd – standard deviation; nc – not computed. Bold indicated p<0.05 is statistically significant. 
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Chapter 7 
General Discussion 
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BC is the most frequent type of cancer in women representing about one-third of all new 
diagnosis.27 Portugal is not an exception to this rule and BC is the main cause of cancer-related 
death in women.29 As such, BC emerges as one of the most important models to be studied if we 
want to contribute to impact on cancer in general. 
Given that survival rates decrease rapidly from localized to metastatic stages, the early 
detection of this cancer, as well as all others, is the most key factor for the success of its 
treatment.27 Other crucial factors that should be taken into consideration, if we aim to decrease 
BC incidence, is the knowledge concerning risk factors. The proper identification of such risk 
factors can enable the modification of lifestyle habits to decrease the probability of developing 
BC.38-41 Nevertheless, although environment factors play a very relevant role in the etiology of 
BC, most of our knowledge is related to luminal BC (estrogen receptor positive), leaving triple-
negative and HER2-positive BCs, which represent more aggressive forms of BC, outside of this 
possible intervention.42 
Molecular classification of BC has transformed our understanding about this disease and the 
application of this methodology into different models has revolutionized cancer classification. 
Even though gene expression profiling has been available for more than 15 years, the molecular 
classification is not a current practice, being applied to very specific cases with very specific 
questions in mind.94 On the other side, old markers such as histologic classification and grading 
are a mandatory requirement in any BC pathology report, being important prognostic factors 
correlating with disease-free and overall survival.61 
Finally, IHC studies finish the evaluation of BC cases, providing valuable information 
regarding prognosis and, more importantly, prediction to targeted-therapy.98-100,103-106 
Additionally, IHC can even be used to classify BC cases into molecular subtypes, which has 
163 
 
been shown to be clinically useful.60 The application of these markers, as well as others that 
complement the pathology report, try to provide the most accurate and personalized 
classification and stratification of BC patients. Nevertheless, patients with the same classification 
and stratification present different outcomes. For these reasons, improving prognostication in 
BC, through the refinement of current biomarkers and identification of new ones, remains an 
important task to delineate the precise risk of BC patients and provide them with personalized 
treatment. 
As such, in this thesis, we studied three biomarkers, starting with the oncogene HER2 to 
improve its value in the identification of patients to targeted therapy. The first work aimed to 
understand the impact of the new ASCO/CAP guideline for HER2 test in BC. The 2013 
ASCO/CAP guideline came to replace the previous 2007 guideline and presented a double 
change: modification of IHC criteria, that changes the classification of which cases are selected 
to reflex testing, and modification of ISH criteria, that changes the classification of which cases 
are positive or negative for HER2 gene amplification. For this purpose, we collected cases that 
were classified before and after the introduction of the new ASCO/CAP guideline. The different 
classification of the cases reveals that the 2013 ASCO/CAP guideline has a relevant impact on 
the classification of BC cases (significantly increasing the number of HER2-positive cases), 
although not revealing if the change was due to the modification of IHC criteria, ISH criteria or 
both. To answer this question, we compared the cases from before and after the new guideline 
classifying with the same ISH criteria, allowing the determination of the value of IHC in the 
impact of the new guideline. The absence of different results in this setting reveals that the 
modification of IHC criteria had negligible effect on the final change of the new guideline, as 
expected.238 On the other hand, the classification of the two case series with different ISH criteria 
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(2007 and 2013) revealed an increase of HER2-positive cases, showing that the final change of 
the new guideline is more related to the change of ISH criteria rather than IHC criteria. 
Additionally, we also underlined an important fact: only ~50% of the positive cases fulfil both 
ISH criteria (HER2/CEP17 ratio and average HER2 copy number), highlighting the importance 
of a control probe in the classification of HER2 gene amplification. Finally, we addressed the 
issue of equivocal cases (HER2/CEP17 ratio <2.0 and average HER2 copy number ≥4.0 and 
<6.0 signals per cell), which represent a new category not really appreciated by most clinicians. 
In fact, the equivocal cases should not be compared with the previous “borderline” cases from 
the 2007 guideline (HER2/CEP17 ratio ≤2.2 and ≥1.8), that just represented cases near the 
threshold of positivity. In practice, these cases were previously subdivided using the criteria from 
the first-generation of clinical trials (HER2/CEP17 ratio < or ≥2.0) to decide for targeted-
therapy.155 Currently, an equivocal result by ISH technique requires additional testing to achieve 
a more definite result using either another block of the same specimen or another specimen 
(NCB, SES, lymph node or metastatic lesion). If, after this cycle of tests, the result remains to be 
equivocal, the oncologist may consider HER2-targeted therapy based on patient status and 
preferences.97 
The second work aimed to determine the concordance of the HER2 gene amplification assay 
among different observers by counting increasing numbers of invasive cancer cells. It is 
remarkable that this question wasn´t done by anyone until now: what is the minimum cell count 
that allows for acceptable concordance rate and low variability between different measurements 
or observers? As expected, the increase in cell count from 20 to 60 invasive cells increased the 
concordance rate between different observers (interobserver) and within the same observer 
(intraobserver). This performance was mainly due to the decrease of the variability of the 
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HER2/CEP17 ratio and of the average HER2 copy number measurements. Importantly, we 
showed that only the observer with more experience could achieve near acceptable agreement 
rates just by counting the minimum cells recommended by the current ASCO/CAP guideline (20 
invasive cells). As such, we propose that the minimum cell number of invasive cells should be 
raised to at least 40, and preferably 60 invasive cells (in observers with less experience). 
Additionally, the cases with discordant results presented HER2/CEP17 ratios near the threshold 
of positivity, making it the most probable cause of discordancy and excluding HER2-GH as the 
usual culprit. In such cases, the importance of counting more invasive cells is even greater, as 
well as having a dual count from an experienced observer to guarantee an accurate result. Lastly, 
we showed that the variability of the HER2/CEP17 ratio was significantly higher in HER2-
positive than in HER2-negative cases, given the subjective quantification of the number of HER2 
signals in clusters. Nevertheless, it remains open the hypothesis that genetic instability of HER2 
gene amplification could exist in separate areas of HER2-positive tumors, as it is expected by a 
breakage-fusion-bridge (BFB) mechanism (presence of copy number heterogeneity). 
The third work aimed to compare the amplification status of the HER2 gene between IC and 
adjacent CIS, searching for HER2-GH in both components, providing a way to study the 
relevance of HER2 gene amplification in the progression of CIS to IC. Additionally, we 
characterized all our cases with HER2-GH in IC since the introduction of the 2013 ASCO/CAP 
HER2 guideline, also evaluating the amplification status of the HER2 gene in the CIS 
component if present. This approach could measure the impact of HER2-GH in IC on the result 
of the amplification test and provide evidence of clonality between IC and CIS. Regarding the 
first objective, we showed that all IC cases had an adjacent CIS with the same HER2 status, but 
with 4 cases of CIS presenting HER2-GH. Interestingly, in these 4 cases with HER2-GH in CIS, 
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we found only 2 IC cases presenting homogeneous HER2 gene amplification. This means that 
HER2 gene amplification is not relevant for the transition from CIS to IC, given the fact that the 
remaining 2 IC cases, with adjacent HER2-GH in CIS, had no HER2 gene amplification. It 
would be expected that the CIS component with HER2 gene amplification, which is significantly 
correlated with high nuclear grade and aggressive biological behavior, would be the component 
more likely to become invasive. Nevertheless, we observed that components of CIS without 
HER2 gene amplification could become invasive even in close proximity with components of 
CIS with HER2 gene amplification. Additionally, if the trigger for invasion would originate in 
the stroma we would see both components of CIS, with and without HER2 gene amplification, 
becoming invasive, which we do not. As such, the trigger for invasion probably originates more 
often inside the components of CIS itself. Nevertheless, it remains to be explored if HER2-GH in 
CIS can be clonally related or represent independent lesions colliding with each other. We 
speculate that probably both situations can occur and at least one of the cases of CIS with HER2-
GH represents most likely two independent lesions (low-grade LCIS and high-grade DCIS in 
case 4 from the 1st cohort). Regarding the second objective, we showed that HER2-GH in the IC 
cases according to the 2013 ASCO/CAP HER2 guideline is a rare event (about 1% of the cases) 
introducing low interference on the result of the amplification test in clinical practice. 
Furthermore, these heterogeneous cases had adjacent CIS without HER2 gene amplification, 
showing that the development of HER2 gene amplification occurred after invasion. Interestingly, 
it has been shown that almost always the HER2-positive and HER2-negative components of IC 
cases with HER2-GH are clonally related, given that their patterns of CNAs are highly similar.271 
Nevertheless, it has also been shown that independent collision tumors can exist creating a single 
tumor mass with and without HER2 gene amplification.270 
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Finally, the study of stromal TILs and PDL1 expression in BC aimed to measure the 
importance of these biomarkers in clinical practice. First, we correlate both stromal TILs and 
PDL1 expression with classical pathological features in addition to molecular subtype and 
prognosis. We showed that stromal TILs and PDL1 expression in BC were correlated with each 
other as well as with BC presenting aggressive features. Moreover, in these cases the presence of 
stromal TILs was significantly associated with better prognosis. Although stromal TILs were not 
further characterized, it is extraordinary that the quantification of the associated inflammatory 
response against tumor tissue provides useful information. In future work, we intend to evaluate 
the clinical impact of the presence of different inflammatory cells in BC tissue, such as B cells, T 
cells (including cytotoxic and immunosuppressive) and macrophages. Second, we also correlate 
these biomarkers with CSCs and EMT markers, showing important associations, particularly in 
PDL1-positive BC cases, providing an important link between stemness and immune resistance. 
Furthermore, we showed for the first time that the presence of stromal TILs in vimentin-positive 
BC were independently associated with better prognosis, reflecting an active antitumor immune 
response. Additionally, in the same setting, PDL1 expression in BC tissue was independently 
associated with worse prognosis, suggesting that these cases (vimentin+/PDL1+) could be the 
ones more responsive to immunotherapy. Third, we compared the expression of stromal TILs 
and PDL1 in both in situ and invasive BC, using pair-matched cases, to undercover their role in 
the progression from in situ to invasive cancer. We observed a high concordance rate of stromal 
TILs and PDL1 expression between DCIS and invasive BC, showing expression of PDL1 in 
DCIS cells for the first time and that the immune response to tumors not only begins at initial 
stages of carcinogenesis but also that it is probably related with different molecular subtypes, 
168 
 
that possess intrinsic immunogenicity. As such, stromal TILs and PDL1 expression probably are 
not relevant in the progression from in situ to invasive BC. 
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CHAPTER 8 
CONCLUSIONS AND FUTURE PERSPECTIVES 
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Regarding the studies performed concerning the oncogene HER2, the conclusions are as follow: 
1.1 The application of the 2013 ASCO/CAP guideline increased the number of HER2-
positive cases, selecting more patients for anti-HER2 targeted therapy. 
1.2 The change of the 2013 ASCO/CAP guideline is mostly due to modifications of ISH 
criteria rather than of IHC criteria. 
1.3 The HER2-positive cases are the primary result of HER2/CEP17 ratio revealing the 
importance of a control probe in the classification of HER2 gene amplification. 
 
2.1 The increase in cell count improved the intraobserver and interobserver concordance 
rate of the HER2 test. 
2.2 Counting 20 invasive cells is not sufficient and the minimum cell number should be 
raised to at least 40, and preferably 60 invasive cells. 
2.3 The cases with discordant results are more frequent when HER2/CEP17 ratio is near 
the threshold of positivity. 
 
3.1 All BC cases showed IC and adjacent CIS with the same HER2 gene amplification 
status. 
3.2 According to the latest definition, HER2-GH is a rare event and can be present in 
both in situ and invasive BC. 
3.3 HER2 gene amplification is not relevant in the progression from in situ to invasive 
BC. 
 
Regarding the study concerning the presence of stromal TILs and PDL1 expression in BC, the 
conclusions are as follow: 
4.1 Stromal TILs and PDL1 expression are associated with high grade and ER-negative 
BC, as well as with the expression of basal cells markers. 
4.2 PDL1 expression in BC is strongly associated with CSCs markers. 
4.3 Stromal TILs and PDL1 expression are not relevant in the progression from in situ to 
invasive BC. 
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Following the above-mentioned conclusions, we propose novel studies to highlight the 
role of these tumor-based biomarkers in prognostication of BC: 
1. Study the concordance of HER2 gene amplification test between different ISH 
techniques (FISH and SISH) with the application of the new guideline to clarify its 
role in the classification of equivocal results. 
 
2. Study the quantification of HER2 gene amplification by imaging analysis (in ISH) 
and by molecular techniques to determine HER2 gene amplification more accurately. 
 
3. Study the clonal relationship of HER2-positive and HER2-negative components of 
HER2-GH in both IC and CIS. 
 
4. Study the clinical impact of B cells, T cells, including cytotoxic (CD8+) and 
immunosuppressive (CD4+/FOXP3+), and macrophages (M1 and M2) in BC tissue. 
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Abstract The aim of this study is to assess the impact of
changes of the 2013 ASCO/CAP guideline on the results of
HER2 testing in breast cancer. A series of 916 primary inva-
sive breast cancer cases, assessed as HER2 2+ by IHC in part
using the 2007 and in part the 2013 ASCO/CAP criteria, was
evaluated for HER2 amplification status by SISH and classi-
fied according to both 2007 and 2013 ASCO/CAP ISH guide-
line criteria. We observed a significant increase of HER2-
positive cases (12.4 to 16.8 %) and a decrease of HER2-
equivocal cases (3.6 to 0.7 %). Of the cases studied, 52.1 %
fulfilled both criteria of HER2/CEP17 ratio and average
HER2 copy number per cell to be classified as HER2-positive.
Reclassification of the cases from before the introduction of
the new ASCO/CAP guideline with the 2013 ISH criteria
resulted in an increase of cases with a HER2-positive status
(12.4 to 14.2 %) and in a decrease of HER2-equivocal cases
(3.6 to 1.6 %). The 2013 ASCO/CAP guideline selects more
patients for anti-HER2 targeted therapy, mostly based on the
modifications of criteria to evaluate ISH-HER2.
Keywords ASCO/CAP . Breast cancer . HER2 . SISH
Introduction
In the western world, breast cancer (BC) is the most common-
ly diagnosed malignancy among women, representing about
30 % of all new cancer cases, and after lung cancer the second
leading cause of cancer death [1, 2]. The current cancer care
guidelines for BC recommend that estrogen receptor (ER),
progesterone receptor (PgR), and human epidermal growth
factor receptor 2 (HER2) status must be routinely determined
in all patients with invasive BC, BC recurrence and BC me-
tastases [3, 4]. These guidelines were published to help im-
prove laboratory performance in the determination of these
markers, which provide useful predictive information regard-
ing response to targeted therapy.
HER2, located on the long arm of chromosome 17 (17q12),
is amplified and/or overexpressed in about 15 to 20 % of
invasive BC. Cases with a HER2-positive status represent a
clinically important subset of BC associated with poor out-
come but also with a high likelihood of response to HER2-
targeted therapy [5–8]. Several studies have shown that anti-
HER2 therapy given during and/or after chemotherapy results
in a significant improvement in disease-free and overall sur-
vival [9–11]. Therefore, HER2 is a helpful marker for therapy
decision making in patients with BC and appropriate evalua-
tion of HER2 status ensures that the right patient receives the
right treatment [3].
At present, HER2 protein expression is determined in
BC samples by immunohistochemistry (IHC) resulting
in three possible outcomes: negative (score 0 or 1+),
equivocal (score 2+), and positive (score 3+). If the
IHC result is equivocal, reflex testing should be per-
formed on the same specimen using an alternative assay,
such as in situ hybridization (ISH) [3].
The new 2013 ASCO/CAP (American Society of Clinical
Oncology/College of American Pathologists) guideline has
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updated the definition of HER2-positive status by modifying
both IHC and ISH criteria, reducing the thresholds for post-
analytical interpretation of positive results in comparison with
the previous 2007 ASCO/CAP guideline [3, 12]. In the new
guideline, a HER2 score 3+ is defined as the presence of
complete and intense membrane staining, in at least 10 % of
tumor cells [3]. This represented a return to the IHC criteria
originally used in the first-generation clinical trials [13]. A
similar approach was used regarding ISH criteria (see below).
In this study, we aim to compare the impact of the change
from the 2007 to the 2013ASCO/CAP guidelines on the result
of HER2 amplification test in BC.
Materials and methods
Cases
A series of 916 primary invasive BC cases was retrieved from
the archives of Ipatimup Diagnostics, including cases evalu-
ated 1 year before (494 cases fromNovember 2012 to October
2013) and 1 year after (422 cases from December 2013 to
November 2014) the publication of the new ASCO/CAP
guideline (November 2013). All BC cases (core biopsies and
surgical specimens) had been fixed in 10 % formalin, embed-
ded in paraffin, and were referred to our institution (national
reference center for HER2 ISH) with an equivocal IHC HER2
score (2+) to perform the HER2 amplification assay with a
HER2 Dual ISH DNA Probe with a silver marker (SISH).
Ethics approval and informed consent were not required for
this study.
SISH
SISH testing was performed on 3-μm sections of formalin-
fixed, paraffin-embedded tissue of all BC cases using dual-
hapten, dual-color ISH (DDISH). The dual-probe assay (IN-
FORMHER2 Dual ISH DNA Probe Cocktail Assay; Ventana
Medical Systems, Inc., Tucson, Arizona) contains a HER2
locus-specific probe and a control probe specific for the cen-
tromere of chromosome 17 (CEP17). The entire procedure
was carried out on an automated staining system (Ventana
BenchMarkTM XT Staining System) according to the manu-
facturer’s instructions. Positive and negative controls were
used for each staining run.
Evaluation of the results included recording the number of
HER2 and CEP17 signals in at least 20 nuclei in two different
areas. The samples were classified by pathologists (AP and
FS) according to the 2007 and 2013 ISH criteria for HER2
amplification. Corresponding hematoxylin and eosin staining
were used for the identification of the invasive component of
the tumor.
The 2007 ASCO/CAP guideline defines HER2 amplifica-
tion as positive at a HER2/CEP17 ratio >2.2, equivocal at a
HER2/CEP17 ratio ≤2.2 and ≥1.8, and negative at a
HER2/CEP17 ratio <1.8 [12]. The 2013 ASCO/CAP guide-
line establishes the result of HER2 amplification as positive at
a HER2/CEP17 ratio ≥2.0 or a HER2/CEP17 ratio <2.0 and
an average HER2 copy number per cell of ≥6.0, equivocal
when HER2/CEP17 ratio <2.0 and average of HER2 copy
number ≥4.0 and <6.0 signals per cell, and negative when
HER2/CEP17 ratio <2.0 and average HER2 copy number of
<4.0 signals per cell [3].
Chromosome 17 polysomy was defined as an average of
≥3.0 CEP17 signals per cell [14]. Genomic heterogeneity was
also recorded and considered present if a discrete population
of tumor cells with HER2 amplification represented at least
10 % of the total tumor cell population [3].
Statistical analysis
Statistical analyses were performed using the Statistical Pack-
age for the Social Sciences (SPSS) version 21.0 for Windows.
The Pearson’s chi-square (χ2) test and McNemar test were
used for comparison of qualitative variables and the t test for
quantitative variables. The level of significance was set at
p<0.05.
Results
The 916 BC cases concerned 97.2 % women and 1.2 % men.
The age ranged from 24 to 103 years, with a median age at
diagnosis of 59 years.
The distribution of gender, age, HER2/CEP17 ratio, and
average HER2 copy number per cell were not statistically
different between the pre- and post-new guideline cases
(Table 1 and Fig. 1). The only parameters that changed signif-
icantly with the new guideline were the average CEP17 copy
number per cell and the presence of chromosome 17
polysomy (4.1 to 0.9 %; p=0.003; Table 1).
Table 2 and Fig. 2a present the results of HER2 test per-
formed on the pre-new guideline cases (using the ISH criteria
from the 2007 ASCO/CAP guideline): 415 cases (84.0 %)
HER2-negative, 18 cases (3.6 %) HER2-equivocal, and 61
cases (12.4 %) HER2-positive. Table 2 and Fig. 2b present
the results of HER2 test performed on the post-new guideline
cases (using the ISH criteria from the 2013 ASCO/CAP
guideline): 348 cases (82.5 %) HER2-negative, 3 cases
(0.7 %) HER2-equivocal, and 71 cases (16.8 %) HER2-posi-
tive. The differences are statistically significant (Table 2—sta-
tistical analysis A; p=0.003). We also observed that 52.1% of
the positive cases (37/71) fulfill both criteria of HER2/CEP17
ratio ≥2.0 and average of HER2 copy number per cell ≥6.0
(Table 3 and Fig. 2b). We furthermore classified the pre- and
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post-new guideline cases using the 2007 and 2013 ISH criteria
and observed a slight but non-significant increase in HER2-
positive cases and a similar decrease in HER2-equivocal cases
(Table 2—statistical analysis B and C; p = 0.185 and
p=0.261, respectively).
In the reclassification of the two case series using the
2007 and 2013 ISH criteria, we observed an increase in
HER2-positive cases (12.4 to 14.2 % and 15.9 to
16.8 %, respectively) and a decrease in HER2-
equivocal cases (3.6 to 1.6 % and 2.4 to 0.7 %, respec-
tively). This was statistically significant in the pre-new
guideline cases (Table 2—statistical analysis D;
p = 0.011) and near significant in post-new guideline
cases (Table 2—statistical analysis E; p= 0.071).
In the pre-new guideline cases, the 2013 ISH criteria
reclassified 22 (4.5 %) of the cases, 9 as HER2-positive (from
HER2-equivocal), 7 as HER2-negative (from HER2-equivo-
cal), and 6 as HER2-equivocal (from HER2-negative). All
HER2-positive cases according to the 2007 guideline
remained HER2 positive with the 2013 guideline (Table 4).
In the post-new guideline cases, genomic heterogeneity
was detected in 0.47 % of the cases (2/422), the proportion
of HER2 amplified cells varying between 25 and 40 % of the
tumor cell population.
Discussion
Our center (Ipatimup) is one of the reference centers for SISH
test of BC in Portugal. In our center, the introduction of the
updated ASCO/CAP guideline for HER2 test by SISH result-
ed in a significant increase of positive cases (12.4 to 16.8 %)
and decrease of equivocal cases (3.6 to 0.7 %).
Several studies recently reported an increase of HER2-
positive cases evaluated by FISH but also an increase of
Table 1 Differences between the
cases before and after the
introduction of the 2013
ASCO/CAP guideline
Cases before
2013ASCO/
CAP guideline
Cases after 2013ASCO/
CAP guideline
p
Gender
(female/male/NI)
481/6/7 409/5/8 ns (0.974)a
Age
(mean± sd)
58.17 ± 13.76 59.12 ± 14.10 ns (0.346)b
HER2/CEP17 ratio
(mean ± sd)
1.68 ± 1.57 1.68± 1.50 ns (0.930)b
Average of HER2 copy number per cell
(mean ± sd)
3.17 ± 2.56 2.88± 2.42 ns (0.077)b
Average of CEP17 copy number per cell
(mean ± sd)
1.98 ± 0.51 1.78± 0.42 <0.001b
Chromosome 17 polysomy
(present/absent)
20 (4.1 %)/474 (95.9 %) 4 (0.9 %)/418 (99.1 %) 0.003a
NI not informed, ns not significant
a Pearson chi-square test
b t test
Fig. 1 Examples of results of
HER2 detection by SISH
technique (×400). a HER2-
positive; b HER2-negative
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HER2-equivocal cases with the introduction of 2013
ASCO/CAP guideline [15–19]. However, the study by the
group of Garbar et al. had results similar to ours using FISH,
with an increase of HER2-positive cases and a slight decrease
in HER2-equivocal cases [20]. The explanation for these dif-
ferences is not clear, but this might be related to the number of
cases, pre-analytical conditions, and different ISH platforms.
We did not review centrally the IHC performed externally,
which might explain the decrease in equivocal cases in com-
parison with recent literature.
As yet, the published concordance rates between SISH and
FISH vary between 92 and 99 %, the majority fulfilling the
ASCO/CAP validation requirement of a concordance rate ex-
ceeding 95 % (Table 5) [21–30]. However, the requirement in
the 2013 ASCO/CAP guideline to determine the average of
HER2 copy number (first applied to bright field ISH and now
applied to the FISH test) introduces a problem that did not
exist previously. Autofluorescence in FISH might result in
overestimation of both HER2 and CEP17 signals, resulting
in HER2/CEP17 ratios below 2.0 and average of HER2 copy
numbers above 4 per cell and an increase of equivocal HER2
results [31, 32]. If an increase of HER2-equivocal cases by
FISH and a decrease of HER2-equivocal cases by SISH is
confirmed, the concordance rate of these two ISH tests might
decrease to under 95 %. This would open up the question
which of these techniques provides the most reliable informa-
tion on HER2 amplification status.
For nearly half of the cases studied (52.1 %), both criteria
(HER2/CEP17 ratio and average of HER2 copy number per
cell) were fulfilled to allow them to be classified as HER2-
Table 2 Classification of HER2
test according to the 2007 and
2013 ISH criteria
HER2 result Cases before 2013ASCO/CAP guideline Cases after 2013ASCO/CAP guideline
ISH criteria 2007 ISH criteria 2013 ISH criteria 2007 ISH criteria 2013
Positive 12.4 % (61) 14.2 % (70) 15.9 % (67) 16.8 % (71)
Equivocal 3.6 % (18) 1.6 % (8) 2.4 % (10) 0.7 % (3)
Negative 84.0 % (415) 84.2 % (416) 81.7 % (345) 82.5 % (348)
Total 494 422
Statistical analysis A A
B B
C C
D D E E
A cases before (ISH criteria 2007) vs after (ISH criteria 2013) 2013 ASCO/CAP guideline: p= 0.003a ; B cases
before vs after 2013ASCO/CAP guideline (ISH criteria 2007): p= 0.185a ; C cases before vs after 2013ASCO/
CAP guideline (ISH criteria 2013): p = 0.261a ;D cases before 2013ASCO/CAP guideline—ISH criteria 2007 vs
ISH criteria 2013: p = 0.011b ; E cases after 2013ASCO/CAP guideline—ISH criteria 2007 vs ISH criteria 2013:
p= 0.071b
a Pearson Chi-Square test
bMcNemar test
Fig. 2 Cases before (a) and after (b) the introduction of the 2013 ASCO/CAP guideline
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positive. This is particularly relevant given the fact that half
the cases would be excluded from targeted therapy if HER2
amplification would be evaluated using just the HER2 probe
(as some methods do).
Classification of the pre-new guideline and post-new
guideline case series with the 2007 and 2013 criteria did not
result in significant changes in the HER2 test results. This
suggests that modifying the threshold in IHC, from 30 to
10 % of cells with moderate staining, had little effect on the
HER2 amplification test results. Lee et al. found that cases
with equivocal IHC (score 2+) in 10–30 % of the cells had a
probability of being amplified of 5–12 % [33]. It is then not
surprising that inclusion of these cases does not significantly
change the HER2 amplification test results.
In contrast, classification of pre-new guideline and post-
new guideline cases with different ISH criteria (2007 and
2013) resulted in significant changes in HER2 amplifica-
tion test results. Our findings suggest that the 2013 modi-
fied ISH criteria had a stronger impact on the test results
than the modified IHC criteria. We found that the 2013 ISH
criteria resulted in reclassification of 4.5 % of the cases.
Other publications have shown a reclassification rate of up
to 15 % of cases [16, 17].
Polysomy of chromosome 17 changed from 4.1 to 0.9 %
with the introduction of the 2013 ASCO/CAP guideline,
which is probably due to modification of the definition of
equivocal IHC HER2 staining (score 2+) rather than a change
in the biology of the tumors. Several studies have shown that
polysomy of chromosome 17 (measured on the basis of
CEP17) varies between 3 and 49 % of the cases, depending
on the definitions of polysomy and on the method used [12,
14, 34, 35]. The approach is based on the notion that CEP17
copy number is a surrogate marker for chromosome 17 copy
number. However, molecular karyotyping has revealed that an
increased CEP17 signal number is usually due to gain of the
pericentromeric region rather than to duplication of the entire
chromosome [36–41]. CEP17 might therefore not be a good
marker for polysomy 17, making true polysomy 17 probably a
rare event in BC. Nevertheless, CEP17 amplification can still
be the cause of misleading HER2 amplification and false-
negative test results, excluding patients from anti-HER2
targeted therapy [34].
Tumors with polysomy 17 are thought to be different from
non-HER2 amplified tumors, associated with a more aggres-
sive clinical behavior and not responsive to conventional ther-
apy [14, 42]. However, in BC, the relationship between
polysomy of chromosome 17 and the response to anti-HER2
therapy remains to be determined [43–45].
We found the presence of genomic heterogeneity to be rare as
observed in just 0.47 % of cases. Several studies have addressed
this issue in the past and reported genomic heterogeneity in 5 to
40 % of BC cases [14, 46–49]. Studies on the relationship be-
tween genomic heterogeneity and prognosis have shown that
tumors with a HER2 amplification in at least 30 % of the cells
have a reduced disease-free survival [48, 49]. However, the
definition of genomic heterogeneity has also changed from in-
dividual cells (between 5 and 50 % of tumor cells with HER2
amplification) to discrete populations of tumor cells (at least
10 % of the total tumor cell population with HER2 amplifica-
tion) [3, 50]. Additional work is needed to determine the prev-
alence of genomic heterogeneitywith this new definition and the
response to anti-HER2 targeted therapy in these patients.
In conclusion, we show that the new HER2 guideline results
in an increased number of HER2-positive and a decreased num-
ber of HER2-equivocal cases using the SISH technique, pri-
marily because of modifications of ISH rather than of IHC
criteria. As a consequence, the 2013 ASCO/CAP guideline
selects more patients for anti-HER2 targeted therapy.
Table 3 Classification of the cases after the 2013 ASCO/CAP
guideline
HER2/CEP17 ratio Average of HER2 copy number signals per cell
<4.0 ≥4.0 and <6.0 ≥6.0
<2.0 348 3 0
≥2.0 11 23 37
Table 4 Classification of the cases before the 2013 ASCO/CAP
guideline
2007 ISH criteria 2013 ISH criteria
Positive Negative Equivocal Total
Positive 61 0 0 61
Negative 0 409 6 415
Equivocal 9 7 2 18
Total 70 416 8 494
Table 5 Concordance rates of SISH vs FISH according to the 2007
ASCO/CAP guideline
Publication Concordance (%) Year
Dietel et al. [21] 96 2007
Shousha et al. [22] 94 2009
Bartlett et al. [23] 96 2009
Papouchado et al. [24] 98.9 2010
Koh et al. [25] 97 2011
Lee et al. [26] 96.7 2011
Park et al. [27] 96.5 2012
Jacquemier et al. [28] 97 2013
Lim et al. [29] 93 2013
Unal et al. [30] 92.3 2013
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Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how
many cells are enough?
Aim: To evaluate the intraobserver and interobserver
reproducibility of the HER2 in-situ hybridization (ISH)
test in breast cancer by measuring the impact of count-
ing different numbers of invasive cancer cells.
Methods and results: A cohort of 101 primary inva-
sive breast cancer cases were evaluated for HER2
gene amplification by silver ISH, and the concordance
among four observers with different levels of experi-
ence, counting different numbers of invasive cancer
cells, was determined. The evaluation of the samples
included scoring 20 nuclei, in three different areas.
The cases were scored twice, with a washout interval
of at least 2 weeks. We observed an increase in the
intraobserver concordance rate between the first and
second evaluations with an increase in cell count. A
count of 60 invasive cells was needed to obtain a
concordance rate near 95% and an agreement rate
greater than 0.80 by all observers. The interobserver
concordance rate of the HER2 test also increased
with the increase in cell count, reaching at least a
90% concordance rate with a count of 60 invasive
cells. The median variability of both the HER2/CEP17
ratio and the average HER2 copy number between
different evaluations decreased with the increase in
cell count, being statistically higher in HER2-positive
cases.
Conclusions: The minimal cell number recommended
in current guidelines should be raised to at least 40,
and preferably 60, invasive cells. Moreover, cases
with amplification levels close to the threshold should
be subjected to a dual count from an experienced
observer.
Keywords: ASCO/CAP, breast cancer, HER2, SISH
Introduction
HER2 is a transmembrane protein receptor with tyro-
sine kinase activity, and is amplified and/or overex-
pressed in approximately 15–20% of invasive breast
cancers (BCs).1–3 Numerous clinical trials have
demonstrated that HER2-targeted therapy improves
progression-free survival and overall survival only in
patients with BCs showing HER2 amplification.4–7
For this reason, the accurate assessment of HER2
amplification identifies patients who are most likely to
benefit from targeted therapy.
HER2 evaluation is most frequently performed by
immunohistochemistry (IHC), resulting in three possi-
ble outcomes: negative (score of 0 or 1+), equivocal
(score of 2+), and positive (score of 3+). In cases of
Address for correspondence: F Schmitt, Laboratoire national de
sante, 1, rue Louis Rech, L-3555 Dudelange, Luxembourg. e-mail:
fernando.schmitt@ipatimup.pt
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equivocal results, reflex testing should be performed
with in-situ hybridization (ISH) assays for the assess-
ment of HER2 amplification.8
Regarding ISH assays, the 2013 American Society
of Clinical Oncology (ASCO)/College of American
Pathologists (CAP) guidelines accept bright-field ISH
and recommend counting at least 20 non-overlapping
cells in two separate areas of invasive cancer.8
Although this is usually interpreted as counting a
total of 40 cells (at least 20 cells per area), the sup-
plementary data of the guidelines actually explain
that the minimum cell number is, in fact, a total of
20 cells in two separate areas of invasive cancer (at
least 10 cells per area). It has already been shown
that high ISH interobserver reproducibility exists;
nevertheless, the minimum number of cells that
should be counted to obtain a reproducible result is
yet to be determined.9,10 Even if the current ASCO/
CAP guideline recommendations are adhered to, the
imprecision of HER2 testing remains a relevant issue,
for both IHC and ISH techniques.11,12
In the present study, HER2 amplification status
was determined in a series of primary BC cases by
four different observers, who scored the cases twice
according to the 2013 ASCO/CAP guidelines for
HER2 testing. Specifically, we aimed to evaluate the
intraobserver and interobserver interpretative repro-
ducibility of the HER2 assay in BCs by using bright-
field ISH to evaluate the impact of counting different
numbers of invasive cancer cells.
Materials and methods
C A S E S
A cohort of 101 consecutive primary invasive BC cases
was retrieved from the archives of Ipatimup Diagnostics
from April to June 2015 to determine the concordance
of the HER2 amplification assay among four observers
counting different numbers of invasive cancer cells.
The cases included formalin-fixed paraffin-
embedded core biopsies and surgical specimens
referred to our institution with an equivocal HER2
result by IHC (score of 2+) for performance of an
evaluation of HER2 amplification with bright-field
ISH. All cases were reviewed for diagnosis and histo-
logical grade. Ethical approval and informed consent
were not required for this study.
S I L V E R I S H
Silver ISH was performed on 3-lm-thick sections with
dual-hapten, dual-colour ISH. The dual-probe assay
(INFORM HER2 Dual ISH DNA Probe Cocktail Assay;
Ventana Medical Systems, Tucson, AZ, USA), which
is Food and Drug Administration-approved, contains
an HER2 locus-specific probe (black signal) and a
control probe specific for the centromere of chromo-
some 17 [centromere enumeration probe 17 (CEP17),
red signal] that allows detection of HER2 amplifica-
tion by light microscopy. The entire procedure was
carried out on an automated staining system (Ven-
tana BenchMark XT Staining System; Ventana Medi-
cal Systems, Tucson, AZ, USA) according to the
manufacturer’s instructions. Appropriate positive and
negative controls were used in every set of slides.
Optimal staining consists of an absence of non-speci-
fic background staining, distinct nuclear morphology,
and clear and specific signals within the nucleus.
S I S H I N T E R P R E T A T I O N
The samples were classified by two pathologists (A.P.
and C.E.) and two pathology residents (J.P. and A.B.)
according to the 2013 ASCO/CAP ISH criteria for
HER2 amplification. Pathologists had different levels
of experience, one with >500 cases evaluated per
year (A.P.) and the other with <50 cases evaluated
per year (C.E.). Both pathology residents had attended
a previous molecular pathology training course,
where they learned how to perform SISH interpreta-
tion. Corresponding haematoxylin and eosin staining
was used for the identification of the invasive compo-
nent of the tumour, and only cells with a minimum
of one copy of HER2 and CEP17 each were scored.
The number of HER2 signals was estimated in clus-
ters, except for doublets, which counted as a single
signal.
The evaluation of the samples included scoring 20
nuclei, in three different areas, and recording the
numbers of HER2 and CEP17 signals in groups of 10
invasive cancer cells. This approach allows us to add
groups of 10 cells in each area to groups of 10 cells
in other areas, giving 12 results of scoring 20 cells in
two separate areas (10 cells per area) (Figure 1). The
same can be applied to the evaluation of scoring 40
cells in two separate areas (20 cells per area, adding
the first area to the second and third areas, and the
second area to the third area), creating three results.
Finally, the three areas can be added, generating one
result of scoring 60 cells per case. The cases were
scored twice with a washout interval of at least
2 weeks, in a blinded mode.
The 2013 ASCO/CAP guidelines establish the result
of HER2 amplification as: positive when the HER2/
CEP17 ratio is ≥2.0 or <2.0, and the average HER2
© 2017 John Wiley & Sons Ltd, Histopathology
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copy number is ≥6.0 signals per cell; equivocal when
the HER2/CEP17 ratio is <2.0, and the average
HER2 copy number is ≥4.0 and <6.0 signals per cell;
and negative when the HER2/CEP17 ratio is <2.0,
and the average HER2 copy number is <4.0 signals
per cell.8
Cases with discordant results were reviewed by
both pathologists during a common microscopy ses-
sion to document genomic heterogeneity, defined in
the latest ASCO/CAP guidelines as a discrete popula-
tion of tumour cells with HER2 amplification.8 No
additional testing was performed to resolve the discor-
dance.
Chromosome 17 polysomy was defined as an aver-
age of ≥3.0 CEP17 signals per cell.13
S T A T I S T I C A L A N A L Y S I S
Statistical analyses were performed with SPSS version
24.0 for Windows. Pearson’s v2 test (or Fisher’s exact
test, if appropriate) was used for comparison of quali-
tative variables, and the Mann–Whitney U-test
(MWUT) and Pearson’s correlation coefficient (PCC)
were used for comparison of quantitative variables.
The level of significance was set at P < 0.05.
Agreement rates of the same observer (intraob-
server) and those between each observer (interob-
server) regarding interpretation of the HER2
amplification assay were evaluated with kappa (k)
statistics. k-Values range between zero (chance agree-
ment) and 1 (perfect agreement), and were consid-
ered to be satisfactory if they were >0.80.
Results
The cohort included 82 core biopsies and 19 surgical
specimens, with 97.03% of the cases being diagnosed
in women and 2.97% in men. The age of the patients
ranged from 35 to 93 years, with a median age at
diagnosis of 65 years. The majority of the histological
types were invasive carcinomas of no special type,
with 11.88% of the cases being classified as grade 1,
61.39% as grade 2, and 26.73% as grade 3. The
cohort characteristics are summarized in Table 1.
The final classification of HER2 testing from each
observer (first and second evaluations of 60 invasive
cancer cells) varied between 23% and 26% of HER2-
positive cases (Table 2); there were no cases with
genomic heterogeneity. Moreover, no equivocal
results or chromosome 17 polysomy were reported by
any observer. The intraobserver concordance rate of
10 10 10 10 10 10
Figure 1. Scoring 20 cells in two separate areas (10 cells per area),
giving 12 results.
Table 1. Cohort characteristics
Characteristic Value
Procedure (core biopsy/surgical specimen) (n) 82/19
Gender (female/male) (n) 98/3
Age (years) (mean  SD) 63.67  15.77
Histological type (n)
Invasive carcinoma, NST 94
Lobular carcinoma 5
Mucinous carcinoma 2
Histological grade (n)
Grade 1/Grade 2/Grade 3 12/62/27
NST, No special type; SD, Standard deviation.
Table 2. Classification of HER2 test (first and second evaluation of 60 cells per case)
Pathologist 1 Pathologist 2 Resident 1 Resident 2
1st 2nd 1st 2nd 1st 2nd 1st 2nd
Positive, n (%) 25 (24.8) 25 (24.8) 23 (22.8) 23 (22.8) 25 (24.8) 24 (23.8) 25 (24.8) 26 (25.7)
Negative, n (%) 76 (75.2) 76 (75.2) 78 (77.2) 78 (77.2) 76 (75.2) 77 (76.2) 76 (75.2) 75 (74.3)
Equivocal (n) 0 0 0 0 0 0 0 0
Total (n) 101
© 2017 John Wiley & Sons Ltd, Histopathology
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the HER2 test with different cell counts is shown in
Table 3. We found, for all observers, an increase in
the concordance rate between the first and second
evaluations with the increase in cell count from 20
to 60 invasive cells [93.07–100%, 86.14–94.06%,
92.08–99.01% and 76.24–95.05% for pathologist 1
(P1), pathologist 2 (P2), resident 1 (R1) and resident
2 (R2), respectively]. P1 was the only observer who
reached an intraobserver agreement rate between the
first and second evaluations of >0.80 (0.806) just by
counting 20 invasive cells; the same goal was
achieved by R1 when counting 40 invasive cells
(0.945). Additionally, both P1 and R1 needed to
count at least 40 invasive cells to achieve a concor-
dance rate between the first and second evaluations
of >95% (97.03% and 98.02%, respectively). On the
other hand, P2 and R2 needed to count 60 invasive
cells to reach an intraobserver agreement rate of
>0.80 (0.831 and 0.869, respectively) and a concor-
dance rate of ~95% (94.06% and 95.05%, respec-
tively). We also found that the concordance rates for
different areas within the first or second evaluations
were always higher than those measured between dif-
ferent evaluations. The same trend was observed in
the intraobserver correlation of both the HER2/
CEP17 ratio and the average HER2 copy number,
whereby it increased with the increase in cell count
and was always higher for different areas within each
evaluation than for different evaluations (Tables S1
and S2).
The minimal interobserver concordance rate of the
HER2 test increased with the increase in cell count
from 20 to 60 invasive cells (73.27% in the P2–R2
evaluation of 20 cells, to 97.03% in the P1–R1 eval-
uation of 60 cells) (Table 4). A concordance rate of
95.05% and an agreement rate of 0.861 were
achieved by P1 and R1 with a count of 40 invasive
cells. A count of 60 invasive cells produced a mini-
mal interobserver concordance rate of 90.10% and
an agreement rate of 0.734 (R1–R2). In parallel, the
same trend described above was found for the corre-
lation of both HER2/CEP17 ratio and average HER2
copy number, in which it increased with the increase
in cell count (Tables S3 and S4).
The discordant cases of the observers with higher
interobserver concordance or agreement rates (P1
and R1) showed an HER2/CEP17 ratio of between
1.39 and 2.72 when 20 invasive cells were counted,
of between 1.75 and 2.37 when 40 invasive cells
were counted, and of between 1.82 and 2.24 when
60 invasive cells were counted (Table 5; Figure 2).
The range of average HER2 copy number in discor-
dant cases for each observer with different cell countsT
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is shown in Table S5. Additionally, we observed at
least one discordant case for any observer in 39.02%
of core biopsies (32/82) and in 10.53% of surgical
specimens (2/19) when 20 invasive cells were
counted (v2 test; P = 0.018), and in 14.63% of core
biopsies (12/82) and in 10.53% of surgical specimens
(2/19) when 60 invasive cells were counted (Fisher’s
exact test; P = 1.000).
The median variability of the HER2/CEP17 ratio
between different evaluations decreased with the
increase in cell count from 20 to 60 invasive cells in
both negative cases (0.36–0.06, 0.47–0.15, 0.38–
0.08 and 0.54–0.19 for P1, P2, R1 and R2, respec-
tively) and positive cases (1.83–0.50, 1.04–0.31,
1.32–0.27 and 2.44–0.66 for P1, P2, R1 and R2,
respectively) (MWUT; P < 0.001 for all observers).
Furthermore, the median variability of the HER2/
CEP17 ratio in HER2-positive cases was statistically
higher than that in HER2-negative cases (MWUT;
P < 0.001 for all observers) (Table 6). In discordant
cases the median variability of the HER2/CEP17 ratio
presented values between those of HER2-negative and
HER2-positive cases and decreased with the increase
in cell count (0.65–0.40, 1.01–0.93, 0.96–0.42 and
1.13–0.63 for P1, P2, R1 and R2, respectively), with
the majority being statistically different from negative
cases, positive cases, or both (Table 7). Figure 3
shows the relationship of the average of the HER2/
CEP17 ratio for all observers between the first and
second evaluations with its variability when 60 inva-
sive cells were counted, confirming the increased
variability in cases with a higher HER2/CEP17 ratio
(PCC 0.881; P < 0.001). We also found that, for all
observers, the median variability of the HER2/CEP17
ratio between different areas within the first and sec-
ond evaluations was similar (MWUT; P > 0.05) and
always lower than the variability between different
evaluations (MWUT; P < 0.05). The same pattern
described above was observed in the variability of the
average HER2 copy number with different cell counts
in negative, positive and discordant cases (Tables S6
and S7).
Finally, when we compared the variability of the
HER2/CEP17 ratio with the variability of the average
HER2 copy number, we observed that the former was
always inferior to the latter (MWUT; P < 0.05 for all
observers when counting 60 invasive cells) (Tables 6
and S6).
Discussion
Since the introduction of the new ASCO/CAP guideli-
nes for HER2 testing in BC, numerous studies have
reported an increase in the number of HER2-positive
cases.14–18 Recently, using SISH, we showed that the
updated ASCO/CAP guidelines resulted in a signifi-
cant increase in the number of HER2-positive cases
and a decrease in the number of equivocal cases.19
Most of the published literature shows the concor-
dance rates between SISH and fluorescence ISH to be
>90%, and to almost always fulfil the ASCO/CAP val-
idation requirement of a concordance rate of
>95%.20–22
In the present study, we found an increase in the
concordance rate of HER2 testing between the first
and second evaluations with an increase in cell count
from 20 to 60 invasive cells, as well as a decrease in
Table 4. Interobserver concordance rate of HER2 test results with different cell counts
Pathologist 2 Resident 1 Resident 2 Cells
Pathologist 1 87.13–98.02% (0.628–0.945) 92.08–99.01% (0.776–0.974) 77.23–97.03% (0.461–0.921) 20
91.09–95.05% (0.734–0.865) 95.05–99.01% (0.861–0.973) 88.12–97.03% (0.690–0.921) 40
93.07–95.05% (0.806–0.865) 97.03–98.02% (0.919–0.947) 92.08–97.03% (0.787–0.921) 60
Pathologist 2 81.19–98.02% (0.515–0.946) 73.27–96.04% (0.386–0.884) 20
89.11–97.03% (0.704–0.919) 89.11–95.05% (0.695–0.861) 40
91.09–96.04% (0.750–0.891) 91.09–94.06% (0.751–0.841) 60
Resident 1 77.23–95.05% (0.461–0.869) 20
88.12–96.04% (0.681–0.894) 40
90.10–95.05% (0.734–0.869) 60
Minimal and maximal concordance rate (k statistics).
© 2017 John Wiley & Sons Ltd, Histopathology
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the variability of HER2/CEP17 ratios for all observers,
which demonstrated the value of counting additional
cells. The fact that only the observer with more expe-
rience (P1) could achieve an intraobserver agreement
rate of >0.80 between both evaluations when count-
ing only 20 invasive cells shows that 20 cells might
not be the optimal minimal cell number as recom-
mended by current guidelines. In fact, P1 and R1
needed to count at least 40 invasive cells to reach an
intraobserver concordance rate of >95%, and P2 and
R2 needed to count 60 invasive cells to achieve the
same rate. Additionally, no observer reached an inter-
observer concordance rate of >95% or an agreement
rate of at least 0.80 by counting only 20 invasive
cells. In fact, only two observers (P1 and R1)
achieved that aim, and required a minimal count of
40 invasive cells. The remaining observers required a
count of 60 invasive cells to achieve concordance
rates of >90% of the cases and agreement rates near
0.80. According to our data, the minimal cell num-
ber of 20 invasive cells in HER2 testing in BC is not
sufficient, and should be raised to at least 40 invasive
cells (which is probably already the case in most lab-
oratories) and, preferably, 60 cells if available, which
is almost always manageable in most of the cases in
our experience.
Interestingly, the observers with higher interob-
server concordance/agreement rates were those with
better intraobserver concordance/agreement rates.
Additionally, the major causes of discordance in these
observers were tumours with an HER2/CEP17 ratio
near the threshold, even when 60 invasive cells were
counted. Given that heterogeneity was ruled out, the
discordant cases of the observers with lower perfor-
mance were probably attributable to counting in
non-cancer areas or in areas with excessive back-
ground, showing a wider range of HER2/CEP17
ratios. ISH analysis should start with scanning of the
entire slide prior to counting, and compare with IHC
to define the areas of potential HER2 amplification.
Furthermore, the absence of information on preana-
lytic conditions can jeopardize the execution of the
ISH technique and create artefacts that impair proper
measurement of the signals. Although chromosome
17 polysomy can cause impairment of ISH interpreta-
tion, it was not an issue in this study, given that no
observer found such cases.
Unexpectedly, we found more discordant cases in
core biopsies than in surgical specimens. Although
counting additional cells eliminates this problem, we
think that it is probably related to the higher quan-
tity of tumour in surgical specimens, which allows
for the identification of better scoring areas, with lessT
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background and fewer overlapping cells. Previously,
it has been shown that the identification of amplifica-
tion status by SISH is very robust, as consensus
between several observers cannot be reached in <2%
of cases, although a consensus in discordant cases
was not the aim in this study.20
As previously shown, the cases with amplification
levels close to the thresholds are the most likely to be
discordant.23 For cases in which the HER2/CEP17
ratio lies between 1.80 and 2.20, the ASCO/CAP
guidelines recommend that a different person counts
an additional 20 invasive cells, whereas the updated
UK guidelines recommend counting at least 60 inva-
sive cells (preferably with a dual count by a second
observer).8,24 We agree with the UK guidelines rec-
ommendation, because 20 additional invasive cells
evaluated by a different observer will not be sufficient
to assess doubtful cases with an HER2/CEP17 ratio
around 2.0, as we show in this study. Moreover, the
similar variability of the HER2/CEP17 ratio within
each evaluation, along with the divergent measure-
ments between the first and second evaluations, sug-
gests that the observers have the same error but
different bias in different evaluations. We therefore
recommend counting additional cells immediately
than counting on a different day.
The UK guidelines for HER2 assessment in BC rec-
ommend that, in cases with either clear amplification
or an HER2/CEP17 ratio of <1.5, scoring of 20
tumour cells is sufficient.24 Although our data sup-
port this recommendation for experienced observers,
it is more practical to immediately count 40 tumour
cells and calculate both the HER2/CEP17 ratio and
the average HER2 copy number than to count 20
cells, calculate these values, and then decide to count
additional cells.
Training and experience in the interpretation of
HER2 ISH testing is essential. The UK guidelines rec-
ommend that laboratories perform at least 100 HER2
ISH assays every year, and, when new personnel are
being trained in the interpretation of HER2 testing,
observations of at least 100 ISH tests in parallel with
an experienced scorer should be performed until a
minimum concordance of 95% is achieved.24 In our
study, although both residents had the same level of
experience after training, only one reached a concor-
dance rate of at least 95% with the experienced
observer, which underlines the importance of valida-
tion studies in this field.
The variability of both the HER2/CEP17 ratio and
of the average HER2 copy number in HER2-positive
cases were always statistically higher than in HER2-
negative cases, probably because of the different esti-
mation of the number of HER2 signals in clusters.
Another explanation could be the genetic instability
of HER2 amplification already described between pri-
mary BC and metastatic lesions in HER2-positive
cases, whereby the latter had a significant increase in
HER2 copy number.25 In the same way, separate
areas of HER2-positive tumours could, in fact, have
different HER2/CEP17 ratios and HER2 copy num-
bers, although this needs to be clarified in future
studies. Finally, the lower variability of the HER2/
CEP17 ratio than of the HER2 copy number shows
that the ratio value is probably more reproducible
among observers, probably because the larger size of
the CEP17 signal makes it easy to identify.20,26
Although the ISH technique is the gold standard for
identifying HER2-positive BC cases because it evalu-
ates HER2 amplification only in invasive cancer cells,
it might not be the most accurate method for HER2
quantification. One of the first studies investigating
the effects of the level of HER2 amplification showed
that high-amplification tumours had a significantly
higher rate of pathologically complete response to
neoadjuvant treatment with trastuzumab than low-
amplification tumours.27 However, the same authors
showed later that HER2 amplification level was not
A B C
Figure 2. Examples of results of HER2 detection with the silver in-situ hybridization technique. A, HER2 negative for all observers. B, HER2
positive for all observers. C, HER2 discordancy among observers.
© 2017 John Wiley & Sons Ltd, Histopathology
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correlated with either recurrence-free or overall sur-
vival in the same setting.28 Moreover, the data from
the Herceptin Adjuvant (HERA) trial were also used
to compare the degree of HER2 amplification with
clinical outcome in HER2-positive BC (in both the
untreated and trastuzumab-treated).29 Both the
HER2/CEP17 ratio and the HER2 copy number were
measured, and no significant effect on prognosis or
benefit from trastuzumab was observed with different
levels of HER2 amplification. In contrast, it was
recently reported that there was an increased risk of
death from BC in the first 5 years after diagnosis in
women with HER2 copy numbers of ≥6, as well as of
≥4.0 and <6.0, irrespective of HER2/CEP17 ratio.30
The conflicting clinical data suggest that the variabil-
ity of the HER2/CEP17 ratio and the HER2 copy
number, depending on the number of cells counted,
may determine the accuracy of the final result.
Accordingly, to evaluate the putative clinical implica-
tions of the degree of HER2 amplification, alternative
methodology that quantifies HER2 amplification more
precisely must be used. Therefore, imaging analysis of
ISH tests, counting several hundreds of cells more
objectively, and HER2 quantification by molecular
techniques in separate areas of invasive carcinoma
should be investigated to assess the variability of the
results in HER2-positive BC cases.
In conclusion, we show that counting 20 cells in
the HER2 ISH test is not sufficient to obtain a repro-
ducible result, and that the minimal cell number
should be raised to at least 40, and preferably 60,
invasive BC cells. Additionally, cases with amplifica-
tion levels close to the threshold should have a count
of at least 60 cells, and, if possible, a dual count fromT
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Figure 3. Relationship of the average of the HER2/CEP17 ratio
with its variability when 60 invasive cells are counted.
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an experienced observer. As far as we know, this is
the first time that SISH results have been compared
between multiple observers counting different num-
bers of invasive cancer cells.
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Abstract The aims of this study were to evaluate and com-
pare the HER2 gene amplification status in invasive and ad-
jacent in situ breast carcinoma, using bright-field in situ hy-
bridization, and to document the possible presence of HER2
genetic heterogeneity (HER2-GH) in both components. A co-
hort of 100 primary invasive carcinomas (IC) associated with
carcinoma in situ (CIS) were evaluated for HER2 gene ampli-
fication by SISH according to the 2013 ASCO/CAP HER2
guideline. A second cohort of all the cases with HER2-GH
since the introduction of the updated ASCO/CAP HER2
guideline was also characterized, and an evaluation of the
HER2 gene amplification in the CIS component, if present,
was also done. In the first cohort, the HER2 amplification in
the ICwas negative in 87% of the cases and positive in 13% of
the cases, without the presence of HER2-GH. All the cases
had an associated CIS with the same HER2 status as IC, with
four cases of CIS presenting HER2-GH. In the CIS, we ob-
served a significant relationship of HER2 gene amplification
with high nuclear grade. In the four cases with HER2-GH in
CIS, two cases presented HER2 gene amplification in the IC.
The second cohort included 12 cases with HER2-GH in a total
of 1243 IC cases (0.97%). Additionally, we identified two
cases associated with non-amplified CIS. HER2-GH is a rare
event in IC and can already be present in CIS, not being an
important step in the acquisition of invasive features.
Keywords Breast cancer . HER2 . SISH . Invasive
carcinoma . Carcinoma in situ . Genetic heterogeneity
Introduction
Human epidermal growth factor receptor 2 (HER2) is ampli-
fied and/or overexpressed in about 15 to 20% of invasive
breast cancer (BC), being associated with worse clinical out-
come and predictive of benefit from HER2-targeted therapy
[1–3]. The incidence rate of carcinoma in situ (CIS) of the
breast, the immediate precursor of invasive carcinoma (IC),
has stabilized since the beginning of the millennium in women
older than 50 years, but continues to increase about 2%
every year in younger women [4]. Several studies have
shown that HER2 amplification can already be present in
CIS and that frequently HER2 status is concordant with the
invasive component [5, 6].
Heterogeneity has been noticed in almost all types of can-
cer, including BC, being related to several aspects of disease
progression and clinical outcome [7]. The first recommenda-
tion regarding HER2 genetic heterogeneity (HER2-GH) was
published in 2009 as an extension of the 2007 American
Society of Clinical Oncology/College of American
Pathologists (ASCO/CAP) HER2 guidelines after the ac-
knowledgment that some tumors displayed intratumoral
heterogeneity and such cases could originate discrepant re-
sults between immunohistochemistry (IHC) and in situ
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hybridization (ISH) analysis [8]. At that time, HER2-GH was
defined as HER2 gene amplification in 5 to 50% of invasive
cancer cells. Importantly, the definition was based on studies
that did not include clinical outcome, being the first step to
investigate the clinical significance of HER2-GH and the pos-
sible role of target therapy in this setting [9, 10]. Thereafter,
numerous studies have shown that HER2-GH could be pres-
ent in BC from 5 to 40% of the cases [11, 12]. Additionally, it
was shown that HER2-GH was more frequent in cases near
the threshold of positivity and that heterogeneity measured in
individual cells is not informative of clonal heterogeneity
within a tumor population [13].
Currently, the definition of HER2-GH has changed from
individual cells to discrete population of tumor cells with
HER2 gene amplification. According to the 2013 ASCO/
CAP HER2 guideline, a tumor is considered HER2 positive
if HER2 gene amplification is present in at least 10% of the
total tumor cell population [14].
The aims of the present study are to compare the HER2
gene amplification status in invasive and adjacent in situ BC,
using bright-field ISH, and to document the possible presence
of heterogeneity in both components.
Materials and methods
Case selection
The cases included formalin-fixed, paraffin-embedded needle
core biopsies (NCB) and surgical excision specimens (SES)
referred to Ipatimup Diagnostics with an equivocal HER2
result (score of 2+) in IC by IHC for performance of an eval-
uation of HER2 amplification with bright-field ISH. There
was no information regarding patient treatment.
The first cohort included 100 primary invasive BC cases
associated with CIS retrieved from the archives from
November 2015 to July 2016 to determine the concordance
of HER2 gene amplification in both components. During this
period, 347 cases with an equivocal HER2 result by IHC were
evaluated for HER2 gene amplification. The cohort comprised
66 NCB and 34 SES, all diagnosed in women. The age of the
patients ranged from 31 to 83 years old, with a median age at
diagnosis of 54 years. The majority of the histological types
were invasive carcinomas of no special type (NST), with 14%
of the cases being classified as grade 1, 66% as grade 2, and
20% as grade 3 (Table 1).
The second cohort included all cases with HER2-GH (pri-
mary invasive or metastatic BC) since the introduction of the
2013 ASCO/CAP HER2 guideline (November 2013) to
October 2016. An evaluation of HER2 gene amplification in
the CIS component, if present, was also done. The cohort
comprised 10 NCB and 2 SES with HER2-GH in a total of
1243 cases (0.97%), 11 of which were primary invasive BC
and one lymph nodemetastasis. The age of the patients ranged
from 42 to 74 years old, with a median age at diagnosis of
58 years, and two cases were diagnosed in men. All histolog-
ical types but one were IC, NST, with eight cases being clas-
sified as grade 2 and four cases as grade 3 (Table 2).
All cases were reviewed for histological type and grade
(Nottingham Histologic Score) in the IC. The characterization
of the CIS included nuclear grade, the presence of necrosis,
and microcalcifications.
This study has been performed in accordance with the na-
tional regulative law for the handling of biological specimens
from tumor banks, being the samples exclusively available for
research purposes in retrospective studies, as well as under the
international Helsinki declaration.
Silver in situ hybridization
SISH technique was performed on 3-μm-thick sections in one
block of each case with dual-hapten, dual-color ISH. The
dual-probe assay (INFORM HER2 Dual ISH DNA Probe
Cocktail Assay; Ventana Medical Systems, Inc., Tucson,
AZ, USA), which is Food and DrugAdministration-approved,
contains an HER2 locus-specific probe (black signal) and a
control probe specific for the centromere of chromosome 17
(centromere enumeration probe-CEP17, red signal), which
allows detection of HER2 gene amplification by light
Table 1 Characteristics of the first cohort
Procedure (NCB/SES) 66/34
Gender (female/male) 100/0
Age (mean ± SD) 54.68 ± 12.41
Invasive carcinoma
Histological type
Invasive carcinoma, NST 88
Lobular carcinoma 8
Micropapillary carcinoma 2
Mucinous carcinoma 1
Encapsulated papillary carcinoma 1
Histological grade
Grade 1/grade 2/grade 3 14/66/20
HER2 gene amplification
ISH negative/ISH positive 87/13
Carcinoma in situ
Ductal 93
Lobular 8
Nuclear grade
Low/intermediate/high 3/42/56
Necrosis (absent/present) 58/43
Microcalcifications (absent/present) 73/28
NCB needle core biopsy, SES surgical excision specimen, SD standard
deviation, NST no special type
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microscopy. The entire procedure was carried out on an auto-
mated staining system (Ventana BenchMark XT Staining
System; Ventana Medical Systems, Inc., Tucson, AZ, USA)
according to the manufacturer’s instructions. Appropriated
positive and negative controls were used in every set of slides.
SISH interpretation
The evaluation of the samples included scoring of at least 20
nuclei, in two different areas, recording the number of HER2
and CEP17 signals. Corresponding hematoxylin and eosin
(H&E) staining was used for the identification of the invasive
and in situ components of the tumor, and only cells with a
minimum of one copy of HER2 and CEP17 each were scored.
The number of HER2 signals was estimated in clusters, except
for doublets which counted as a single signal. The samples
were classified by a pathologist (AP) according to the 2013
ASCO/CAP ISH criteria for HER2 gene amplification: posi-
tive when the HER2/CEP17 ratio is ≥2.0 or <2.0 and the
average HER2 copy number is ≥6.0 signals per cell; equivocal
when the HER2/CEP17 ratio is <2.0 and the average HER2
copy number is ≥4.0 and <6.0 signals per cell; and negative
when the HER2/CEP17 ratio is <2.0 and the average HER2
copy number is <4.0 signals per cell [14].
HER2-GH is defined as tumors with discrete population of
tumor cells with different HER2 gene status [14]. The pro-
portion of amplified areas was quantified by measuring the
number of fields (power field of 200×) with HER2 gene
amplification divided by the number of fields of invasive
or in situ carcinoma.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS) version 24.0 for
Windows. The Pearson’s Chi-squared (χ2) test (or the
Fisher’s exact test, if appropriate) was used for comparison
of qualitative variables and theMann-WhitneyU (MWU) test,
the t test, and Pearson’s correlation coefficient (PCC) were
used for comparison of quantitative variables. The level of
significance was set at p < 0.05.
Results
In the first cohort, the HER2 amplification in the IC was neg-
ative in 87% of the cases and positive in 13% of the cases,
without the presence of HER2-GH. All the cases had an asso-
ciated CIS with the same HER2 status than IC, with four cases
of CIS presenting HER2-GH. Because one case presented
both lobular and ductal CIS, we characterized 101 types of
CIS, where 92.1% were ductal CIS (DCIS) and 2.9% of the
cases were classified as low grade, 41.6% as intermediate
grade, and 55.5% as high grade. We also observed necrosis
in 42.6% and microcalcifications in 27.7% (Table 1).
HER2 amplification in the IC was not related with the
procedure, the age of the patients or the histological grade.
However, in the CIS, we observed a significant relationship
of HER2 amplification with high nuclear grade (18.9 vs 4.4%;
p = 0.030), without an association with the remaining charac-
teristics (Table 3).
The distribution of HER2/CEP17 ratio and average of
HER2 and CEP17 copy number per cell were not statistically
different between the IC and CIS (Table S1). Additionally, we
observed a high correlation of HER2/CEP17 ratio and average
HER2 copy number per cell between IC and CIS
(PCC = 0.981; p < 0.001 and PCC = 0.929; p < 0.001, respec-
tively) (Fig. 1 and S1).
In the four cases with HER2-GH in CIS, only one case was
identified in NCB and two cases presented HER2 gene ampli-
fication in the IC (Figs. 2 and 3). The proportion of cells with
HER2 gene amplification in the CIS varied between 30 and
60% of the total CIS represented in the sample, being all high-
grade DCIS (for details, see Table 4 and S2).
In the second cohort, the proportion of cells with HER2
amplification varied between 1 and 50% of the total tumor cell
population represented in the sample. In the negative compo-
nent, HER2/CEP17 ratio varied between 1.00 and 1.52, and in
the positive component between 2.06 and 9.17 (Table S3).
The primary IC cases had similar morphological features in
the amplified and non-amplified components. The lymph
node metastasis case represented a primary lobular carcinoma
of the breast with an equivocal HER2 result (score of 2+) by
IHC and no HER2 gene amplification by SISH (case 2). The
Table 2 Characteristics of the second cohort
Procedure (NCB/SES) 10/2
Gender (female/male) 10/2
Age (mean ± SD) 59.67 ± 10.92
Invasive carcinoma
Histological type
Invasive carcinoma, NST 11
Lobular carcinoma 1
Histologic grade
Grade 1/grade 2/grade 3 0/8/4
Carcinoma in situ
Ductal 2
Nuclear grade
Low/intermediate/high 0/1/1
Necrosis (absent/present) 1/1
Microcalcifications (absent/present) 2/0
NCB needle core biopsy, SES surgical excision specimen, SD standard
deviation, NST no special type
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metastasis showed two types of neoplastic cells, one similar
with the primary lesion and another one with more pleomor-
phic nuclei. After additional IHC in the metastasis, it was
found that the latter areas showed strong and complete mem-
branous staining in 40% of the cells (score of 3+) that were
confirmed by SISH as HER2 amplified (Fig. 4).
Additionally, in the primary IC cases, we identified two
cases associated with non-amplified DCIS (cases 11 and
12—Table 5 and S4). Case 12 was classified as equivocal by
IHC (score of 2+) because it showed strong and complete
membranous staining in small groups of tumor cells, along
with scattered single cells, representing less than 10% of the
total tumor cell population in the sample. After SISH analysis,
the same component presented HER2 gene amplification,
consequently being classified as HER2 ISH negative (Fig. 5).
Discussion
The aim of the present study was to compare the amplification
status of HER2 gene between IC and CIS and search for
HER2-GH in both components. Our results show that in all
the cases, we observed the same HER2 status in both IC and
adjacent CIS, according to previous studies [15, 16].
Although, in this work, we only consider cases with an equiv-
ocal HER2 result by IHC that can bias the results, these are the
cases that require reflex testing making the issue of HER2-GH
in ISH evaluation more important in this setting.
Bright-field ISH allows to better correlate tissue morphol-
ogy and HER2 gene status, clearly identifying HER2-GH in
IC and CIS [17]. In CIS, HER2-GH was recognized more
frequently in SES, in which more tissue is available for
Fig. 1 Relationship between
HER2/CEP17 ratio of in situ and
invasive carcinoma
Table 3 HER2 amplification in
invasive and in situ carcinoma Invasive carcinoma Negative Positive p
Procedure (NCB/SES) 58/29 8/5 0.759a
Age (mean ± SD) 54.52 ± 12.86 55.69 ± 9.29 0.753b
Histological grade (grade 1–2/grade 3) 72/15 8/5 0.129a
Carcinoma in situ
Ductal/lobular 78/8 12/0 0.590a
Nuclear grade (low-intermediate/high) 43/43 2/10 0.030c
Necrosis (absent/present) 52/34 5/7 0.216c
Microcalcifications (absent/present) 65/21 6/6 0.085a
NCB needle core biopsy, SES surgical excision specimen, SD standard deviation
a Fisher’s exact test
b t test
c Pearson’s Chi-squared test
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evaluation. Interestingly, in these cases, only half of IC
presented HER2 gene amplification, confirming that this
amplification is not relevant for the transition from CIS
to IC. In the literature, it has been documented that in
HER2-positive cases, a significant increase occurs in
HER2 copy number between primary BC and metastatic
lesions [18]. The high correlation of HER2/CEP17 ratio
and HER2 copy number between IC and CIS suggests that
the described genetic instability of HER2 gene amplifica-
tion is only present in metastatic stages.
Fig. 3 Carcinoma in situ with HER2 genetic heterogeneity associated
with HER2-negative invasive carcinoma. Case 4 (1st cohort): a1 LCIS,
H&E 200×; a2 non-amplified LCIS, SISH 400×; b1 invasive lobular
carcinoma, H&E 200×; b2 non-amplified invasive lobular carcinoma,
SISH 400×; c1 DCIS, H&E 200×; c2 amplified DCIS, SISH, 400×
Fig. 2 Carcinoma in situ with
HER2 genetic heterogeneity
associated with HER2-positive
invasive carcinoma. Case 1 (1st
cohort): a1 DCIS, H&E 200×; a2
amplified DCIS (left) and non-
amplified DICS (right), SISH
200×; b1 invasive carcinoma,
NST, H&E 200×; b2 amplified
invasive carcinoma, NST, SISH
200×
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In our study, HER2 gene amplification in IC was not asso-
ciated with histological grade, contrary to what has been pub-
lished [6, 19]. Current evidence shows that histological grad-
ing of NCB can only be concordant with SES in about 75% of
the cases [20, 21]. Most of the discordant cases are upgraded
in the SES, generally due to an underscored of the mitotic
frequency on NCB [21, 22]. Although our first cohort includ-
ed a slight increase of grade 2 tumors compared with expected
values in the literature, it might be the result of the large
number of NCB, which can underestimate the histological
grade and compromise the statistical relationship with HER2
gene amplification [20]. Nevertheless, HER2 gene amplifica-
tion in CIS was significantly associated with high nuclear
grade, as previously documented [6, 19].
Before the introduction of the first definition of HER2-GH,
intratumoral heterogeneity was applied to discrete population
of cells and reported as a rare event [23, 24]. Recently, we also
showed the presence of HER2-GH in IC, according to the
updated ASCO/CAP HER2 guideline, to be extremely infre-
quent [25]. In the present work, we identified it in about 1% of
the cases, including cases of male patients.
HER2-GH in the IC was observed more often in NCB,
because most evaluations are performed by this procedure,
which represent the first biological material on which the hor-
mone receptors (HR) and HER2 markers should be first de-
termined [14, 26]. The predominant histologic type was inva-
sive carcinomas, NST, with no cases classified as grade 1, as
previously noticed [23]. Although we had no information
Fig. 4 HER2-negative invasive carcinoma associated with HER2
genetic heterogeneity in the lymph node metastasis. Case 2 (2nd
cohort): a1 invasive lobular carcinoma, H&E 200×; a2 non-amplified
invasive lobular carcinoma, SISH, 400×; b1, c1 same lymph node
metastasis, H&E 200×; b2 non-amplified area in lymph node metastasis;
c2 amplified area in lymph node metastasis, SISH 400×
Table 4 Cases with HER2 amplification discordance between invasive carcinoma and carcinoma in situ
Case Gender Age Procedure IC Histologic grade HER2 status CIS Nuclear grade HER2 status Proportion
1 F 44 SES NST 2 A ductal high A 40%
NA 60%
2 F 53 SES NST 3 A ductal high A 60%
NA 40%
3 F 48 NCB NST 3 NA ductal high NA 40%
A 60%
4 F 78 SES Lobular 1 NA lobular low NA 70%
ductal high A 30%
F female, SES surgical excision specimen, NCB needle core biopsy, NST no special type, A amplified, NA not amplified
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regarding previous treatment, the fact that most IC cases with
HER2-GH were found in NCB shows us that this rare event
can occur in patients without previous treatment.
All primary invasive BC cases presented similar histolog-
ical characteristics in the amplified and non-amplified areas,
with HER2 gene amplification in a minor component,
supporting the idea that most cases develop in a single tumor
that acquired HER2 gene amplification during tumor progres-
sion. Even though molecular analysis has shown that cases
with HER2-GH in the IC can be the result of two distinct
tumors (also known as collision tumors), most cases appear
to be clonally related resulting from clonal divergence from a
single tumor, as previously shown [27, 28]. However, it re-
mains to be shown if the same process can occur in CIS.
In case 2 (second cohort), the HER2-GH was found in the
lymph nodemetastasis rather than the primary tumor. This can
be the result of tumor evolution in the lymph node metastasis
or, eventually, the representation of an independent tumor that
was not identified in the SES. Nevertheless, this case illus-
trates the importance of pathologists in selecting tumor areas
with less differentiation and higher nuclear pleomorphism,
either in the primary IC or in the lymph node metastases,
which most likely are going to be HER2 amplified.
Additionally, according to the 2013 ASCO/CAP guideline,
the HER2 test should also be repeated if results are discordant
with histopathologic findings [14].
Although it has been previously reported that HRs and
HER2 conversion by IHC can occur between primary and
metastatic lesions, the former is much more frequent (prefer-
entially from HR-positivity in the primary tumors to HR-
negativity in the metastasis) [18, 29]. The conversion phe-
nomenon could be explained by HER2-GH in the primary
tumor, which can be more frequently found if more than one
block is tested [30, 31]. In this study, we were restricted to the
analysis of only one block, which can underestimate the prev-
alence of HER2-GH. Additionally, we also not considered
Fig. 5 Invasive carcinoma with
HER2 genetic heterogeneity
associated with HER2-negative
carcinoma in situ. Case 12 (2nd
cohort): a1 DCIS, H&E 200×; a2
non-amplified DCIS, SISH 400×;
b1 invasive carcinoma, NST,
H&E 200×; b2 HER2 genetic
heterogeneity in invasive
carcinoma (HER2 gene
amplification in small groups of
tumor cells (circle areas) along
with scattered single cells
(arrows))
Table 5 Cases with HER2 genetic heterogeneity in invasive carcinoma associated with carcinoma in situ
Case Gender Age Procedure IC Histologic grade HER2 status Proportion CIS Nuclear grade HER2 status
11 F 52 NCB NST 3 A 25%
NA 75% ductal high NA
12 M 73 NCB NST 2 NA 99% ductal intermediate NA
A 1%
F female, M male, NCB needle core biopsy, IC invasive carcinoma, NST no special type, A amplified, NA not amplified, CIS carcinoma in situ
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cases with HER2-GH by IHC (score 3+ in >10 and <100%).
Interestingly, it has also been shown that patients with HER2-
GH have worse outcome compared to patients with homoge-
neous amplified or non-amplified HER2 gene, suggesting that
mixed tumors behave more aggressively [32, 33].
Furthermore, it has been described that the majority of ICs
with HER2-GH have non-amplified DCIS, consistent with
our study, again supporting the idea that IC originates from
CIS and that HER2 gene amplification can also be acquired in
later stages [23]. Cases with HER2-GH in the IC associated
with amplified DCIS probably represent distinct tumors, given
the fact that the loss of the HER2 gene amplification is an
unlikely event.
Finally, regarding case 12 (second cohort), which presented
HER2 gene amplification in less than 10% of the total tumor
cell population, a comment was made in the report
recommending repetition of HER2 test by IHC in the SES to
find and accurately quantify the HER2 positive component.
Moreover, focally amplified small populations can be
overlooked and IHC should be used to guide ISH analysis,
searching for areas of potential amplification [14]. All cases
exhibiting HER2-GH on NCB by ISH should have HER2 test
repeated on the SES, according to the updated United
Kingdom guidelines [34]. Additionally, clinical trials have
not so far been based on the new 10% cut-off for ISH as
provided by the 2013 ASCO/CAP guideline [35–39]. In fact,
the presence of HER2 gene amplification was enough for
inclusion of patients to HER2-targeted therapy, irrespective
of the proportion of amplified cells. Fortunately, the rare pres-
ence of HER2-GH probably did not influence the clinical
results given that any random group of cells evaluated will
represent, most of the times, the whole tumor [40].
However, it remains to be demonstrated what is the minimal
proportion of amplified tumor cell population that achieves
clinical response to HER2-targeted therapy.
In conclusion, we show that HER2-GH is a rare event in IC
and can already be present in CIS, not being an important step
in the acquisition of invasive features. As far as we know, this is
the first time that HER2-GH, according to the updated ASCO/
CAP HER2 guideline, has been evaluated in both IC and adja-
cent CIS using bright-field ISH. Although intratumoral hetero-
geneity of HER2 gene amplification can have clinical signifi-
cance, not only affecting the selection of patients but also
explaining some of the variability of the response to targeted
therapy, this is a rare event in breast cancer cases.
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ABSTRACT
Aim The present work aims to evaluate the presence of
stromal tumour-inﬁltrating lymphocytes (TILs) and
programmed cell death-ligand 1 (PDL1) expression in
breast carcinomas and their correlation with available
clinicopathological features.
Methods Two independent series of invasive breast
cancer (IBC), one including ductal carcinoma in situ
(DCIS) pair-matched cases, were selected, and
quantiﬁcation of TILs was accomplished in each case.
Immunohistochemistry was also performed to evaluate
the expression of PDL1.
Results In both cohorts evaluated, increased stromal
TILs and PDL1 expression were present in about 10% of
IBCs, being signiﬁcantly associated with each other and
both with grade 3 and triple-negative subtype. We
observed a similar distribution of stromal TILs and PDL1
expression between DCIS and IBC. Finally, we observed
that increased stromal TILs and PDL1 expression were
signiﬁcantly associated with cancer stem cell (CSC)
markers, basal cell markers and vimentin expression.
Interestingly, in IBC cases with vimentin expression,
increased stromal TILs, as well as decreased PDL1
expression, disclosed a better clinical outcome,
independently of the main classical BC prognostic
factors.
Conclusions We have conﬁrmed the association of
stromal TILs and PDL1 expression with aggressive forms
of BC and that both are already found in in situ stages.
We also showed that stromal TILs and PDL1 expression
are associated with clinical outcome in cases enriched
for a mesenchymal immunophenotype. We describe for
the ﬁrst time a close relationship between CSC markers
and PDL1 expression.
INTRODUCTION
In the Western world, breast cancer (BC) is the
most frequently diagnosed malignancy among
women, representing about one-third of all new
cancer cases and the second leading cause of
cancer death after lung cancer.1 BC development
and progression is dependent on a complex
system of different factors, including genetic and
epigenetic alterations, and on factors from the
tumour microenvironment, such as stromal and
immune cells.2 In fact, in recent years, numerous
studies have focused on the presence and function
of the host immune system and its relationship
with tumour progression in a variety of solid
tumours, including BC, showing that spontaneous
intratumoural lymphocytic inﬁltrate is related to
patient prognosis.3–9
Although the BC’s inﬂammatory inﬁltrate has
been studied for several decades with conﬂicting
results, large cohorts have recently shown an associ-
ation between the presence of tumour-inﬁltrating
lymphocytes (TILs) with improved prognosis and
better response to neoadjuvant chemotherapy,
regardless of the absence of information of its spe-
ciﬁc immune cells.10 11 In triple-negative (TN) BC,
for instance, the presence of stromal TILs in
tumour tissue at diagnosis associates with better
patient outcome after adjuvant anthracycline-based
chemotherapy.12 Similarly, in human epidermal
growth factor receptor 2 (HER2)-positive BC, the
number of TILs in tumour tissue associates with a
better response to trastuzumab treatment.13
However, in contrast to the presumed protective
effect of TILs in tumour tissue, it has been shown
that immune cells can cause the acquisition of stem
cell properties by tumour cells, as well as a more
pronounced mesenchymal phenotype, which are
features related with a worse patient prognosis.14
Moreover, it was also shown that tumour cells
express antigens that should be recognised by
patient’s immune system, although most of the
time the immunological response is unable to elim-
inate the cancer cells. Currently, many efforts have
been made to identify molecular mechanisms that
enable tumour cells to escape from the host immune
system.2 An example of tumour escape from immu-
nosurveillance is the expression of PDL1 (pro-
grammed cell death-ligand 1) by neoplastic cells,
which is a cell surface glycoprotein that conveys an
inhibitory signal to T lymphocytes, through the
interaction with its receptor PD1 (programmed cell
death protein 1). This speciﬁc binding leads to a
decrease in cytokine production and an increase of
T lymphocyte apoptosis, which protect tumour cells
from elimination.15–18 Accordingly, the inhibition of
this inhibitory signal by speciﬁc monoclonal anti-
bodies, against either PDL1 or PD1, has been shown
to promote tumour cell death induced by the host
immune system in many cancer models.17 19
Based on these data, the expression of PDL1 is
already being evaluated in several solid tumours,
such as melanoma, non-small cell lung carcinoma
and renal cell carcinoma, since it brings additional
information to patient prognosis and to the selec-
tion of immunotherapy currently available targeting
these molecules speciﬁcally.20 In line with these
studies, the aim of the present work was to evaluate
the relationship between the presence of stromal
TILs and PDL1 expression with clinicopathological
features in two independent BC series. The
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association with disease-free-survival (DFS) and overall survival
(OS) was also evaluated.
MATERIALS AND METHODS
Tumour samples
Two independent series of BC cases were studied, both with clin-
ical and pathological characterisation performed by our group,
previously described and structured in tissue microarrays (TMAs).
The ﬁrst cohort includes 440 primary and sporadic invasive ductal
carcinomas retrieved from the Pathology Department, Hospital
Xeral-Cíes, Vigo, Spain, diagnosed between 1978 and 1992, with
a median age of 60.0 years (from 28 to 92 years) and a median
follow-up time of 120 months (1–120 months).21 Several para-
meters were extracted from the group database, including age,
tumour size, histological grade, lymph node status, oestrogen
receptor (ER), progesterone receptor (PgR), HER2 and Ki67
expression, as well as the expression of basal cell markers (CK5,
CK14, epidermal growth factor receptor (EGFR) and P-cadherin),
cancer stem cell (CSC) markers (CD24, CD44, CD49f and
ALDH1) and the epithelial–mesenchymal transition (EMT)
markers E-cadherin and vimentin. Data concerning molecular
subtype, DFS and OS were also available. The main features are
detailed in online supplementary table S1.
The second cohort includes 94 primary in situ and invasive BC
(IBC) cases, including 32 pair-matched cases, collected from the
Pathology Institute of Araçatuba, São Paulo, Brazil, diagnosed
between 1996 and 2006, with a median age of 55.0 years (from
32 to 96 years).22 The data retrieved from the database include
age, histological grade, lymph node status, hormone receptor
(ER and PgR), HER2, Ki67 and molecular subtype. The main
features are detailed in online supplementary table S2.
This study has been performed in accordance with the
national regulative law for the handling of biological specimens
from tumour banks, the samples being exclusively available for
research purposes in retrospective studies, as well as under the
international Helsinki declaration.
Quantiﬁcation of TILs
Histopathological analysis of the lymphocytic inﬁltrate was per-
formed according to the guidelines for clinical and research
practice.23 Brieﬂy, mononuclear cells, including lymphocytes
and plasma cells (granulocytes excluded), were quantiﬁed in the
stromal compartment as a continuous variable of 10% incre-
ment, within the borders of the invasive tumour, using visual
assessment of H&E-stained sections. Thresholds were then used
to categorise the continuous variable (absent—absence of TILs;
slight—TILs up to 30%; moderate—TILs between 30% and
60%; marked—TILs in more than 60%). In ductal carcinoma in
situ (DCIS), the lymphocytic inﬁltrate was quantiﬁed around the
lesion using the same classiﬁcation.
PDL1 immunohistochemistry
Immunohistochemical staining for PDL1 was performed in
2–3 mm sections from TMAs, using a rabbit monoclonal anti-
body (clone SP142; 1:60 dilution; Spring Bioscience,
Pleasanton, California, USA). The assay was carried out on an
automated immunostaining system (Ventana BenchMark XT
Staining System), using the OptiView DAB IHC Detection Kit
(Ventana Medical Systems, Tucson, Arizona, USA) according to
manufacturer’s instructions. Positive (human placenta) and nega-
tive staining controls were performed in parallel with parafﬁn
sections. Positivity was deﬁned as membranous and cytoplasmic
staining ≥1% in both tumour cells and stromal TILs.24
Statistical analysis
Statistical analyses were performed using the Statistical Package
for the Social Sciences (SPSS), V.21.0, for Windows. Pearson’s
χ2 test (or Fisher’s exact test, when appropriate) was used for
comparison of qualitative variables, and the t-test or the
Mann-Whitney U test for quantitative variables.
Survival rate curves were calculated according to the
Kaplan-Meier method and compared by the log-rank test. DFS
time was deﬁned as the interval between diagnosis and BC
recurrence or metastasis, whereas OS time was deﬁned as the
interval between diagnosis and BC-related death or between
diagnosis and the last follow-up time for surviving patients.
Multivariate survival analyses were based on the Cox propor-
tional hazard regression model. The level of signiﬁcance was set
at p<0.05.
RESULTS
Association of stromal TILs and PDL1 expression with
clinicopathological characteristics
The quantiﬁcation of stromal TILs in the ﬁrst cohort ranged
between 0% and 80% (median of 10%), with a minority of cases
having more than 30% (moderate to marked—9.2%) (table 1 and
ﬁgure 1). However, the presence of moderate to marked stromal
TILs was signiﬁcantly increased in G3 (13.6%; p<0.001), in
ER-negative cases (16.2%; p<0.001), in TNBC subtype (19.0%;
p<0.001) and in cases with high expression of Ki67 (20.0%;
p=0.019) (table 2). A signiﬁcant association between moderate
and marked stromal TILs with all the evaluated basal cell markers
was also observed (CK5—22.4%; p<0.001/CK14—28.6%;
p=0.005/EGFR—25.0%; p=0.021/P-cadherin—15.1%; p=0.007)
(table 3). Additionally, we still found a signiﬁcant association
between stromal TILs and the expression of the CSC marker
ALDH1 (33.3%; p=0.014), as well as with the expression of
vimentin (17.2%; p=0.008) (table 3).
The expression of PDL1 was mainly found at the cell mem-
brane (in both tumour cells and stromal TILs) and only present
in 6.4% of the cases (table 1 and ﬁgure 1). Although PDL1
expression was not observed in normal breast tissue, it was sig-
niﬁcantly associated to G3 (10.1%; p=0.002) and ER-negative
carcinomas (11.1%; p=0.001), as well as with the TNBC
subtype (16.2%; p<0.001) and with cases with high expression
of Ki67 (16.0%; p=0.002) (table 2). We also observed a signiﬁ-
cant direct association between PDL1 expression and all the
evaluated basal cell markers (CK5—18.6%; p<0.001/CK14—
18.2%; p=0.031/EGFR—20.0%; p=0.022/P-cadherin—13.1%;
p<0.001), all the evaluated CSC markers (CD44+/CD24−/low—
8.4%; p=0.044/CD49f—15.2%; p=0.011/ALDH1–23.1%;
p=0.033) and with the expression of vimentin (12.3%;
p=0.036) (table 3).
Stromal TILs and PDL1 expression were still signiﬁcantly
associated between each other (64.3%; p<0.001) (table 4).
Table 1 Stromal TILs and PDL1 expression in BC cases from the
first cohort
TILs
Absent/slight 178 (41.0%)/216 (49.8%)
Moderate/marked 36 (8.3%)/4 (0.9%)
PDL1 expression
Negative 407 (93.6%)
Positive 28 (6.4%)
BC, breast cancer; PDL1, programmed cell death-ligand 1; TILs, tumour-infiltrating
lymphocytes.
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Figure 1 Stromal tumour-inﬁltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PDL1) expression in invasive breast cancer (IBC)
(200×). (A) 1—BC without stromal TILs (H&E); 2—PDL1 negative expression. (B) 1—BC with increased stromal TILs (H&E); 2—PDL1 expression in
cancer cells. (C) 1—BC with increased stromal TILs (H&E); 2—PDL1 expression in stromal TILs.
Table 2 Association between clinicopathological features with stromal TILs and PDL1 expression in invasive breast cancer (first cohort)
Stromal TILs PDL1 expression
Clinicopathological features Absent/slight Moderate/marked p Value Negative Positive p Value
Age (average±SD) 59.40±13.11 54.88±13.48 0.052* 58.89±13.27 60.26±11.57 0.763*
Tumour size 0.397† 0.069†
≤2 cm 87 (94.6%) 5 (5.4%) 92 (98.9%) 1 (1.1%)
<2 cm to ≤5 cm 191 (92.3%) 16 (7.7%) 192 (92.3%) 16 (7.7%)
>5 cm 45 (88.2%) 6 (11.8%) 48 (92.3%) 4 (7.7%)
Histological grade <0.001† 0.002†
G1 71 (98.6%) 1 (1.4%) 72 (100%) 0 (0%)
G2 105 (97.2%) 3 (2.8%) 106 (97.3%) 3 (2.7%)
G3 171 (86.4%) 27 (13.6%) 179 (89.9%) 20 (10.1%)
Lymph node 0.164† 0.612†
Negative 126 (88.7%) 16 (11.3%) 133 (93.0%) 10 (7.0%)
Positive 164 (93.2%) 12 (6.8%) 168 (94.4%) 10 (5.6%)
ER <0.001† 0.001†
Positive 246 (95.4%) 12 (4.6%) 253 (96.9%) 8 (3.1%)
Negative 114 (83.8%) 22 (16.2%) 120 (88.9%) 15 (11.1%)
PgR 0.874† 0.080†
Positive 175 (91.6%) 16 (8.4%) 184 (96.3%) 7 (3.7%)
Negative 186 (91.2%) 18 (8.8%) 190 (92.2%) 16 (7.8%)
HER2 0.308‡ 0.757‡
Negative 308 (91.9%) 27 (8.1%) 317 (94.6%) 18 (5.4%)
Positive 50 (87.7%) 7 (12.3%) 55 (93.2%) 4 (6.8%)
Ki67 0.019* 0.002*
<14% 342 (92.2%) 29 (7.8%) 354 (94.9%) 19 (5.1%)
≥14% 20 (80.0%) 5 (20.0%) 21 (84%) 4 (16.0%)
Molecular subtype <0.001†§ <0.001‡§
Luminal A 248 (95.4%) 12 (4.6%) 253 (97.7%) 6 (2.3%)
Luminal B 24 (85.7%) 4 (14.3%) 26 (86.7%) 4 (13.3%)
HER2-positive 26 (89.7%) 3 (10.3%) 29 (100%) 0 (0%)
TNBC 64 (81.0%) 15 (19.0%) 67 (83.8%) 13 (16.2%)
Bold indicated p<0.05 is statistically significant.
*Mann-Whitney U test.
†Pearson’s χ2 test.
‡Fisher’s exact test.
§TN versus others.
ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; PDL1, programmed cell death-ligand 1; PgR, progesterone receptor; TILs, tumour-infiltrating lymphocytes;
TNBC, triple-negative breast cancer.
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Association of stromal TILs and PDL1 expression with
patient prognosis
Overall, neither stromal TILs nor PDL1 expression were sig-
niﬁcantly associated with DFS or OS rates (table 4). However,
in both G3 and ER-negative cases, the presence of more than
30% of stromal TILs was signiﬁcantly associated with better
DFS rates (94.26 vs 76.36; p=0.045 and 93.01 vs 68.02;
p=0.044, respectively). Additionally, also in G3 BC cases,
PDL1 expression was signiﬁcantly associated with improved
DFS (96.79 vs 77.39; p=0.043). In vimentin-positive BC
cases, increased stromal TILs were also signiﬁcantly associated
with better DFS and OS rates (110.18 vs 77.35; p=0.037
and 113.36 vs 85.39; p=0.047, respectively) (see online
supplementary table S3).
Table 3 Association between basal cell markers, CSC markers and EMT markers with stromal TILs and PDL1 expression in invasive breast
cancer (first cohort)
Stromal TILs PDL1 expression
Absent/slight Moderate/marked p Value Negative Positive p Value
Basal cell markers
CK5 <0.001* <0.001*
Negative 317 (93.8%) 21 (6.2%) 327 (96.5%) 12 (3.5%)
Positive 45 (77.6%) 13 (22.4%) 48 (81.4%) 11 (18.6%)
CK14 0.005* 0.031*
Negative 347 (92.5%) 28 (7.5%) 357 (94.9%) 19 (5.1%)
Positive 15 (71.4%) 6 (28.6%) 18 (81.8%) 4 (18.2%)
EGFR 0.021* 0.022*
Negative 347 (92.3%) 29 (7.7%) 359 (95.0%) 19 (5.0%)
Positive 15 (75.0%) 5 (25.0%) 16 (80.0%) 4 (20.0%)
P-cadherin 0.007† <0.001†
Negative 278 (93.6%) 19 (6.4%) 289 (96.7%) 10 (3.3%)
Positive 84 (84.9%) 15 (15.1%) 86 (86.9%) 13 (13.1%)
CSC markers
CD44+/CD24−/low 0.165† 0.044†
Negative 204 (93.2%) 15 (6.8%) 210 (96.3%) 8 (3.7%)
Positive 157 (89.2%) 19 (10.8%) 163 (91.6%) 15 (8.4%)
CD49f 0.251* 0.011*
Negative 318 (91.9%) 28 (8.1%) 330 (95.4%) 16 (4.6%)
Positive 38 (86.4%) 6 (13.6%) 39 (84.8%) 7 (15.2%)
ALDH1 0.014* 0.033*
Negative 354 (92.2%) 30 (7.8%) 365 (94.8%) 20 (5.2%)
Positive 8 (66.7%) 4 (33.3%) 10 (76.9%) 3 (23.1%)
EMT markers
E-cadherin 0.708* 0.628*
Negative/low 21 (95.5%) 1 (4.5%) 22 (100%) 0 (0%)
Positive 339 (91.1%) 33 (8.9%) 352 (93.9%) 23 (6.1%)
Vimentin 0.008† 0.036*
Negative 307 (93.0%) 23 (7.0%) 316 (95.5%) 15 (4.5%)
Positive 53 (82.8%) 11 (17.2%) 57 (87.7%) 8 (12.3%)
Bold indicated p<0.05 is statistically significant.
*Fisher0s exact test.
†Pearson’s χ2 test.
CSC, cancer stem cell; EMT, epithelial–mesenchymal transition; PDL1, programmed cell death-ligand 1; TILs, tumour-infiltrating lymphocytes.
Table 4 Association between stromal TILs and PDL1 expression in invasive breast cancer (first cohort)
Stromal TILs PDL1 expression
Absent/slight Moderate/marked p Value Negative Positive p Value
PDL1 expression <0.001* NA
Negative 380 (94.8%) 21 (5.2%) – –
Positive 10 (35.7%) 18 (64.3%) – –
DFS (mean of months) 86.5 97.8 0.087† 87.5 92.3 0.327†
OS (mean of months) 91.7 99.8 0.108† 92.7 92.9 0.568†
Bold indicated p<0.05 is statistically significant.
*Fisher’s exact test.
†Kaplan-Meier method/log-rank p value.
DFS, disease-free-survival; NA, not applicable; OS, overall survival; PDL1, programmed cell death-ligand 1; TILs, tumour-infiltrating lymphocytes.
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However, in multivariate analysis, only increased stromal TILs
in vimentin-positive BC were independently associated with
better DFS and OS (HR=0.10, p=0.017 and HR=0.06,
p=0.019, respectively). Interestingly, also within vimentin-
positive cases, PDL1 expression was, in contrast, signiﬁcantly
associated with a decreased OS (HR=7.12, p=0.018) (see
online supplementary table S4 and ﬁgure 2).
Concerning molecular subtypes, we observed that moderate
to marked stromal TILs were associated with better DFS (100.4
vs 72.6) and OS (103.8 vs 79.9) rates (p=0.096 and p=0.080,
respectively) in TNBC, although without reaching statistical sig-
niﬁcance (see online supplementary table S5).
Stromal TILs and PDL1 expression in matched in situ and
invasive carcinomas
When stromal TILs and PDL1 expression were compared
between DCIS and IBC, a similar distribution was found (TILs
—13.0% vs 13.8%, p=0.911; PDL1 expression—8.7% vs
13.8%, p=0.399, respectively), as actually happened for all the
other characteristics previously evaluated (ﬁgure 3, tables 5 and
online supplementary table S2).
Validating the results found in the ﬁrst cohort, the presence
of moderate to marked stromal TILs was signiﬁcantly increased
in G3 (26.9%; p=0.001), in TNBC subtype (25%; p=0.023)
and in cases with PDL1 expression (63.6%; p<0.001) (see
online supplementary table S6). We also observed an increase
of stromal TILs in ER-negative cases and in cases with high
expression of Ki67 (20%; p=0.059 and 20%; p=0.057,
respectively). Additionally, we found a similar association of
increased stromal TILs and HER2-positive subtype (25%;
p=0.023). In DCIS, moderate to marked stromal TILs were
enriched in G3 (23.5%; p=0.071), TNBC and HER2-positive
subtypes (20% and 40%, respectively; p=0.073) and in cases
with PDL1 expression (50%; p=0.077), although without reach-
ing statistical signiﬁcance.
Concerning PDL1 expression, it was signiﬁcantly associated
with G3 (26.9%; p=0.005) and all molecular subtypes, except
luminal A (0%; p=0.005) (see online supplementary table S7).
Interestingly, we also observed PDL1 expression enriched in
cases with high expression of Ki67 (30%; p=0.061), without
reaching statistical signiﬁcance.
DISCUSSION
Our study conﬁrms that increased stromal TILs are present in a
minority of IBC cases and that are already present in in situ
stages, as previously shown.10 25 Although PDL1 expression has
been reported in the literature from 20% to nearly 60% of the
cases, we only observed in a small proportion of IBCs and, for
the ﬁrst time, even in DCIS cells.26–30
In IBC, increased stromal TILs and PDL1 expression were
associated with each other and with G3 and TNBC subtype,
with statistical signiﬁcance in both cohorts, which also validates
previous reports.25 27 28 The association of increased stromal
TILs and PDL1 expression with the evaluated basal cell markers
also reinforces the relationship with the TNBC molecular
subtype.
Stromal TILs include several types of T and B lymphoid
cells in different proportions with distinct associations with clin-
ical outcome that we did not discriminate in our study. For
instance, cytotoxic (CD8+) T cells are signiﬁcantly increased
in high-grade, ER-negative BC and BC with increased prolifera-
tive activity, as well as associated with improved clinical
outcome.31–33 On the other side, immunosuppressive (CD4
+/FOXP3+) T cells have been shown to be associated with worse
prognosis in IBC and even with increased risk of relapse in
DCIS.34–36 These data suggest that cytotoxic T cells are respon-
sible for the antitumour immune activity and that immunosup-
pressive T cells can inhibit this response. Furthermore, B
lymphocytes are also associated with higher histological grade,
ER-negative cases and basal phenotype, as well as with better
prognosis.37 This indicates that humoral immune response, along
with cell-mediated immune response, acts in convergence to
achieve effective antitumour response. Based on this knowledge,
it would be important to evaluate the clinical value of subtyping
the composition of stromal TILs in BC and reveal the potential
predictive role of these markers in response to immunotherapy.
Nonetheless, it is remarkable that the quantiﬁcation of stromal
TILs alone, regardless of its speciﬁc subpopulation of lymphoid
cells, has prognostic and predictive information.
Although the use of TMAs in this work could, eventually,
miss quantify stromal TILs evaluation, several reports suggest
that TMAs are a valid choice, as the majority of BC are not het-
erogeneous regarding stromal TILs distribution throughout the
tumour.23 26 32 38 While recent guidelines recommend the
evaluation of TILs as a continuous variable, we were able to
show that the cut-off values used in this work enclose clinical
signiﬁcance and may be used to easily categorise this parameter,
possibly reducing the interobserver variability.
Concerning PDL1 expression, in addition to tumour cells, it
has been reported that it can be also present in stromal TILs, as
observed by us, speciﬁcally in CD4+/FOXP3− T cells.28
However, PDL1 expression is not associated with T cell
Figure 2 Survival curves showing the signiﬁcant disease-free-survival and overall survival for patients with vimentin-positive breast cancer (BC)
relatively to stromal tumour-inﬁltrating lymphocytes (TILs) (A and B) and programmed cell death-ligand 1 (PDL1) expression (C).
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exhaustion markers, which means that PDL1 is only partially
inhibiting T cells.27 Nevertheless, this does not contradict the
idea of blocking PDL1 in order to reactivate partially inhibited T
cells and further increase the antitumour immune response.
Concerning DCIS, a similar trend in association between
stromal TILs and PDL1 expression with histological grade and
molecular subtype was also detected, suggesting that, as we pre-
viously reported, these features correlate well with the invasive
counterpart.22 Very recently, the expression of PDL1 has been
described in about 80% of stromal TILs associated with DCIS
cases, as well as an association with TNBC subtype.39 In that
work, there was no expression of PDL1 in DCIS cells, unlike
our observation, in which we detected in both DCIS cells and
associated stromal TILs.
Figure 3 Stromal tumour-inﬁltrating
lymphocytes (TILs) and programmed
cell death-ligand 1 (PDL1) expression
in pair-matched in situ and invasive
breast cancer (IBC) (200×). (A) 1—
ductal carcinoma in situ (DCIS) without
stromal TILs (H&E); 2—PDL1-negative
expression in DCIS; 3—IBC with few
stromal TILs (H&E); 4—PDL1-negative
expression in IBC. (B) 1—DCIS with
increased stromal TILs (H&E); 2—PDL1
expression in DCIS; 3—IBC with
increased stromal TILs (H&E); 3—PDL1
expression in IBC.
Table 5 Tumour-infiltrating lymphocytes and PDL1 expression in
BC cases from the second cohort
DCIS Invasive carcinoma p Value
Tumour-infiltrating lymphocytes 0.911*
Absent/slight 40 (87.0%) 69 (86.2%)
Moderate/marked 6 (13.0%) 11 (13.8%)
PDL1 expression 0.399*
Negative 42 (91.3%) 69 (86.2%)
Positive 4 (8.7%) 11 (13.8%)
*Pearson’s χ2 test.
BC, breast cancer; DCIS, ductal carcinoma in situ; PDL1, programmed cell
death-ligand 1.
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The above-mentioned ﬁndings in DCIS samples indicate
that the immune response to tumours exists even at early
stages and that distinct molecular subtypes have different
immunogenicity. The characterisation of immune checkpoint
markers, in both invasive and DCIS cases, may result in
potential targets for therapy, such as anti-PDL1 treatment.
Moreover, we also report a similar distribution of stromal
TILs and PDL1 expression between DCIS and IBC pair-
matched cases. This means that stromal TILs and PDL1
expression might not be relevant for the progression from in
situ to IBC, but instead represent a response to intrinsic
characteristics of different molecular subtypes.
Finally, we observed that stromal TILs and PDL1 expression
were associated with CSC markers and vimentin expression.
Our results are expected because stromal TILs and PDL1
expression are associated with TNBC subtype, which in turn is
associated with a higher proportion of cells with stem cell
phenotype (CD44+/CD24−/low, CD49f and ALDH1) and EMT
features, as shown by our group in the past.21 40 41 In addition,
as stated above, both stromal TILs and PDL1 expression were
associated with basal cell markers, including P-cadherin, which
was previously demonstrated by our group to be upregulated in
basal-like subtype and associated with stem cell properties in BC
cell lines.40–43
Although the association of stromal TILs with stem cell
phenotype has been previously reported, as far as we know, this
is the ﬁrst time that PDL1 expression in BC cases is associated
with CSC markers (CD44+/CD24−/low, CD49f and ALDH1),
which is probably related to the close relationship with stromal
TILs and TNBC subtype.31 However, we observed an associ-
ation of PDL1 expression with all CSC markers, while stromal
TILs were only associated with ALDH1. This probably means a
potential role of CSCs in the activation of PDL1 expression,
both in tumour cells and stromal TILs, directly regulating the
antitumoural immune response.
Despite the association of stromal TILs with CSC markers,
the ﬁnal effect in BC tissue is a protective one, given the fact
that, in vimentin-positive BC, the presence of more than 30%
of stromal TILs was independently associated with increased
DFS and OS rates, reﬂecting an active antitumour immune
response with an impact on patient outcome. Although contra-
dictory information has been published regarding PDL1 expres-
sion and BC prognosis, in theory, the expression of PDL1 in BC
should have a deleterious effect on prognosis, given the inhibi-
tory effect of PDL1 in the antitumour immune response.30 We
also showed that in vimentin-positive BC, PDL1 expression is
independently associated with worse OS. Although it has been
reported that PDL1 expression can be related with better sur-
vival rates in BC, it is probably due to the close association of
PDL1 with the presence of increased stromal TILs, the true
effectors against tumour cells.27 44 Finally, because IBC with
mesenchymal traits is strongly associated with TNBC, a subtype
associated with worse prognosis and limited treatment strategies,
immunological modulators may represent an alternative
approach to improve clinical outcome of these patients.11 30 45
In conclusion, we have conﬁrmed the association of stromal
TILs and PDL1 expression with aggressive BC (G3 and TNBC/
basal subtype) and that both are already expressed in in situ
stages. We also showed that increased stromal TILs and PDL1
expression are associated with clinical outcome in BC with
vimentin expression. Notably, we describe a close relationship
between CSC markers with stromal TILs, and for the ﬁrst time,
with PDL1 expression.
Take home messages
▸ Increased stromal tumour-inﬁltrating lymphocytes (TILs) are
signiﬁcantly associated with PDL1 expression in breast
cancer (BC).
▸ PDL1 expression is present in in situ BC lesions.
▸ PDL1 expression is associated with cancer stem cell markers.
▸ Stromal TILs and PDL1 expression are independent
prognostic markers in vimentin-positive BC cases.
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